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Abstract
In modern pharmacy, biotechnology-based products provide medication for
many diseases otherwise hard to treat. The so-called biopharmaceuticals
are highly effective but difficult to produce. Both facts are reflected by
the biopharmaceuticals’ market values. In 2016, biopharmaceuticals con-
tributed eight out of ten of the most valuable pharmaceutical products.
The production of biopharmaceuticals relies on their expression in biore-
actors by host cells. The resulting fermentation broth is however not pure
but consists of a wide range of metabolites, proteins, Deoxyribonucleic Acid
(DNA), and Ribonucleic Acid (RNA) for cell maintenance and proliferation.
Furthermore, biotechnological production also results in numerous product-
related heterogeneities, many of which may be contaminants. This mixture
cannot be directly administrated to a patient. Instead, a second stage of
biopharmaceutical production, Downstream Processing (DSP), focuses on
purifying the product.
DSP of biopharmaceuticals comprises a number of steps for purifying,
modifying, and concentrating the product. Frequently applied unit oper-
ations are chromatography for purification, batch reactions for chemical
modifications, and Cross-Flow Filtration (CFF) for buffer exchange and
concentration. Due to uncontrolled variations during fermentation and the
DSP process, variability is introduced into the biopharmaceutical product.
In general, such variability is unwanted as it may lead to changing efficacy
and side-effects in patients. Regulatory agencies and industry have taken a
systematic, knowledge-based approach to reducing process variability. Next
to Quality by Design (QbD), Process Analytical Technology (PAT) can help
to improve process understanding during development and in production by
providing rich and timely information on the performed process. Ideally,
the selected PAT allows to measure Critical Quality Attributes (CQAs) and
Critical Process Parameters (CPPs). Based on the obtained information,
improved process control can be realized.
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The objective of this thesis was to developed a toolbox of spectroscopic
PAT sensors for DSP and apply them to different unit operations of bio-
pharmaceuticals. To achieve sensitivity towards a wide variety of CQAs
and CPPs, the sensors were selected to measure based on multiple different
physical principles. Sensors were furthermore selected such that all protein
structural levels were covered to allow for measuring multiple orthogonal at-
tributes. Selected sensors were Ultraviolet/Visible (UV/Vis) spectroscopy,
Fourier-Transform Infrared (FTIR) spectroscopy, Static Light Scattering
(SLS), and Dynamic Light Scattering (DLS). All sensors were adapted to
flow-through measurements and implemented in- or on-line. By relying on
a knowledge-based sensor selection, the sensors were applied to different
unit operations and biopharmaceuticals.
The first step in DSP is commonly a chromatographic Protein A cap-
ture. Due to the high costs of the Protein A resin, it is economically im-
portant to maximize resin utilization. During the load phase, monitoring
is however difficult as the chemical composition of the column effluent is
complex and continuously changing. UV/Vis spectroscopy demonstrated
previously a high sensitivity and selectivity for proteins even in complex
mixtures. Thus, UV/Vis spectroscopy in conjunction with Partial-Least
Squares (PLS) modeling was applied to monitor the load phase of a mono-
clonal Antibody (mAb) capture step. This approach allowed to accurately
predict the product breakthrough. Based on the predicted product concen-
tration, a process control was realized. The load step was terminated as
soon as a threshold concentration was reached.
Since UV/Vis spectroscopy is sensitive (i.e. proteins have relatively high
absorption coefficients), the method is also prone to detector saturation
at high concentrations. This poses a challenge for application of UV/Vis
spectroscopy at high protein concentrations typical during e.g. the elution
step in preparative chromatography. To address this problem, Variable
Pathlength (VP) UV/Vis spectroscopy in conjunction with PLS modeling
was investigated. While former allowed to measure UV/Vis spectra in a
significantly extended concentration range, latter allowed to predict single
protein concentrations in mixtures. The method was applied to monitor
elutions in-line of Cation-Exchange (CEX) chromatography steps at high
loading densities. First, the separation of cytochrome c from lysozyme
was observed. Second, mAb was separated from High Moleculare Weight
Variants (HMWs) and also monitored in-line. The protein concentration
predicted from the PLS model were in subsequent runs used to control the
fractionation of the run. Product was collected as long as certain purity
criteria of the produced pools were met.
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UV/Vis spectroscopy is partly so powerful for monitoring DSP, as it
measures many protein structural elements simultaneously including the
solvatization of aromatic amino acids. The solvatochromic sensitivity of
UV/Vis spectroscopy may however also be used for monitoring other chro-
mophores. In a study for monitoring the batch conjugation reaction of a
mAb with two different surrogate drugs UV/Vis spectroscopy was selected
as PAT. Changes in the solvatization of the drugs were expected during the
conjugation reaction since they move from an aqueous into a proteinous
environment. This hypothesis was tested at two scales. In a microplate
format, in situ spectral measurements were performed with a UV/Vis plate
reader. In a lab-scale setup, a Diode Array Detector (DAD) was imple-
mented on-line. Based on the acquired spectra, the conjugation could be
monitored at both scales and with both drugs.
While UV/Vis spectroscopy showed sensitivity for the primary, tertiary,
and weakly for quaternary protein structure, it did not allow to measure
the secondary structure. Furthermore, many chemicals are not absorbing
in the accessible UV/Vis spectral range. As an alternative method, FTIR
spectroscopy was explored. FTIR spectroscopy shows sensitivity for almost
any molecule which makes it an interesting method for process monitor-
ing. Furthermore, FTIR spectroscopy is a frequently used analytical tool
for assessing protein secondary structures. To evaluate FTIR spectroscopy
as a PAT for chromatography, a setup was developed with in-line Attenu-
ated Total Reflection (ATR) flowcell. With this setup, first the separation
of mAb and lysozyme was monitored. The two proteins have significant
differences in secondary structure and could thus be selectively quantified
by PLS regression. Second, the separation of different Polyethylene Glycole
(PEG) lysozyme conjugates was observed. PEG is not active in UV/Vis but
could easily be detected in Infrared (IR). Third, a process related impurity
was selectively monitored in the flow-through during the load.
Virus-Like Particles (VLPs) are promising new biopharmaceuticals with
potential applications to many diseases. To realize their full potential and
meet the necessary purity, un-enveloped VLPs need to be disassembled and
subsequently reassembled. A multimodal spectroscopic approach was cho-
sen to monitor the reassembly of Hepatitis B core Antigen (HBcAg) VLPs
by CFF. A novel experimental setup was established consisting of a com-
mercial CFF unit with custom-made on-line measurement loop and control
software. The on-line measurement loop included a UV/Vis spectrometer
and a light-scattering photometer. UV/Vis spectroscopy provided informa-
tion on the protein concentration and the solvatization of aromatic amino
acids. Hydrophobic interactions of tyrosines are essential for HBcAg assem-
bly. The change in the measured hydrophobicity by UV/Vis spectroscopy
vii
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was thus related to the rate of assembly. DLS and SLS measurements pro-
vided information on the particles sizes and concentration in solution. This
setup was used for monitoring VLP reassembly of three different constructs
each at three different Transmembrane Pressures (TMPs). The results not
only allowed to follow the VLP assembly process but also provided evidence
on adverse effects of aggregates on VLP assembly.
The last performed study focused on the data analysis of protein chro-
matograms. Most of the previously performed data analysis of protein
chromatograms relied on PLS regression. PLS regression is however a cor-
relative method requiring model calibration prior to application. Calibra-
tion as well as model maintenance can however involve significant effort.
Therefore, the final part of this thesis focused on developing a calibration-
free method for factorizing protein chromatograms. With a combination of
second-derivative spectral pretreatment and hard-constraint Multivariate
Curve Resolution (MCR), bilinear chromatograms were successfully fac-
torized into concentrations and protein spectra. The method was tested
for multiple case studies including the separation of a ternary mixture,
the simultaneous factorization of multiple binary chromatograms, and the
preparative separation of an Antibody Drug Conjugate (ADC) from the un-
conjugated mAb. The estimated elution peak shapes corresponded closely
to the measured concentration from off-line analytics. The estimated pro-
tein spectra allowed to identify the different species based on a protein spec-
tral library. In summary, the method provided a powerful calibration-free
method for factorizing protein chromatograms and may in future simplify
the analysis of bilinear protein chromatograms.
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Zusammenfassung
In der modernen Pharmazie ermöglichen biotechnologische Produkte die
Bekämpfung vieler Krankheiten, die ansonsten schwierig zu behandeln sind.
Die sogenannten Biopharmazeutika sind häufig sehr effektiv aber kompli-
ziert herzustellen. Beide Aspekte spiegeln sich im hohen Marktwert von
Biopharmazeutika wieder. Im Jahr 2016 gehörten acht der zehn umsatz-
stärksten Medikamente zur Gruppe der Biopharmazeutika. Die Produktion
der biotechnologischen Produkte findet in Bioreaktoren mittels gentech-
nisch veränderter Wirtszellen statt. Die resultierende Fermentationsbrühe
enthält aber nicht reines Produkt sondern besteht aus einer komplexen Mi-
schung aus Metaboliten, Proteinen, Desoxyribonukleinsäuren (DNS) und
Ribonukleinsäuren (RNS), die von den Wirtszellen zur Homöostase und zur
Vermehrung produziert werden. Des Weiteren entstehen während der Kulti-
vierung viele mit dem Zielprodukt verwandte Produktheterogenitäten. Die
Fermentationsbrühe kann daher nicht direkt einem Patienten verabreicht
werden. Stattdessen folgt ein zweiter Produktionsabschnitt, das sogenannte
Downstream Processing (DSP), der sich insbesondere mit der Aufreinigung
des Produktes beschäftigt.
Das DSP von Biopharmazeutika umfasst eine Reihe von Schritten zur
Aufreinigung, aber auch zur chemische Modifizierung und zur Aufkonzen-
trierung des Produktes. Häufig eingesetzte Prozessschritte sind Chroma-
tographie, Batchreaktionen und Querstromfiltration. Durch unkontrollier-
te Einflüsse während der Fermentierung und im DSP entsteht Variabilität
im finalen Biopharmazeutikum. Solch eine Variabilität ist generell uner-
wünscht, da sie sich auf die Effizienz des Biopharmazeutikums in Patienten
auswirken oder auch zu unerwarteten Nebenwirkungen führen kann. Die re-
gulatorischen Behörden und pharmazeutische Industrie haben einen syste-
matischen, wissensorientierten Ansatz gewählt, um die Produktvariabilität
zu reduzieren. Neben dem Ansatz Quality by Design (QbD) können Pro-
zess Analytische Technologien (PAT) helfen das Prozessverständnis wäh-
rend der Entwicklung und in der Produktion zu verbessern. PAT zielt darauf
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ab zeitnah zum laufenden Prozess Messungen durchzuführen, die reich an
Informationen über den Prozess sind. Idealerweise erlauben die PAT kriti-
sche Qualitätsattribute und kritische Prozessparameter zu messen. Mit den
gemessenen Daten kann dann eine verbesserte Prozesskontrolle umgesetzt
werden.
Das Ziel dieser Arbeit war es, eine vielseitig einsetzbare Auswahl an
spektroskopischen Sensoren für das DSP zu evaluieren und einzusetzen, um
verschiedene Prozessschritte und Biopharmazeutika zu überwachen. Um ei-
ne gute Sensitivität für viele kritische Qualitätsattribute und Prozesspa-
rameter zu erreichen, wurden Sensoren ausgewählt, die auf verschiedenen
physikalischen Messprinzipien beruhen. Insbesondere wurde beachtet, dass
die Sensoren die verschiedenen Strukturebenen von Proteinen abdecken um
verschiedene orthogonal Attribute messen zu können. Die gewählten Senso-
ren waren UV/Vis-Spektroskopie, Fourier-Transform-Infrarotspektroskopie
(FTIR-Spektroskopie), sowie statische und dynamische Lichtstreuung. Al-
le Sensoren wurden für Durchflussmessungen angepasst und in- oder on-
line eingesetzt. Die verwendeten Sensoren wurden in verschiedene Studien
getestet, wobei für die jeweilige Problemstellung die vielversprechendsten
Sensoren ausgewählt wurden.
Der erste Schritt im DSP von mAbs und verwandten Produkten ist
häufig eine Protein A Affinitätschromatographie. Durch die hohen Kosten
von Protein A Chromatographiemedien ist es ökonomisch wichtig, die aus-
genutzte Kapazität der Chromatographiesäule zu maximieren. Jedoch ist
besonders während der Beladung der Chromatographiesäule die Überwa-
chung des Prozesses schwierig, da die Zusammensetzung des Säuleneffluents
sehr komplex ist und sich kontinuierlich ändert. UV/Vis-Spektroskopie hat
sich bereits in früheren Studien durch die hohe Sensitivität und Selektivität
für Proteine ausgezeichnet. Für die Überwachung der Beladungsphase ei-
nes Protein A Affinitätschromatographieschrittes mit einem monoklonalen
Antikörper (engl. monoclonal Antibody – mAb) wurde deshalb UV/Vis-
Spektroskopie kombiniert mit Partial-Least Squares (PLS) Regression aus-
gewählt. Dieser Ansatz ermöglichte die genaue Vorhersage des Produkt-
durchbruches im Beladungsschritt. Basierend auf der vorhergesagten Pro-
teinkonzentrationen wurde anschließend der Prozess kontrolliert. Die Bela-
dung der Säule wurde unterbrochen, sobald die Produktkonzentration im
Durchbruch einen Grenzwert überschritten hatte.
Da UV/Vis-Spektroskopie relativ sensitiv ist (Proteine daher hohe Ab-
sorptionskoeffizienten besitzen), ist die Methode bei hohen Konzentratio-
nen auch oft von Detektorsaturierung betroffen. Dies macht es schwierig,
UV/Vis-Spektroskopie für hochkonzentrierte Lösungen einzusetzen, wie sie
zum Beispiel während der Elution bei präperativer Chromatographie auftre-
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ten können. Um dieses Problem zu reduzieren, wurde Variable-Pfadlängen
(VP) UV/Vis-Spektroskopie zusammen mit PLS Regression untersucht und
eingesetzt. Ersteres erlaubt dabei, den linearen Bereich von UV/Vis-Spek-
troskopie deutlich zu erweitern. Letzteres ermöglicht die Vorhersage von
Einzelproteinkonzentrationen in Mischungen. Diese Methode wurde zur in-
line Überwachung der Elution bei der Kationenaustauschchromatographie
bei hohen Ladungsdichten eingesetzt. Zuerst wurde die Auftrennung von
Cytochrom c und Lysozym beobachtet. Eine zweite Untersuchung befasste
sich mit der Auftrennung von mAb Proteinaggregaten von nativem mAb.
In beiden Fällen erlaubte die Methode die selektive Quantifizierung der
Proteine. In anschließenden Experimenten wurden die vorhergesagten Pro-
teinkonzentrationen der PLS Modelle dafür ausgenutzt, die Produktsamm-
lung zu kontrollieren. Dafür wurden Reinheitskriterien für den Produktpool
bestimmt. Das Produkt wurde dann solange gesammelt, wie die Reinheits-
kriterien für den Pool eingehalten wurden.
UV/Vis-Spektroskopie ist unter anderem deshalb so nützlich für die
Prozessüberwachung im DSP, weil sie viele verschiedene Strukturelemen-
te von Proteinen gleichzeitig messen kann. Dazu gehört auch die Solvati-
sierung aromatischer Aminosäuren. Die solvatochromische Sensitivität von
UV/Vis-Spektroskopie kann aber auch dafür genutzt werden andere Chro-
mophore zu überwachen. In einer Studie zur Überwachung der Batchkonju-
gierung eines mAbs mit zwei verschiedenen Ersatzwirkstoffen zu Antibody
Drug Conjugates (ADCs) wurde deshalb auch UV/Vis-Spektroskopie aus-
gewählt. Während der Konjugationsreaktion findet ein Übergang des Wirk-
stoffes vom gelösten Zustand in die Proteinumgebung statt. Dieser Über-
gang wurde mit UV/Vis-Spektroskopie gemessen und zur Überwachung des
Fortschrittes der Konjugation genutzt. Die Überwachung wurde in zwei ex-
perimentellen Maßstäben getestet. In einer Mikrotiterplatte wurden spek-
trale Messungen in situ mit einem UV/Vis-Plattenlesegerät durchgeführt.
Im Labormaßstab wurde die Batchreaktion on-line mittels eines Photodi-
odenzeilendetektors überwacht. Mit den spektralen Daten und einem PLS
Modell konnten anschließend in beiden Maßstäben und mit beiden Wirk-
stoffen der Reaktionsfortschritt überwacht werden.
Während UV/Vis-Spektroskopie die primäre, tertiäre und schwach die
quartäre Proteinstruktur messen kann, zeigte sie keine Sensitivität für die
Sekundärstruktur von Proteinen. Wichtig ist auch, dass viele Chemikalien
nicht in der zugänglichen UV/Vis-Region absorbieren. Als alternative Me-
thode wurde deshalb FTIR-Spektroskopie untersucht. FTIR-Spektroskopie
ist eine häufig eingesetzte Methode um die Sekundärstruktur von Proteinen
zu messen. Außerdem zeigt FTIR-Spektroskopie eine gewisse Sensitivität
für fast alle Moleküle. Um FTIR-Spektroskopie als PAT für Chromatogra-
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phie zu testen, wurde ein experimenteller Aufbau entwickelt, bei dem ein
FTIR-Spektrometer in-line mit Attenuated Total Reflection (ATR) Fluss-
zelle an einen präperativen Chromatographen angehängt wurde. Mit die-
sem Aufbau wurde zuerst die präperative chromatographische Trennung von
mAb und Lysozym überwacht. Die zwei Proteine unterscheiden sich stark in
der Sekundärstruktur und konnten deshalb selektiv mittels PLS Regression
quantifiziert werden. Ein zweites Experiment zielte auf die Überwachung
der präperativen Auftrennung von verschiedenen Polyethylenglycol (PEG)-
Lysozymkonjugate ab. PEG absorbiert nicht im UV/Vis-Spektrum, aber
konnte mit FTIR-Spektroskopie einfach detektiert werden. In einem drit-
ten Experiment wurde eine prozessspezifische Kontaminante während dem
Beladungsschritt selektiv überwacht und quantifiziert.
Virusartige Partikel (engl. Virus-Like Particles – VLPs) bilden eine viel-
versprechende Klasse neuartiger Biopharmazeutika mit potentiellen Anwen-
dungen für viele verschiedene Krankheiten. Damit sie ihr volles Potential
als Biopharmazeutika erreichen, müssen insbesondere VLPs ohne Hülle dis-
und anschließend reassembliert werden. Um die Reassemblierung von He-
patitis B core Antigen (HBcAg) VLPs während einer Querstromfiltration
zu überwachen, wurde ein multimodaler spektroskopischer Ansatz gewählt.
Dazu wurde ein kommerzielles Querstromfiltrationsgerät mit einem on-line
Messaufbau und einer spezialisierten Kontrollsoftware erweitert. Der on-line
Messaufbau enthielt dabei ein UV/Vis-Spektrometer und ein Lichtstreu-
messgerät. Das UV/Vis-Spektrometer maß die Proteinkonzentration und
ermöglichte die Überwachung der Solvatisierung aromatischer Aminosäu-
ren. Für die Assemblierung von HBcAg VLPs ist die hydrophobe Interak-
tion eines Tyrosinrests mit dem benachbarten Homodimer essentiell. Die
Veränderung der Solvatisierung der Tyrosinreste spiegelte deshalb die As-
semblierungsgeschwindigkeit der VLPs wieder. Dynamische und statische
Lichtstreuungsmessungen ermöglichten eine kombinierte Messung aus Pro-
teingröße und -konzentration. Dieser Versuchsaufbau wurde genutzt, um
die Reassemblierung von drei modifizierten VLP-Konstrukten bei drei ver-
schiedenen Transmembrandrücken zu überwachen. Die Resultate erlaubten
nicht nur der VLP-Assemblierung zu folgen, sondern zeigten auch, dass sich
VLP-Aggregate negativ auf die Assemblierung auswirkten.
Die letzte durchgeführte Studie untersuchte einen neuen datenanalyti-
schen Ansatz für die Auswertung von präperativen Proteinchromatogram-
men. Die meisten in dieser Arbeit durchgeführten Datenanalysen für die
Evaluierung von Proteinchromatogrammen nutzten PLS Regression. PLS
Regression ist jedoch eine korrelative Methode, muss also vor der Anwen-
dung kalibriert werden. Die Modellkalibrierung und der Unterhalt des Mo-
dells kann viel Arbeit verursachen. Deshalb wurde im letzten Teil dieser
xii
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Thesis eine kalibrierungsfreie Methode entwickelt, um Proteinchromato-
gramme in Konzentrationen und Spektren zu faktorisieren. Die Metho-
de verwendete dabei eine vorbereitende zweite Ableitung der spektralen
Daten sowie das Multivariate Curve Resolution (MCR) Verfahren mit zu-
sätzlichen Bedingungen zum Elutionsverhalten von Proteinen. Mit diesem
Ansatz konnten verschiedene bilineare Proteinchromatogramme erfolgreich
faktorisiert werden. Die Methode wurde für die Faktorisierung eines tertiä-
ren Proteinchromatogrammes, mehrerer binärer Chromatogramme und für
die Faktorisierung eines ADC-Chromatogrammes verwendet. Die geschätz-
ten Elutionskurven und die Referenzanalytik zeigten dabei sehr ähnliche
Verläufe. Durch die geschätzten Spektren konnten Proteine mittels einer
Proteinspektrenbibliotheke identifiziert werden. Zusammenfassend ermög-
licht die Methode die Analyse von Proteinchromatogrammen mit limitier-
tem Vorwissen und ist deshalb potentiell ein wertvolles Instrument für die
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Briskot1, and Jürgen Hubbuch1
1 Institute of Engineering in Life Sciences, Section IV: Biomolecular
Separation Engineering, Karlsruhe Institute of Technology (KIT),
Germany
In 2004, the United States’ Food and Drug Administration (FDA) published
Guidance for industry. PAT – A framework for innovative pharmaceutical
development, manufacturing and quality assurance [1]. Within the guid-
ance, FDA promotes the implementation of Process Analytical Technol-
ogy (PAT) into all unit operations to monitor Critical Quality Attributes
(CQAs). PAT is described as being part of process design and further-
more intended to contribute to process control, i.e. to be taken actively
into account for process decisions. While being intended for both small
molecules and biologics, the implementation into these two domains of phar-
maceuticals is advancing at different paces. In the past, PAT was adopted
more quickly in the production of small molecules. For an extensive review
thereof, the authors defer to [2]. This article will focus on biologics only.
In contrast to most small molecules, biologics are produced in living
organisms which are very sensitive to a wide variety of external factors.
Most biologics are complex proteins. They do not consist of one chemical
entity but a distribution of many species. Already slight process changes
can affect the product quality profile [3]. In order to ensure a consistent
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product quality and to reduce batch-to-batch variability, PAT for biologics
is of great interest [4]–[8]. Furthermore, current trends towards continuous
manufacturing may require an improved process control for keeping a steady
state over prolonged periods of time. Such a control may be simplified by
the possibility to monitor critical quality attributes in real-time [9].
Other advantages of PAT include the simplification of root cause anal-
ysis [10] and improvement of process understanding. Eventually, the im-
proved process understanding and real-time monitoring capabilities may
lead to the implementation of the concept of real-time release [1]. Thus,
the CQA profile of the final product can be guaranteed to lie within accept-
able quality limits solely based on real-time measurements and production
batches can be released based on this data.
Early approaches to PAT for biologics widely addressed the problem by
implementing on-line analytical chromatography. Already before the re-
lease of the PAT guidance, on-line High Performance Liquid Chromatogra-
phy (HPLC) has been used to control column loading and pooling decisions
during chromatographic purification steps [11]–[13]. Subsequently, on-line
and at-line HPLC was further used for a variety of applications [14]–[16].
Recently, at-line HPLC has been also implemented in the control of con-
tinuous chromatography equipment [17]. HPLC provides high resolution of
different species. However, it is complex regarding the required equipment,
consisting of a device for sampling as well as the chromatograph itself. This
may be undesirable in a manufacturing environment as reliability may be
an issue. Furthermore, automated sampling and the analytical separation
also lead to non-negligible time delays. Depending on the decision time of
a unit operation, this may lead to late notice of process deviations or even
completely prevent real-time monitoring.
Spectroscopy is a powerful tool for process monitoring [18]. Spectro-
scopic equipment has similar investement costs ($20k to $200k) as on-line
HPLC. Measurement times are fast, typically in the subsecond range up
to a few minutes. Furthermore, measurements can often readily be per-
formed in-line. Fast measurement times are especially important for prepar-
ative chromatography, the workhorse in current Downstream Processing
(DSP). Preparative chromatographic processes are highly non-linear and
feature sharp concentration fronts [19]. Thus, CQAs of the effluent such
as the mass fraction of impurities are quickly changing. To reliably control
such processes, the used monitoring method needs to have short response
times. Typical decision times for preparative protein chromatography lie
in the range of 30 s to several minutes. In contrast to at-line HPLC, spec-
troscopy provides signals with limited selectivity for different components.
To overcome this limitation, a combination of multivariate measurements
2
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and mathematical tools for Multivariate Data Analysis (MVDA) is gener-
ally applied to extract information from spectroscopic measurements.
Following this argumentation, this article is focusing in a first part on the
review of two widely used chemometric tools for the analysis of spectroscopic
data. Subsequently, the current state-of-art of spectroscopic PAT in DSP
is discussed.
1.1 Multivariate Data Analysis for PAT
The implementation of the PAT framework is often accompanied by the ap-
plication of multivariate mathematical approaches [1], also known as chemo-
metrics. In chemometrics, mathematical and statistical tools are used to
extract useful chemical information from large amounts of multivariate mea-
surements or raw data [20]. The multivariate nature of spectroscopic data
for PAT arises out of necessity, since no univariate process analyzer has
significant selectivity to monitor a specific CQA without interferences from
other properties [18]. Chemometrics can be used for a wide variety of tasks,
including experimental design (DoE) and MVDA [21]. The present article
does not aim to give a complete review of all elements in chemometrics, but
focuses solely on MVDA. Furthermore, only the two most common MVDA
tools in PAT are discussed more closely: Principal Component Analysis
(PCA) and Partial-Least Squares (PLS). A more thorough review of chemo-
metric tools is given in the textbook of Bakeev [18].
1.1.1 Multivariate Projection Methods
Multivariate projection (decomposition) to latent structures forms the basis
of many approaches in MVDA [22]. According to Kvalheim [23], [24], the
Latent Variables (LV) projection of a data matrix X = (~x1, ..., ~xk), with n
observations and k variables, can most easily be understood by reference
to variable and objective space, as illustrated in Figure 1.1. The former
case (Fig. 1.1a) reveals relationships between observations by plotting the
observations in a space spanned by the k variables in X. In the object
space (Fig. 1.1b), the coordinate system is defined by the n observations.
It visualizes information about the relationship between variables [23]. The
main goal of latent projection methods is to reduce the dimensions in the
variable space by summarizing variables with similar information in LVs.
All latent projection methods help getting fundamental insights into com-
plex multivariate data by (1) discovering groupings in the data, (2) data
compression, (3) regression, and more [25].The variable decomposition into
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Figure 1.1: Visualization of a data matrix X consisting of three obser-
vations with three variables in the variable space (a) and object space (b).
Observations in the variable space are projected on a latent structure de-
fined by the weight vectors ~wi, leading to the projection coordinates (scores)
~ti. Projection coordinates (loadings) of the variables in the object space are
summarized in the loading vectors ~pi.
LVs can geometrically be interpreted as a projection of the data in the vari-
able and object space on a-dimensional hyperplanes, whereby a represents
the number of LVs. Since the projection is performed in both spaces, the
maximum number of LVs is min(n, k). The projection coordinates (scores)
of the observations in the variable space on the i-th LV are summarized in
the score vector ~ti and are obtained by projecting the samples on the cor-
responding weight vector ~wi [24]. The vectors ~ti and ~wi are orthogonal and
orthonormal, respectively. Any latent projection method can be derived
over the definition of ~wi [21]. The projection coordinates (loadings) of the
variables in the object space are summarized in the loading vector ~pi. The
loading vectors ~pi are not necessarily orthogonal.
1.1.2 Principal Component Analysis
PCA is a common tool in exploratory data analysis and is used for data re-
duction, simplification, outlier detection, classification, and noise reduction
[26]. Data decomposition of a matrix X according to
X = TP T + EX (1.1)
is performed with the objective to explain as much as of the variance in X
by a linear combination of a complementary set of scores T = (~t1, ...,~ta) and
loadings P = (~p1, ..., ~pa). In order to differentiate the data decomposition
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by PCA from other latent projection methods, the LVs are referred to as
principal components (PCs). In PCA, the loadings ~pi are equal to the
weights ~wi and thus orthonormal. They give a quantitative measure of
the part of variance and observed variable shares with the PC [23]. Thus,
the whole information regarding the linear relationship between variables is
compressed in the loading matrix P . The hidden structure of X concerning
the object space can be visualized by loading plots, where the loadings ~pi are
plotted against each other [26]. Variables having similar loading values on a
PC are linear dependent (collinear) and are redundant concerning this PC.
For mean centered data, as illustrated in Fig. 1.1, collinearity between two
variables can graphically be visualized by the cosine of the angle between
the two variables in the object space. In the same manner as relationships
between variables can be illustrated by loading plots, relationships between
observations can be visualized by score plots [26]. Score plots can reveal
patterns, clusters, and outliers in the observations (measurements). Usually,
two or three PCs are already sufficient to reveal hidden patterns in X by
loading and score plots, since the most useful information (variance) in
X is explained by the first few PCs. The remaining ones are assumed to
comprise predominantly noise [26]. By neglecting these minor PCs, PCA
achieves a data simplification and noise reduction in X. Since both scores
and loadings are orthogonal, PCA is also able to reduce collinearity in X,
which is why it also plays a central role in regression analysis.
1.1.3 Partial Least Square Regression
Linear regression methods like PLS are tools in exploratory data analysis,
relating one or more response variables Y with several predictor variables
X, by a linear multivariate model
Y = XB + EY (1.2)
where B contains the regression coefficients connecting the predictor vari-
ables to the responses. The deviation between model responses and mea-
surements is summarized in the residual matrix EY . In the simplest case,
when the matrix X is of full rank, multiple linear regression (MLR) can be
applied and the regression coefficients can be obtained by the least square
solution
B = (XTX)−1XTY. (1.3)
In most PAT applications, however, the observation to variable ratio is
rather low and the X-variables are collinear and noisy. In such cases, pre-
diction abilities of MLR models can be very poor since the estimated regres-
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sion coefficients become unstable and can deviate substantially from their
expected values [27], [28].
An alternative way to determine the regression coefficients B is by us-
ing latent projection methods like principal component regression (PCR)
and PLS. In PCR the collinearity problem is solved by (1) decomposing
the predictor matrix X to orthogonal PCs and (2) regressing the responses
Y on the orthogonal scores T instead of X. The score matrix T is of full
rank and allows the prediction of stable regression coefficients. Further-
more, data decomposition prior to regression allows noise reduction and
thus the calibration of more robust models. A major drawback of PCR
is that data decomposition is performed under the objective to explain as
much as possible of the variance in X. However, the variance in X that is
relevant for the prediction of Y could be rather small in comparison with
the total variance in X. Thus, much of the relevant variance could be lost
by PCA [18].
In contrast to PCR, PLS performs a simultaneous decomposition of X
and Y with the objective to explain as much as possible of the covariance
between the data sets [29]. The decomposition of X and Y can be described
by
T = XW (1.4)
and
Y = UCT + EC (1.5)
where U = (~u1, ..., ~ua) contains the corresponding Y -scores ~ui on the i-th
latent variable, EC represents the Y -residuals, and C = (~c1, ...,~ca) denotes
the linear transformation defined by the orthogonal Y -loadings ~ci. Since
the weight matrix W is determined under the objective of maximizing co-
variance between X and Y , the scores T are good predictors of the original
data X
X = TP T + EX (1.6)
and model also the responses [30]
Y = TCT + EY . (1.7)
In contrast to PCA, weights ~wi and loadings ~pi are not equal. The orthonor-
mal weights can be considered as tilted X-loadings since they describe the
effective relationship between X and Y . Depending on how strong Y effects
W , the weights ~wi deviate more or less from the loadings ~pi [31]. The X-
loadings are not orthogonal to each other [25]. Comparing Eq. (1.2) with
Eq. (1.7) leads to the regression coefficient
B = WCT . (1.8)
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Since the regression model B is calculated from the orthogonal latent struc-
tures W and C, PLS is able to analyze data with strongly collinear, noisy,
and numerous X-variables [30].
1.2 Spectroscopy for Process Monitoring in
DSP
In the past, spectroscopic methods have been widely used as tools for
structural analysis of proteins [32]–[34]. From a biochemical point of view
the analysis of proteins can be split into the assessment of primary, sec-
ondary, tertiary and quaternary structures. Spectroscopic methods provide
information about each of these layers of abstraction within the protein
structure (cf. Figure 1.2) [32]. To assess the sequence and total concentra-
tion of protein, especially Ultraviolet/Visible (UV/Vis) spectroscopy and
Fourier-Transform Infrared (FTIR) spectroscopy are of interest. UV/Vis
spectroscopy mainly measures the primary structure, i.e. the content of aro-
matic amino acids as well as weak spectral shifts due to the solvochromatic
effects [32]. The secondary structure of proteins has been frequently mea-
sured by vibrational spectroscopy such as FTIR and Raman spectroscopy
[33], [35], [36]. The methods allow to measure the vibrational modes of the
backbone of polypeptides. The tertiary structure of proteins is accessible
over the fluorescence of the aromatic amino acids. The tryptophan emis-
sion is solvatochromatic, reacting to changes in the local polarity around
tryptophan residues [32], [34]. Thus, structural changes which affect the
local environment of tryptophan residues can be detected by fluorescence
spectroscopy. Finally, the quaternary structure of proteins, i.e. assembly
of multiple subunits or native aggregation of protein monomers, may be
assessed over the protein size by light scattering methods including Static
Light Scattering (SLS) and Dynamic Light Scattering (DLS) [4], [32].
All of the above mentioned methods are of major interest for process
monitoring as each method provides access to orthogonal information about
the product. Key aspects of the different methods have been summarized
in Table 1.1. In literature, especially UV/Vis absorption and FTIR have
been used for a variety of PAT applications (cf. Subsection 1.2.1 and 1.2.2).
Literature for fluorescence spectroscopy as well as DLS is less broad. How-
ever interesting applications exist (cf. Subsection 1.2.3). In the following
sections, the different applications will be discussed.
7




















































































































































































































































































































































































































































































































































Figure 1.2: (Continued on the following page.)
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Figure 1.2: Based on the example of ovomucoid, the four different level
of protein structure are illustrated. To each level, suitable spectroscopic
methods are listed with a short explaination of what is measured. The lists
are not extensive but rather correspond to the most promising methods in
the authors eyes. Protein structure retrieved from PDB ID: 1OVO [37], [38].
UV/Vis spectra obtained from [39].
1.2.1 UV/Vis Spectroscopy
UV/Vis spectroscopy measures the absorption of proteins generally in the
range between 240 to 340 nm. Mainly due to the content of aromatic amino
acids (phenylalanine, tyrosine, and tryptophan) proteins significantly ab-
sorb in this region (cf. Figure 1.2, primary structure) [19], [32], [39]. Due
to the sensitivity, reproducibility of signals and robustness of the spectrom-
eters, UV/Vis absorption at 280 nm is widely used as a primary detection
method of protein concentrations. While current applications mainly rely
on univariate UV/Vis measurements, it has been shown that UV/Vis spec-
tra contain a significant amount of information on proteins and may be used
for selective quantification even if only minute spectral differences exist [39].
Multivariate UV/Vis spectroscopy in conjunction with PLS modeling
for selective protein quantification first appeared in 1994 [40]. Arteaga et
al. demonstrated the quantification of the three main bovine caseins by PLS
regression on the fourth derivative UV/Vis spectra. The PLS model was cal-
ibrated based on designed mixing ratios. In contrast to latter publications
which focus on (near)-real-time assays, Areaga et al. intended the proposed
method as an off-line analytical assay. In the scope of the publication, the
method was not applied to process samples.
The first at-line application for chromatography was only reported in
2011 as a tool to circumvent the analytical bottleneck created by high
throughput experimentation [41]. Similar to Arteaga et al., a PLS model
was calibrated based on designed mixing ratios of pure protein components.
The calibrated PLS model was used to selectively quantify the protein con-
tent in elution fractions of multiple co-eluting species from miniaturized and
parallelized chromatography experiments. The results were later confirmed
by [52]. Subsequently, the method was transferred to an in-line setup with
a diode array detector and applied for a selective and real-time quantifica-
tion of 3 model proteins [42]. It was shown that the deconvoluted signal
from the detector could be directly used in a feed-forward controller to trig-
ger product pooling. Experiments were performed in diluted conditions to
prevent detector saturation.
9

































































































































































































































































































































































































































































































































































































































































































































While the above mentioned publications provided accurate predictions
of protein concentrations in multi-protein mixtures, they all relied on de-
signed mixing ratios of pure proteins. This may pose major difficulties
when calibrating a PLS model for applied examples, e.g. the purification
of a monoclonal Antibody (mAb) from its High Moleculare Weight Vari-
ants (HMWs). Brestrich et al. addressed this problem by using process
based samples for the PLS model calibration [43]. Instead of using pure
protein samples to produce designed mixing ratios, chromatographic runs
at variable conditions were performed to span a model calibration space.
The column effluent of those experiments was fractionated and analyzed by
suitable off-line analytics. They applied the newly designed method to dif-
ferent separation problems including the diluted separation of a mAb from
its impurities and the at-line measurement of different protein species in
human blood fractionation. As a supportive tool, it was applied together
with mechanistic modeling for a generic root-cause investigation for model
proteins [10]. In summary, UV/Vis spectroscopy is currently among the
most promising PAT tools for DSP.
1.2.2 FTIR Spectroscopy
FTIR spectroscopy is frequently applied as a PAT technology for small
molecule production [2]. For proteins, FTIR was first established as a tool
for assessing the secondary structure [32], [33], [35], [36]. Proteins are de-
tected by the vibration of the polypeptide backbone. Multiple vibrational
modes correspond to different detected amide bands (cf. Figure 1.2, primary
and secondary structure). The absorption of the amide bands is directly
proportional to the amount of polypeptide backbone. The most prominent
proteinogenic band, the amide I band, is mainly caused by C=O stretch-
ing. Secondary structural elements induce band shifts of the amide bands.
This phenomenon can be used to quantify the proportion of different sec-
ondary structural elements, e.g. by taking the second derivative or applying
Fourier self-deconvolution. Thus, FTIR is a promising candidate for moni-
toring the overall protein mass as well as the structural integrity of proteins
by their secondary structure. The application is however hindered by the
strong absorption of water in the same spectral region. It is a non-trivial
task to correct for the water absorption. To prevent total extinction in the
transmission cell, typical pathlengths need to be very short (approximately
5µm), which however also reduces the sensitivity towards proteins. De-
spite the existing problems, a number of promising applications have been
reported.
11
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Publications demonstrated the possibility to selectively detect mAbs,
HMWs and Host Cell Proteins (HCPs) [45], [46] with FTIR for biopharma-
ceutical applications. Experiments were performed in an at-line setup. The
approach was later extended to further downstream processing unit oper-
ations [47]. Capito et al. demonstrated the use of a calibrated PLS model
to selectively quantify mAb, HMW and HCP concentrations of samples
drawn from different unit operations. Again experiments were performed
at-line. mAb could be quantified down to concentrations of 0.7 g/l while
HMW concentrations as low as 1% [w/w] were detected.
During the refolding process of an inclusion body of an autoprotease,
FTIR was applied as an in-line PAT tool to monitor the relative content of
different secondary structural elements [48]. A time evolution of the relative
content of structural elements could be shown during the refolding process.
However, the results did not allow prediction of the refolding yield based
on the computed content of secondary structural elements.
Recently, an approach was published to monitor the in-column binding
behaviour of mAb during a Protein A capture step by FTIR [49]. A micro-
column was packed on top of an Attenuated Total Reflection (ATR) crystal.
With a PLS model, the total protein content of resin in contact with the
ATR crystal was measured over multiple process steps. The publication
showed, that the clean-in-place steps do not seem to be able to reliably
remove all bound protein. While being an interesting scientific approach,
a transfer to a larger scale system may be difficult. The proposed setup
samples the resin very locally, which may not be representative for the
overall column. Furthermore, lateral stress had to be applied to generate
an increased contact area between resin and ATR crystal. Nevertheless, the
approach shows the versatility of FTIR spectroscopy.
1.2.3 Other Spectroscopic PAT Tools
To the best of our knowledge, other spectroscopic methods have only been
studied by two articles as PAT technologies for DSP of biologics. Fluores-
cence spectroscopy was proposed as an at-line PAT tool for a chromato-
graphic purification step of a fusion protein [50]. Here, it was shown that
the fluorescence signal could be correlated with the fraction purity from an
hydrophobic interaction chromatography step separating misfolds from the
product. DLS was used to investigate the unfolding and refolding process
of a recombinant fusion protein from an inclusion body and its dependence
on a chaotropic agent [51]. Yu et al. could accurately predict the aggrega-
tion and folding state compared to reference analytics. The method was





Biopharmaceuticals provide new treatments for many diseases. Despite sig-
nificant research and development spendings of pharmaceutical companies,
the reproducible and efficient production of biopharmaceuticals remains
challenging. This is reflected by changing CQAs over different lots as well
as high manufacturing costs. A major goal of regulatory agencies and in-
dustry is therefore to improve process understanding and control. Already
in 2004, the FDA stated: “As pharmaceutical manufacturing evolves from
an art to a science and engineering based activity, application of this en-
hanced science and engineering knowledge [...] should improve the efficiency
and effectiveness of both manufacturing and regulatory decision-making.”
Next to more widely adopting risk management strategies such as Quality
by Design (QbD), the implementation of PAT is discussed.
Monitoring qualtity attribtues in biopharmaceutical processes is gener-
ally not straight-forward because proteins are highly complex molecules.
In DSP, spectroscopic PAT sensors are of special interest. They often fea-
ture fast measurement times, the possibility for in-line implementation, and
maintainable costs. Furthermore, a rich body of literature is available on
protein structure determination by spectroscopy. Spectroscopic methods
have been developed to measure the primary, secondary, tertiary and qua-
ternary structure of proteins. For process monitoring, it is also interesting
to measure the different protein structural levels. Each structural level con-
tains some orthogonal information on a protein. Accessing an additional
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structural level thus increases the selectivity of process monitoring and may
provide crucial information on a certain quality attribute. Most spectro-
scopic methods only cover a fraction of all structural information. In con-
sequence, one type of sensor may not be adequate for measuring all quality
attributes. The implementation of whole sensor arrays may however not be
feasible because of the linked investment costs. Instead, a conscious selec-
tion of different sensors or sensor combinations could be a viable solution.
This is especially important since the product portfolio of biopharmaceu-
ticals is broadening. New formats such as conjugated proteins, Virus-Like
Particles (VLPs), antibody fragments, nanobodies, and Fc-fusion proteins
are emerging, each of which may have different requirements towards a
monitoring solution.
The ultimate goal of this thesis is to provide a PAT toolbox with spec-
troscopic sensors for different DSP unit operations and products. Spec-
troscopic sensors are selected such that all levels of protein structure are
covered. The investigated sensors should permit flow-through measure-
ments to enable in- or on-line data acquisition. Software-wise, a flexible
framework with a clear, modular implementation is beneficial for an easy
addition and exchange of sensors. Thus, this thesis also includes work on a
generic software framework.
Based on literature, UV/Vis, FTIR, and light scattering methods are
potentially sensitive to a wide range of quality attributes. These techniques
also cover all levels within the protein structure. UV/Vis absorption spec-
troscopy in conjunction with MVDA has previously been shown to be a
powerful PAT tool for chromatography by measuring primary, tertiary, and
– with low sensitivity – quarternary structure. The method still needs to
be evaluated for complex mixtures typically occurring during capture steps
as well as highly concentrated protein solutions frequent during prepara-
tive elution steps. FTIR provides insight on the secondary structure of
proteins and has been applied for monitoring protein purification at-line.
In-line application promises faster measurement times and the possibility
to implement closed-loop control. Finally, to provide a sensor with high
sensitivity towards quarternary structure, DLS or SLS are evaluated. To
reflect the current trends in biopharmaceutical industries, PAT sensors are
not only tested on model proteins and mAbs but also on multiple new for-
mats, including Antibody Drug Conjugates (ADCs), PEGylated proteins,
and VLPs.
As a final topic of this thesis, Multivariate Curve Resolution (MCR) is
studied as a calibration-free method to deconvolute chromatograms. Cur-
rent approaches to spectroscopic data in protein chromatography widely
focus on statistical models such as PLS regression. However, statistical
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models require a significant amount of data for calibration. They are fur-
thermore prone to degenerate over time due to effects not attributed by
the model, such as sensor fluctuations or due to changes of the contami-
nant levels. MCR promises to extract information from spectroscopic data
without the need for extensive model calibration and can thus simplify the
application of many spectroscopic PAT tools.
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2.2 Overview of Research Papers
In this section, an overview is given of the research papers written in the
scope of this thesis. Chapter 3, 4, and 5 investigated the application of UV/
Vis spectroscopy as PAT to different DSP unit operations. In Chapter 6,
FTIR spectroscopy was implemented in-line in a preparative chromatogra-
phy system and tested for different applications. Chapter 7 applies a multi-
modal spectroscopic approach to monitoring the assembly of VLPs. Finally,
in chapter 8, the calibration-free factorization of bilinear chromatograms by
MCR is investigated. In the following, the different papers are listed with
a short summary and the respective publication status.
3. Real-time Monitoring and Control of the Load Phase of a
Protein A Capture Step
Matthias Rüdt1, Nina Brestrich1, Laura Rolinger, Jürgen Hubbuch (1 con-
tributed equally)
This manuscript investigates UV/Vis spectroscopy for monitoring the load
phase during a Protein A capture step. By combining in-line UV/Vis spec-
tral measurements and PLS regression, the break-through concentration of
mAb was estimated in real-time. Based on the predicted protein concen-
tration, the termination of the load phase was automated.
Manuscript published in Biotechnology and Bioengineering, 114, 368-373, 2017.
4. Selective Protein Quantification for Preparative Chro-
matography using Variable Pathlength UV/Vis Spec-
troscopy and Partial Least Squares Regression
Nina Brestich1, Matthias Rüdt1, Daniel Büchler, Jürgen Hubbuch (1 con-
tributed equally)
In this paper, Variable Pathlength (VP) UV/Vis spectroscopy is tested
in multiple case studies for preparative chromatography. To prevent de-
tector saturation at high protein concentrations, the optical pathlength is
dynamically reduced in VP UV/Vis spectroscopy. The approach allowed
to measure spectra at concentrations typically occurring during the elution
phase of preparative chromatography. To retrieve single component concen-
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trations from the spectral data, PLS regression was applied. The approach
was subsequently used to control product pooling.
Manuscript published in Chemical Engineering Science, 176, 157-164, 2018.
5. Monitoring of Antibody-Drug Conjugation Reactions with
UV/Vis Spectroscopy
Sebastian Andris1, Matthias Rüdt1, Jonas Rogalla, Michaela Wendeler,
Jürgen Hubbuch (1 contributed equally)
This study focuses on establishing a fast approach for monitoring the con-
jugation reaction during the production of ADCs. The applicability of UV/
Vis spectroscopy was demonstrated relating the reaction to changes in the
solvatization of chromophores. Based on the UV/Vis spectral data, the
progress of the reaction of a mAb with two different surrogate drugs could
be observed. Experiments were performed at two scales with two different
detectors to investigate the reproducibility and scalability.
Manuscript published in the Journal of Biotechnology, 288, 15-22, 2018.
6. In-line Fourier-transform Infrared Spectroscopy as a Versa-
tile Process Analytical Technology in Preparative Protein
Chromatography
Steffen Großhans1, Matthias Rüdt1, Adrian Sanden1, Nina Brestrich,
Josefine Morgenstern, Stefan Heissler, Jürgen Hubbuch (1 contributed
equally)
FTIR spectroscopy provides orthogonal information compared to the more
common monitoring methods in DSP. So far, it has however never been im-
plemented in-line for preparative protein chromatography. Here, a custom-
made setup was realized and applied to multiple studies with industrial
relevance. Next to monitoring the elution of Polyethylene Glycole (PEG)-
modified species, the method was used for selective protein quantification
based on differences in the secondary structure. Finally, in-line FTIR was
used to selectively quantify a process-related impurity.
Manuscript published in the Journal of Chromatography A, 1547, 37-44, 2018.
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7. Process Monitoring of Virus-Like Particle Reassembly by
Diafiltration with UV/Vis and Spectroscopy Light Scatter-
ing
Matthias Rüdt1, Philipp Vormittag1, Nils Hillebrandt, Jürgen Hubbuch
(1 contributed equally)
VLPs are promising new biopharmaceuticals for many applications. To
achieve their full potential, they need to be dis- and reassembled in vitro.
This study established a new experimental setup with multimodal spec-
troscopic sensors to enable a holistic monitoring of the assembly process
by diafiltration. UV/Vis spectroscopy allowed to measure the protein con-
centration and monitor the VLP tertiary structure. The VLP quaternary
structure was observed by SLS and DLS. Based on the rich information
provided by the sensors, aggregate inhibition of VLP assembly was iden-
tified as a potential bottleneck of the unit operation. To realize real-time
monitoring of the VLP concentration, a PLS model was calibrated on the
UV/Vis spectral data.
Manuscript under review.
8. Factorization of Preparative Protein Chromatograms with
Hard-Constraint Multivariate Curve Resolution and Second
Derivative Pretreatment
Matthias Rüdt, Sebastian Andris, Robin Schiemer, Jürgen Hubbuch
In this study, the application of MCR is investigated for the factoriza-
tion of preparative protein chromatograms. Currently, PAT for protein
chromatography only focuses on calibrated statistical models. This study
demonstrates the applicability of hard-constraint MCR for evaluating this
type of data. To increase spectral differences between proteins and reduce
spectral drifts, MCR was extended to deal with second derivative data.
The method was tested in multiple case studies and the results compared
to reference data.




Control of the Load Phase of a
Protein A Capture Step
Matthias Rüdt∗,1, Nina Brestrich∗,1, Laura Rolinger1, Jürgen
Hubbuch1
* Contributed equally
1 Institute of Engineering in Life Sciences, Section IV: Biomolecular
Separation Engineering, Karlsruhe Institute of Technology (KIT),
Germany
Abstract
The load phase in preparative Protein A capture steps is commonly not
controlled in real-time. The load volume is generally based on an off-line
quantification of the mAb prior to loading and on a conservative column ca-
pacity determined by resin-life time studies. While this results in a reduced
productivity in batch mode, the bottleneck of suitable real-time analytics
has to be overcome in order to enable continuous mAb purification. In this
study, PLS modeling on UV/Vis absorption spectra was applied to quan-
tify mAb in the effluent of a Protein A capture step during the load phase.
A PLS model based on several breakthrough curves with variable mAb
titers in the harvested cell culture fluid was successfully calibrated. The
PLS model predicted the mAb concentrations in the effluent of a validation
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experiment with a Root Mean Square Error (RMSE) of 0.06mg/ml. The
information was applied to automatically terminate the load phase, when
a product breakthrough of 1.5mg/ml was reached. In a second part of the
study, the sensitivity of the method was further increased by only consid-
ering small mAb concentrations in the calibration and by subtracting an
impurity background signal. The resulting PLS model exhibited a RMSE
of prediction of 0.01mg/ml and was successfully applied to terminate the
load phase, when a product breakthrough of 0.15mg/ml was achieved. The
proposed method has hence potential for the real-time monitoring and con-
trol of capture steps at large scale production. This might enhance the
resin capacity utilization, eliminate time-consuming off-line analytics, and
contribute to the realization of continuous processing.
3.1 Introduction
A capture step is the first unit operation in the protein purification process
which is used to bind the target protein from crude Harvested Cell Culture
Fluid (HCCF). It increases product concentration as well as purity and
prevents proteolytic degradation. Due to its high selectivity, Protein A
capture is widely used in current mAb purification platform processes [53]–
[57].
A difficulty in Protein A capture is a lack of real-time analytics for mAb
quantification in the HCCF and in the column effluent during loading. As
both the mAb and impurities contribute to the absorption at 280 nm (A280),
single wavelength measurements are not suitable as selective analytics [58].
To determine the mAb titer in the HCCF, elaborate off-line analytics is
commonly performed [12], [13]. As mAb titers are influenced by variability
in the cell culture, this off-line analytics has to be repeated for every lot in
order to adapt the load volume onto the column [12]. While this results in
a reduced productivity in batch mode, the bottleneck of suitable real-time
analytics has to be overcome to enable continuous mAb purification.
In addition to the mAb titer in the HCCF, the optimal load volume onto
the column is also influenced by the resin capacity. Due to leaching and
degradation of the Protein A ligands as well as pore and ligand blocking by
leftover impurities or product, the capacity of the resin decreases over cylce
time [59]. In batch mode, a conservative loading is commonly applied to
avoid breakthrough of the expensive product at the cost of productivity. In
contrast to that, columns are overloaded in continuous mode to maximize
productivity [60]. In this case, the determination of the the percentual
product breakthrough is necessary for process control [61].
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To perform (near) real-time process monitoring and control, several PAT
tools have been developed to enable fast mAb quantification in the cell cul-
ture fluid and in the column effluent during loading. For instance, at-line
mid-IR spectroscopy in combination with multivariate data analysis has
been applied for secreted mAb quantification during a Chinese Hamster
Ovary (CHO) cell culture process [62]. Selective mAb quantification in up-
stream processing was also successfully realized by at-line matrix-assisted
laser desorption/ionization mass spectrometry [63]. For the control of the
load phase of a two column continuous protein A chromatography process,
which was connected to a CHO perfusion culture, at-line analytical chro-
matography was applied [64]. At-line monitoring however bears the risk of
human errors resulting in contamination, time-delays, or missing data.
In order to minimize human impact, automated sampling can be ap-
plied. Automated analytical chromatography has been used in upstream
processing to monitor the mAb titers [65]–[67]. In downstream processing,
this technique was successfully used for mAb quantification in the column
effluent during the load phase of Protein A chromatography. As soon as
1% mAb breakthrough was detected, the load phase was automatically ter-
minated [12]. Automated analytical chromatography is relatively easy to
develop and equipment is commercially available. However, the equipment
is expensive and the technique error-prone. Besides from the risk of con-
tamination, the time delay between sampling and analytical results bears
the risk of late reaction or requires a slow-down of the process.
PAT tools that operate in real-time, such as Ultraviolet (UV)-based
methods, overcome these limitations. In a patent application, a UV-based
control method for determining binding capacities in Protein A capture was
disclosed [68]. The method is based on the calculation of a difference signal
between two detectors situated at the column in- and outlet. During the
load phase, the post column signal is supposed to stabilize and is referred
to as impurity baseline. As soon as the mAb breaks through, there is an
increase in the post-column UV signal above the impurity baseline which
corresponds to a breakthrough level of the product. Consequently, the
method is very suitable for determining column switching times in continu-
ous Protein A capture. It allows for an equal loading in terms of percentual
breakthrough regardless of the mAb titer variability in the feed or decreas-
ing column capacities. However, it requires two detectors posing a risk of
unequal detector drifts. A further limitation might be displacement effects
of contaminants that prevent a stabilized impurity baseline. The technique
might also be limited to the equipment of the future patent holder.
Another recently published UV/Vis-based method for monitoring and
control in protein chromatography applies UV/Vis absorption spectra in-
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stead of single wavelength measurements [42], [43]. Different protein species
exhibit distinct variations in their UV absorption spectra. Consequently,
PLS technique has been used to correlate absorption spectra with selective
protein concentrations. The method was successfully applied for a selective
in-line protein quantification and for product purity-based pooling decisions
in real-time. However, no load control in Protein A chromatography has
been performed so far using this technique.
In this study, PLS models correlating UV/Vis absorption spectra with
mAb concentrations were applied for real-time monitoring and control of
the load phase in Protein A chromatography. In contrast to previous pub-
lications in this field, this application requires the monitoring of one pro-
tein in the background of many protein and non protein-based contami-
nants. For the PLS model calibration, several breakthrough experiments
were performed and the corresponding absorption spectra of the effluent
were acquired. In order to generate variable mixing ratios of mAb and
contaminants for a PLS model training data set, experiments with variable
mAb titers in the feed were performed. The column effluent was collected
in fractions and analyzed using analytical Protein A chromatography. The
recorded absorption spectra were averaged according to the fraction time
and correlated with the determined mAb concentrations using PLS tech-
nique. The PLS model was eventually applied for a real-time control of the
load phase and terminated loading, when 5% or 50% product breakthrough
was reached.
3.2 Materials and Methods
3.2.1 Cell Culture Fluid and Buffers
HCCF and mock were obtained from Lek Pharmaceuticals d.d. (Mengeš,
Slovenia) and stored at −80◦C before experimentation. The HCCF and
mock were filtered with a cellulose acetate filter with a pore size of 0.22µm
(Pall, Port Washington, NY, USA) before use. In order to achieve a variable
mAb concentration in the feed, the HCCF was diluted with mock.
For all preparative runs, the following buffers were applied: Equilibra-
tion with 25mM tris and 0.1M sodium chloride at pH 7.4, wash with 1M
tris and 0.5M potassium chloride at pH 7.4, elution with 20mM citric acid
at pH 3.6, sanitization with 50mM sodium hydroxide and 1M sodium chlo-
ride, and storage with 10mM sodium phosphate, 130mM sodium chloride,
20% ethanol.
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For analytical Protein A chromatography, column equilibration was car-
ried out using a buffer with 10mM phosphate (from sodium phosphate and
potassium phosphate) with 0.65M sodium ions (from sodium chloride and
potassium chloride) at pH 7.1. Elution was performed with the same buffer,
but titrated to pH 2.6 with hydrochloric acid. All buffer components were
purchased from VWR, West Chester, USA. The buffers were prepared with
Ultrapure Water (PURELAB Ultra, ELGA LabWater, Viola Water Tech-
nologies, Saint-Maurice, France), filtrated with a cellulose acetate filter with
a pore size of 0.22µm (Pall), and degassed by sonification.
3.2.2 Chromatographic Instrumentation
All preparative runs were realized with an Akta Pure 25 purification sys-
tem controlled with Unicorn 6.4.1 (GE Healthcare, Chalfont St Giles, UK).
The system was equipped with a sample pump S9, a fraction collector F9-
C, a column valve kit (V9-C, for up to 5 columns), a UV-monitor U9-M
(2mm pathlength), a conductivity monitor C9, and an I/O-box E9. Addi-
tionally, an UltiMate 3000 Diode Array Detector (DAD) equipped with a
semi-preparative flow cell (0.4mm optical pathlength) and operated with
Chromeleon 6.8 (Thermo Fisher Scientific, Waltham, USA) was connected
to the Akta Pure. The DAD was positioned between the conductivity mon-
itor and the fraction collector.
The communication between Unicorn and Chromeleon was implemented
analogous to the protocol published in [42]. Shortly, Unicorn triggers the
DAD data acquisition by sending a digital signal to a Matlab script (Math-
Works, Natick, USA), which communicates with Chromeleon via a Visual
Basics for Application Macro (Microsoft, Redmond, USA). If a certain con-
dition such as a defined mAb concentration is fulfilled, the Matlab script
sends a signal back to Unicorn to terminate a phase in the chromatographic
method.
Reference analysis of collected fractions was performed using a Dionex
UltiMate 3000 rapid separation liquid chromatography system (Thermo
Fisher Scientific). The system was composed of a HPG-3400RS pump, a
WPS-3000 analytical autosampler, a TCC-3000RS column thermostat, and
a DAD-3000RS detector.
3.2.3 Chromatography Runs
In order to generate variable mixtures between mAb and impurities for the
PLS model calibration and validation, breakthrough experiments with vari-
able mAb titers in the feed were performed. The mAb titers in the different
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experiments were 2.7, 2.85, 3, 3.15, and 3.3mg/ml. For each experiment,
a Sartobind 2ml Protein A membrane (Sartorius, Göttingen, Germany)
was first equilibrated for 3 membrane volumes (MVs) and then loaded with
33.15mg of mAb. At the beginning of the load phase, the DAD was trig-
gered to record absorption spectra between 200-410 nm and the membrane
flow-through was collected in 200µl fractions. After a first wash with equi-
libration buffer for 4.5MVs, the membrane was flushed with wash buffer for
5.5MVs and with equilibration buffer for 4.5MVs. Elution was carried out
for 5MVs followed by a re-equilibration of 1.5MVs. Eventually, the column
was sanitized for 5MVs and, between the runs, kept in the storage buffer.
The flow rate was 1ml/min for all phases and experiments.
3.2.4 Analytical Chromatography
As displayed in Figure 3.1, the collected fractions of all runs were examined
by analytical Protein A chromatography to obtain the mAb concentrations.
For each sample, a 2.1x30mm POROS prepacked Protein A column (Ap-
plied Biosystems, Foster City, USA) was equilibrated with 2.6 column vol-
umes (CVs) of equilibration buffer, flowed by an injection of 20 µl sample.
The column was then equilibrated with 0.8CVs of equilibration buffer and
eluted with 1.4CVs of elution buffer. The flow rate was 2ml/min for all
phases and experiments.
3.2.5 Data Analysis
For the correlation of the absorption spectra with the mAb concentrations,
PLS technique was applied using SIMCA (MKS Data Analytics Solutions,
Umeå, Sweden). SIMCA applies the NIPALS-algorithm for PLS. Before
performing PLS, all spectra were preprocessed by mean centering using
SIMCA. PLS finds variation in the spectral data matrix, which is relevant
for the correlation with the mAb concentrations and thereby separates in-
formation in the matrix from detector noise [22], [69], [70]. In order to
achieve this separation, collinearity in the data is reduced by summarizing
variables (here wavelengths) with similar information in LVs. This is done
in a way such that the content of relevant information for the correlation
included in each LV is highest for the first LV and decreases for the follow-
ing ones. The number of applied LVs in a PLS model is hence a measure
of data reduction and only a few LVs are required to obtain the correlation
between absorption spectra and mAb concentrations.
24

























































































Figure 3.1: Experimental procedure for the PLS model calibration: For
each calibration run, 200µl fractions were collected and analyzed by analyt-
ical Protein A chromatography to obtain the mAb breakthrough curves. In
addition, averaged spectra corresponding to the fraction size were calculated
from the time, wavelength, and absorption 3D-field. Averaged spectra and
mAb concentrations were eventually correlated using PLS technique.
The number of applied LVs has to be evaluated thoroughly to avoid
under- or overfitting of a model. In order to determine a reasonable number
of LVs, the root mean square error (RMSE) for the prediction of validation
samples is usually determined in dependence on the number of LVs applied
in a PLS model. The minimum corresponds to the optimal number of
LVs. In this study, cross validation was performed to determine an optimal
number of LVs. Therefore, the calibration data was separated into seven
groups. One group was then excluded during model calibration and the
RMSE for theses samples was calculated subsequently. For every number of
LVs, this procedure was performed until each group was excluded. Based on
the so obtained number of LVs, completely independent runs were predicted
to evaluate the final models.
A first PLS model calibration was based on the results of the runs with
the following mAb titers in the feed: 2.7, 2.85, 3.15, and 3.3mg/ml. The
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results of the corresponding spectral acquisitions are time, wavelength and
absorption 3D-fields. The 3D-fields were averaged in time according to the
fraction duration as displayed in Figure 3.1. The results of theses calcula-
tions were stored in an absorption matrix. Afterwards, PLS was carried
out to correlate the mAb concentrations of the collected fractions with the
the corresponding absorption matrix. For lower protein concentrations, a
second PLS model was calibrated. Only samples with mAb concentra-
tions below 0.5mg/ml were considered in the model calibration. For those
samples, a background subtraction was performed. As soon as the change
in absorption signal after impurity breakthrough fell under a predefined
threshold, an average absorption was calculated for every wavelength. This
impurity background was subtracted from the absorption of all following
data points.
3.2.6 Real-Time Monitoring and Control
The first calibrated PLS model was subsequently applied for a real-time
monitoring of the mAb concentrations in a run with a mAb titer of 3mg/ml
in the feed. While the calibration of the PLS model was performed using
averaged spectra, predictions were based on the 3D-fields. This means that
the a spectrum at each time point was applied to predict the mAb concen-
trations. The absorption spectra of the effluent were recorded and trans-
lated into mAb concentrations in real-time by the calibrated PLS model.
The calculation of the mAb concentrations was executed in Matlab. In a
first run, a stop criterion of 1.5 mg/ml mAb concentration (50% product
breakthrough) was set in the Matlab evaluation script. As soon as the
termination criterion was reached, a digital signal was send from Matlab
to Unicorn and the load phase was terminated. In a second run, the stop
criterion to terminate the load phase was set to a target concentration of
0.15mg/ml (5% product breakthrough). For this condition, the second
PLS model was used.
3.3 Results and Discussion
As described above, the breakthrough of mAb was monitored in real-time by
UV/Vis spectroscopy in combination with a PLS model. To calibrate the
PLS model, 4 chromatographic runs at mAb concentrations of 2.7, 2.85,
3.15 and 3.3mg/ml in the feed were performed and analyzed by off-line
analytics. The model was eventually confirmed by performing a real-time
control of two runs with a mAb titer of 3mg/ml. The difference in the
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mAb titers in the feed ensured variable mixing ratios between product and
contaminants. This was done to imitate variability in upstream processing
and to span a calibrated design space for the PLS model.
3.3.1 PLS Model Calibration
The results of the model calibration are illustrated by Figure 3.2. It com-
pares the A280 (recorded at a pathlength of 0.4mm and displayed as dashed
black line) to the concentrations measured by off-line analytics (blue bars)
and the signal calculated by the calibrated PLS model (solid red lines). The
number of LVs was set to 4 based on a minimal RMSE of 0.08mg/ml in the
cross validation. The calibrated PLS model was applied to evaluate all 3D-
fields. In contrast to model calibration, where averaged spectra were used,
the spectral raw data at each time point was translated into concentrations.
The estimated concentrations by the PLS model closely follow the measured
values by off-line analytics. It is worth noting that no clear plateau of the
A280 is reached after the breakthrough of media components. Instead, the
A280 continuous to increase. This may be caused by different impurities
being retained differently on the membrane. Indeed, it has previously been
shown, that major interactions between HCPs, the stationary phase and
mAbs may occure [71], [72]. The advent of mAb breakthrough cannot be
clearly distinguished from A280 alone. Based on the multivariate spectral
data, the PLS model is able to predict protein concentrations, which allows
for real-time monitoring and control.
3.3.2 Real-Time Monitoring and Control
For the confirmation of the obtained results, the calibrated PLS model was
used to control the load phase of a Protein A capture step in real-time.
In a first run, a target breakthrough concentration of 1.5mg/ml was set,
which corresponds to 50% product breakthrough. Figure 3.3A shows the
A280 (dashed black line), the real-time prediction of mAb concentrations
(solid red line) and the corresponding off-line analytics (blue bars). The
model reached an RMSE for prediction of 0.06mg/ml compared to the
off-line analytics. This approach may be of interest for controlling a con-
tinuous chromatography system. In this context, the prediction of lower
mAb concentrations is not so crucial.For a possible application in batch
chromatography, the sensitivity of the model was further improved. A sec-
ond PLS model was hence calibrated based on the calibration data set as
described in the method section. The recalibration was performed to in-
crease the sensitivity in the given concentration range. It was noticed, that
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Figure 3.2: Results of the PLS model calibration. The A280 (measured
at a pathlength of 0.4mm and displayed as dashed black line) is compared
with the results of the off-line analytics for mAb quantification (blue bars).
The PLS model prediction is illustrated as red lines. The four runs exhibited
variable mAb titers in the feed A: 3.3mg/ml, B: 3.15mg/ml, C: 2.85mg/ml,
D: 2.7mg/ml.







































































Figure 3.3: Results of the model evaluation by performing a real-time con-
trol of the load phase using a mAb titer of 3mg/ml in the feed. The PLS
model prediction (red lines) is compared with the results of the off-line an-
alytics (blue bars) as well as the A280 (measured at a pathlength of 0.4mm
and displayed as dashed black line). The load phase was automatically ter-
minated, when a mAb concentration in the effluent of A: 1.5mg/ml or B:
0.15mg/ml was reached. The sudden decrease in the A280 arises from the
background subtraction.
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it is difficult to accurately calibrate a PLS model for broad concentration
ranges. By reducing the concentration calibration range, smaller RMSE
values could be achieved. The model was used predict and stop a load
phase in a second run at 0.15mg/ml, which corresponds to 5% product
breakthrough. The results of this second run are displayed in Figure 3.3B.
As an impurity background was subtracted to increase the sensitivity of the
method, the A280 suddenly decreases. The second PLS model reached an
RMSE for prediction of 0.01mg/ml.
During both runs, the respective load phases were successfully termi-
nated close to the intended breakpoints. In Table 3.1, a summary of in-
tended and measured mAb concentrations in the last fraction of both con-
firmation runs is shown. The Matlab script sent a digital signal to Unicorn
and terminated the load phase, when the targeted breakthrough concen-
tration was reached. As the targeted breakthrough set points were con-
centrations at discrete time points, they are expected to be slightly higher
than the concentrations of the last fraction determined by off-line analytics.
This was observed for both confirmation runs (cf. Table 3.1). For an easier
comparison between model and off-line analytics, a concentration based on
an averaged absorption spectrum was calculated for the last fractions of
both runs and compared with the corresponding off-line analytics. For the
first run, the deviation between prediction and reference was 8.0%, while
for the second run a deviation of 2.3% was found. This demonstrates that
the described method can be successfully used to control the load phase in
a Protein A capture step.
Table 3.1: Results of both confirmation runs: The targeted concentration
to terminate loading is compared with the mAb concentration in the last
fraction determined by off-line analytics. In addition, a PLS model prediction
for the last fraction based on an averaged absorption spectrum is shown for
comparison.
ctarget [mg/ml] canalytics [mg/ml] cmean,PLS [mg/ml]
1.5 1.36 1.469
0.15 0.129 0.126
3.4 Conclusion and Outlook
A real-time monitoring and control of the load phase in a Protein A capture
step was successfully realized in this study. It was demonstrated that PLS
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modelling on UV/Vis absorption spectra can be applied to quantify mAb in
the effluent during the load phase despite of the background of many protein
and non protein-based impurities. Based on the quantification, the load
phase was automatically terminated, when a product breakthrough con-
centration of 1.5mg/ml or 0.15mg/ml was reached. Consequently, the pro-
posed method has potential for the monitoring and control of capture steps
at large scale production. In batch chromatography, the loading volume
may be defined dynamically to allow for increased resin capacity utilization
while still keeping the product loss small. Additionally, time-consuming
off-line determination of the mAb titer in HCCF could be eliminated. The
method may also be interesting for controlling column switching times in
continuous chromatographic capture steps. Future challenges are especially
related to the scale up and robustness of the method. Regarding the latter,
especially upstream variations should be calibrated into the PLS model.
Research will now focus on the migration of the method to the control of
continuous capture steps.
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Abstract
In preparative protein chromatography, broad dynamic ranges of protein
concentrations as well as co-elution of product and impurities are common.
Despite being the standard in biopharmaceutical production, monitoring of
preparative chromatography is generally limited to surrogate signals, e.g.
UV absorbance at 280 nm. To address this problem, VP spectroscopy in
conjunction with PLS was used to monitor preparative chromatography.
While VP spectroscopy enabled the acquisition of absorbance data for a
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broad concentration range, PLS modeling allowed for the differentiation
between the protein species. The approach was first implemented for mon-
itoring the separation of lysozyme from cytochrome c at an overall loading
density of 92 g/L. The same method was then applied to the polishing
step of a mAb at 40 g/L loading density. For PLS model prediction of the
mAb monomer and the HMWs, the RMSE was 1.07 g/L and 0.42 g/L re-
spectively. To demonstrate the usability of the approach for in-line control,
pooling decisions for both separation problems were subsequently taken
based on the computed concentrations or thereof derived purities. In sum-
mary, VP spectroscopy in conjunction with PLS modeling is a promising
option for in-line monitoring and control of future chromatography steps at
large scale.
4.1 Introduction
In current purification processes of biopharmaceuticals, preparative liquid
chromatography is key for separating the target product from media com-
ponents, Deoxyribonucleic Acid (DNA), host cell proteins, and product
related impurities [19]. The method is used because of its high separative
power while minimizing product loss. Despite being the standard, monitor-
ing of preparative chromatography is generally limited to surrogate signals,
e.g. UV absorbance at 280 nm. The PAT initiative of the US FDA however
promotes the acquisition of critical quality attributes in (near) real-time [1].
Especially for chromatography, PAT is an active field of research [8], [73].
Preparative chromatographic processes are generally run at high load-
ing densities to realize efficient processes [19]. High loading densities sub-
sequently lead to a broad range of protein concentrations eluting from the
column. Thus, monitoring techniques must feature a broad dynamic range
to capture the peak concentration as well as lower concentrated impurities
in the peak flanks. Furthermore, due to the limited resolution of prepara-
tive chromatography, baseline separation between product and impurities
is rarely achieved. PAT techniques should therefore selectively quantify the
product and the main impurities. Due to the rapid changes in chromatog-
raphy, the typical decision time within chromatographic processes is limited
[73], [74].
In literature, a number of different approaches have been proposed for
(near) real-time monitoring of chromatography. On-line monitoring and
control of preparative chromatography has been realized by automated sam-
pling and subsequent analysis by high performance liquid chromatography
[11], [16], [75]. The broad concentration ranges in preparative liquid chro-
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matography can be managed easily by varying injection volumes. Disad-
vantages comprise time delay due to sample handling and assay times as
well as the risk of contamination.
FTIR spectroscopy has been applied for at-line monitoring of down-
stream processes [62]. Samples were taken at various stages of downstream
processing, dried and subsequently measured by FTIR. The method allowed
to quantify product, high molecular weight variants (HMWs), and host cell
proteins over a broad range of concentrations. Despite showing promising
results, at-line measurements bear the risk of introducing operator errors
and may increase the risk of contamination. Furthermore, the delay due
to sample handling and measuring times may be too long for the typical
decision times in chromatography.
Previously, UV/Vis spectroscopy has been proposed as a method for in-
line monitoring of chromatographic processes [42], [43], [76]. Its usefulness
was shown for multicomponent mixtures of model proteins and for real-life
separation problems. Based on UV/Vis spectral data and PLS modeling,
process decisions were taken such as the beginning and end of product
pooling. Other applications include high throughput process development
[41], [77] and coupling with chromatography modeling [10]. While being
very fast and accurate, previous applications of in-line monitoring using
UV/Vis spectroscopy only took process decisions for separation problems
in diluted conditions. The problem of broad concentration ranges occurring
in preparative liquid chromatography was not addressed.
To increase the dynamic range of spectroscopic acquisitions, measure-
ment cells have been designed which allow to continuously change the opti-
cal pathlength to achieve ideal sensitivity for virtually any analyte concen-
tration [78], [79]. This approach in conjunction with PLS modeling was later
successfully applied for monitoring the chemical oxygen demand of wastew-
ater [80]. The methodology has also been further developed by a commercial
vendor for protein related applications. With the commercialized product,
spectra of proteins were acquired at a broad range of concentrations [81].
Samples were studied for spectral effects of protein-protein interactions in
UV/Vis with protein concentrations up to 250 g/L. Recently, an additional
product line has been launched for in-line VP measurements. The device
is theoretically able to provide measurement results up to absorbances of
approximately 80AU/mm corresponding to a mAb concentration of almost
600 g/L.
In this publication, we demonstrate in-line monitoring of preparative
chromatography runs by UV/Vis VP spectroscopy in conjunction with PLS
modeling. While VP spectroscopy allowed to monitor chromatographic pro-
cesses at almost arbitrary protein concentrations, PLS models selectively
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quantified multiple co-eluting species from spectral data. The approach
was first implemented for the separation of a mixture of the model proteins
lysozyme (lys) and cytochrome c (cyt c) at high loading densities. Former
was considered the product, latter the contaminant with high respectively
low concentration in the feed. Subsequently, a preparative polishing step of
mAb monomer and its HMWs was monitored. To demonstrate the useful-
ness of this approach for process control, the pooling of products in both
separation problems was controlled in-line based on either the predicted
concentrations of eluting proteins for the model system or on the calcu-
lated purity for the mAb purification.
4.2 Materials and Methods
In both studies, cation exchange chromatography runs with different gra-
dient lengths were executed for PLS model calibration and confirmation.
Thereby, different mixing ratios and concentrations of proteins were ob-
tained in order to span a calibration space for the PLS models.
4.2.1 Chromatography Instrumentation
All preparative chromatography experiments were performed on an ÄKTA
Pure 25 system equipped with a sample pump S9, a fraction collector F9-
C, a column valve kit (V9-C, for up to 5 columns), a UV-monitor U9-M
(2mm pathlength), a conductivity monitor C9, and an I/O-box E9. The
system was controlled with Unicorn 6.4.1. (all GE Healthcare, Chalfont
St Giles, UK). The column effluent was monitored using a FlowVPE VP
UV/Vis spectrometer (C Technologies, Bridgewater, US). It was integrated
into the flow path of the ÄKTA system between the conductivity monitor
and fraction collector.
The reference analytics of collected fractions was performed using a
UltiMate 3000 rapid separation liquid chromatography system (Thermo
Fisher Scientific, Waltham, US). The system was composed of a HPG-
3400RS pump, a WPS-3000 analytical autosampler, a TCC-3000RS column
thermostat, and a DAD-3000RS detector.
4.2.2 VP Spectroscopy
The FlowVPE VP spectrometer uses a mobile optical fiber to change the
pathlength L of the flow cell (cf. Figure 4.1). A VP measurement cycle
consists of a screening phase and a subsequent acquisition phase. During
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the screening phase, optimal pathlengths for the acquisition phase are esti-
mated based on 3 measurements at Ls ∈ {5, 25, 100} µm at 280 nm. During
the acquisition phase, absorbances Aw,i are measured at five different path-
lengths i ∈ {1, . . . , 5} for each wavelength of interest w. Based on the
Lambert-Beer law, a linear correlation is assumed between the absorbance
estimate Ãw and the pathlength L (Equation (4.1)). By solving the least
squares problem in Equation (4.2), slope mw and intercept bw of the regres-
sion are estimated.






Aw,i − Ãw(Li; bw,mw)
)2
(4.2)
As slope spectra are obtained during a whole chromatography run, the
result of an experiment is a point set in (time, wavelength, slope), thus a 3-
dimensional chromatogram. By equating Equation (4.1) and the Lambert-





This shows, that the obtained slope spectra are correlated with the protein
concentrations C over the absorbance coefficients εw. Since only the slopes
are of interest, the fiber offset has no impact on the final result. Generally,
for mid-UV spectra measurement cycles take approximately 30 s.
4.2.3 Case Study I: Separation of Cyt c from Lys
Proteins and Buffers
As model system, a protein mixture consisting of lys from hen egg white and
cyt c from equine heart was used (both Sigma-Aldrich, St. Louis, US). For
the preparative runs, the equilibration buffer was 20mM sodium phosphate
(pH 7). Elution was carried out with 20mM sodium phosphate and 500mM
sodium chloride (pH 7). For the in-line pooling decision, the sodium chloride
concentration was increased to 550mM to simulate a process disturbance.
For reference analytics (analytical Cation-Exchange (CEX)), equilibration
was performed with 20mM Tris (pH 8) and elution was carried out with
20mM Tris and 700mM sodium chloride (pH 8). All buffer components
were purchased from VWR, West Chester, US. The buffers were prepared
with Ultrapure Water (PURELAB Ultra, ELGA LabWater, Viola Water
Technologies, Saint-Maurice, France), filtrated with a cellulose acetate filter
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Figure 4.1: VP spectroscopy in chromatography: Each measurement cycle,
variable pathlengths L are set by actuating the optical fiber of the FlowVPE.
After the screening phase for the identification of the optimal measurement
pathlengths, UV absorbance spectra at five different pathlengths are ac-
quired. The slope mw is calculated for each wavelength giving a slope spec-
trum. For a whole chromatography run, this results in a 3-dimensional chro-
matogram in (time, wavelength, slope).
with a pore size of 0.22 µm (Pall, Port Washington, US), and degassed by
sonification before usage.
Chromatography Runs
A HiTrap 16mm× 25mm column prepacked with SP Sepharose FF (GE
Healthcare) was first equilibrated for 5CV and then loaded with 418mg lys
and 41.8mg cyt c. After a wash of 1CV with equilibration buffer, the pro-
teins were eluted by performing a linear gradient from 0% to 100% elution
buffer. The gradient length was 2CV, 4CV, 6CV, and 8CV. While the
results of the runs with gradient lengths 2CV, 4CV, and 8CV were applied
for the PLS model calibration, the run with a gradient length of 6CV was
used to confirm the model. At the beginning of each linear gradient, data
acquisition of the FlowVPE was started and slope spectra from 240 nm to
300 nm with 2 nm resolution were obtained. After the linear gradient elu-
tion, the column was regenerated for 3CV with the elution buffer. The flow
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rate was kept constant at 0.5mL/min for all steps and experiments. During
the elution and regeneration, 1000 µL fractions were collected in deep well
plates (VWR).
Reference Analytics
The collected fractions were analyzed by analytical cation exchange chro-
matography. For each injection, the Proswift SCX-1S 4.6mm× 50mm col-
umn (Thermo Fisher Scientific) was first equilibrated for 2min, loaded with
sample, washed for 0.5min with equilibration buffer, and eluted with a lin-
ear salt gradient from 10% to 100% elution buffer in 2min. The column
was subsequently regenerated with 100% elution buffer for 1min. The flow
rate was constant at 1.5mL/min for all steps.
4.2.4 Case Study II: Separation of HMWs from mAb
Monomer
Proteins and Buffers
mAb Protein A pool was obtained from Lek Pharmaceuticals d.d. (Mengeš,
Slovenia) and stored at −80 ◦C before experimentation. Because of the low,
not detectable HMW content of the mAb Protein A pool, it was partly
low pH stressed to reach an overall HMW level of 10%. For the prepara-
tive runs, an equilibration buffer consisting of 20mM sodium citrate (pH 6)
was used. Elution was performed with 20mM sodium citrate and 500mM
sodium chloride (pH 6). For the in-line pooling decision, the sodium chloride
concentration was increased to 550mM to simulate a process disturbance.
For reference analytics (analytical size exclusion chromatography), a buffer
with 200mM potassium phosphate and 250mM potassium chloride (pH 7)
was used. All buffer components were purchased from VWR. All buffers
were prepared with Ultrapure Water. Prior to the experiments, the buffers
and the feed were filtrated with a cellulose acetate filter with a pore size of
0.22 µm (Pall). The buffers were also degassed by sonification before usage.
Chromatography Runs
The HiTrap 16mm× 25mm SP Sepharose FF column was first equilibrated
for 5CV and then loaded with 200mg mAb (monomer and HMWs). After
a wash of 3CV with equilibration buffer, variable linear gradients from
0% to 100% elution buffer were performed. Gradient length was set to
4CV, 5CV, 6CV, and 7CV. The results of the runs with gradient lengths
4CV, 6CV, and 7CV were used to calibrate the PLS model, while the
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run with a gradient length 5CV was applied to confirm the model. As for
the model protein study, data acquisition of the FlowVPE was started at
the beginning of the gradient and slope spectra from 240 nm to 340 nm with
2 nm resolution were recorded. After the linear gradient elution, the column
was regenerated for 3CV with the elution buffer. The flow rate was kept
constant at 0.5mL/min for all steps and experiments. During the elution
and regeneration, 1000 µL fractions were collected in deep well plates.
Reference Analytics
As reference analytics, Size-Exclusion Chromatography (SEC) was per-
formed with the collected fractions to determine the concentration of mAb
monomer and HMWs. Samples were injected into a 4.6mm× 150mm
TSKgel SuperSW mAb HTP column (Tosoh, Tokio, Japan). The flow rate
was set to 0.3mL/min.
4.2.5 Data Analysis
Protein slope spectra were extracted from the 3-dimensional chromatograms
while pure protein eluted according to off-line analytics. Each slope spec-
trum was normalized by dividing by its average slope.
As the total duration of a measurement cycle of the FlowVPE (including
the screening for the linear range) varied slightly, the results of the off-line
reference analytics were linearly interpolated such that they matched the
slope spectra. The slope spectra were then preprocessed by mean centering
and correlated with the results of the off-line analytics using PLS1 regression
[22], [69], [70]. PLS1 was used as little correlation was observed between the
measured concentrations of the different species [29]. The number of latent
variables in the corresponding PLS model was based on the minimization
of the RMSE of the model prediction in a cross validation.
For both case studies, the concentrations of the different species were
subsequently smoothed over time by a Savitzky-Golay filter in Matlab
(MathWorks, Inc., Natick, US) [82]. This filtering approach was chosen
as the PLS model does not consider time-wise correlation of the data. The
Savitzky-Golay filter allows to smooth data over time. For the calibration
and validation runs, the Savitzky-Golay filter was used in a symmetric form
smoothing the central data point in a given frame (frame size: 11 points,
2nd order polynomial). The Savitzky-Golay filter was not applied for the
in-line pooling decision to avoid a time delay. For calculating the mass bal-
ances for purity and yield off-line, the concentrations were again smoothed
as described above. Smoothing in spectral dimension was not applied as
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information crucial to the PLS may be lost in the smoothing process. Fur-
thermore, PLS models already suppress noise in the spectral dimension by
mapping spectral data onto latent variables [29].
4.2.6 In-line Monitoring and Control
The pooling of the products in both case studies was controlled in-line
based on the predicted concentrations of the PLS model. A .NET assembly
provided by the vendor of the FlowVPE triggered a call-back function in
Matlab after each spectral measurement. Matlab subsequently computed
the slope spectra and the protein concentrations. The communication be-
tween Matlab and Unicorn was implemented analogous to the protocol pub-
lished earlier [42]. Shortly, Matlab triggers a block in a Unicorn method by
sending a digital signal when a predefined pooling criterion is fulfilled.
To demonstrate that the method can handle process disturbances, modi-
fied elution buffers with increased salt concentrations (550mM sodium chlo-
ride instead of 500mM sodium chloride in both case studies) were used.
For the second case study, the loading density was additionally decreased
to 150mg as it may occur in production when the remainder of a batch
is loaded on a column. In the first case study, lys was declared as prod-
uct. Lys was automatically collected, as soon as its concentration exceeded
2 g/L and the cyt c concentration fell below 1.8 g/L. Pooling was continued
as long as the lys concentration remained above2 g/L. Pooling in the second
case study was triggered when the mAb monomer concentration exceeded
2 g/L. Pooling was stopped as soon as the purity of the pool fell below 95%.
For calculating the mass balances, negative concentrations computed by the
PLS model were set to 0. The termination of pooling was only allowed after
the eluate was collected for three minutes to prevent a fractionation stop
due to noise in the prediction.
4.3 Results and Discussion
As described above, linear gradients with variable lengths were performed in
both case studies to obtain different mixing ratios and concentrations of the
examined proteins. The acquired slope spectra and the results of the frac-
tion analysis of three runs were used to calibrate a PLS model, i.e. to span
a calibration space for the model. The fourth run was subsequently applied
to test the PLS model in both studies. Before the results of both studies
are discussed in detail, typical chromatograms obtained by the combination
of chromatography and VP spectroscopy will be presented.
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4.3.1 Application of VP Spectroscopy for
Chromatography
In VP spectroscopy, absorbance is measured at different pathlengths. Fig-
ure 4.2A illustrates a typical chromatogram obtained by VP spectroscopy
at 280 nm. The green lines represent the measured absorbance over time at
different pathlengths. The corresponding pathlengths are illustrated by the
grey lines. In orange, the slope over time is depicted. As shown by Equa-
tion 4.3, the slope is linearly dependent on the total protein concentration.
It is worth noting that the absorbance values stay almost constant during
protein elution, while the pathlengths decrease. During the screening phase,
the longest pathlength for the measurement phase is selected such that the
absorbance is expected to be 1AU at 280 nm. In consequence, the set
pathlengths are inversely proportional to the slope and thus to the protein
concentration (cf. Figure 4.2A).While Figure 4.2A displays a typical chro-





























































Figure 4.2: Typical chromatograms obtained by VP spectroscopy for one
wavelength (A) and multiple wavelengths (B). A: The green lines represent
the obtained absorbance values at the different pathlengths (grey lines). At
each point in time, the slope (orange line) was determined by a linear re-
gression between five absorbance values and pathlengths. B: If slope spectra
are recorded during a chromatography run, a 3-dimensional chromatogram
is obtained.
matogram for one wavelength, a chromatogram for multiple wavelengths is
presented in Figure 4.2B. Instead of single wavelength slopes, slope spectra
were acquired. As the slopes were recorded during a whole chromatography
run, this resulted in a 3-dimensional chromatogram in (time, wavelength,
slope). The obtained 3-dimensional chromatograms of the chromatogra-
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phy experiments were the starting point for the PLS model calibration and
confirmation.
4.3.2 Case Study I: Separation of Cyt c from Lys
Cyt c and lys feature significant spectral differences in UV due to the dif-
ferent mass fraction of aromatic amino acids as well as the heme group in
cyt c (cf. Figure 4.3A). The two proteins thus allow to test the proposed
setup for a simple application. Based on the performed cross validation,





















































Figure 4.3: Comparison of normalized protein slope spectra for case study I
(A) and case study II (B).
PLS1 models with 2, respectively 3 latent variables were selected for lys
and cyt c. The resulting PLS model predictions for the three calibration
runs (gradient length of 2CV, 4CV, and 8CV) are displayed in Figure
4.4A, B, and D. The plots compare the PLS model prediction for lys (solid
blue lines) and cyt c (solid red lines) with the results of the correspond-
ing reference analytics (blue bars for lys and red bars for cyt c). A good
agreement was observed between PLS model prediction and reference for all
calibration runs.To confirm the model, predictions for a 6CV gradient run
were made, which closely follow the corresponding reference analytics (cf.
Figure 4.4C). The different shades of blue and red of the PLS model pre-
diction in Figure 4.4 illustrate the unsmoothed and smoothed data (lighter
colors for the unsmoothed and darker colors for the smoothed data). The
RMSE of this run was 0.53 g/L for cyt c and 1.11 g/L for lys. The RMSE
of the smoothed prediction data with a Savitzky-Golay filter was 0.48 g/L
for cyt c and 1.05 g/L for lys. Applying the Savitzky-Golay filter clearly
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Figure 4.4: Comparison of the PLS model prediction for lys and cyt c with
the results of the off-line reference analytics for a gradient length of A: 2CV,
B: 4CV, C: 6CV (confirmation run), and D: 8CV. The different shades of
blue and red of the PLS model prediction illustrate the effects of smoothing.
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improved the RMSE for both the prediction of lys and cyt c (cf. Table 4.1).
The results show that the RMSE of the model predictions is partly due to
random noise but also partly systematic. As Savitzky-Golay filtering helps
to reduce random noise, the method was selected as a suitable post-run data
treatment. The combination of VP spectroscopy and PLS modeling allowed
Table 4.1: RMSE for the prediction in the confirmation runs of the two case
studies: The RMSE of unfiltered predictions is compared with the RMSE of
the filtered data.
Case study I Case study II
lys cyt c mAb monomer HMW
[g/l] [g/l] [g/l] [g/l]
No filter 1.10 0.53 1.26 0.50
Savitzky-Golay filter 1.04 0.48 1.07 0.42
for a selective quantification of lys and cyt c during chromatography runs
with highly loaded columns and lys peak concentrations of up to 80 g/L.
This shows that the method is applicable for the typical concentration range
of preparative chromatography.
4.3.3 Case Study II: Separation of HMWs from mAb
Monomer
In contrast to cyt c and lys, mAb monomer and HMW presumably contain
the same mass fraction of aromatic amino acids and disulfide bridges. Spec-
tral differences are therefore either related to changes in tertiary structure
or due to light scattering [32]. As a result, the differences in the spectra
of mAb monomer and HMW are comparably small (cf. Figure 4.3B). This
makes the quantification by PLS modeling more challenging.
Based on the performed cross validation, a PLS1 model with 4 latent
variables was selected for the mAb monomer, while a PLS1 model with 8
latent variables was used for the HMWs. Figure 4.5A, C, and D display
the PLS model prediction for the three calibration runs (gradient length
of 4CV, 6CV, and 7CV), while Figure 4.5B displays the results of the
confirmation run (5CV gradient). The figures show a comparison between
the PLS model prediction for the mAb monomer (solid blue lines) and the
HMWs (solid red lines) with the results of the reference analytics (blue
bars for mAb monomer and red bars for HMWs). In all four runs, the
model prediction matched the reference analytics closely. The results thus
demonstrate the applicability of the method for proteins with only slight
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differences in the absorption spectra. The RMSE of prediction was 1.26 g/L
for the mAb monomer and 0.50 g/L for HMWs. The RMSE could be further
reduced by smoothing the data with a Savitzky-Golay filter. This led to
RMSE values of 1.07 g/L for mAb monomer and 0.42 g/L for HMWs. Figure
4.4 compares the unsmoothed and the smoothed data for all runs. Applying
the Savitzky-Golay filter improved the RMSE for both the prediction of
the mAb monomer and HMWs indicating the presence of random noise (cf.
Table 4.1).

















































































Figure 4.5: Comparison of the PLS model prediction for mAb monomer
and HMWs with the results of the off-line reference analytics for a gradient
length of A: 4CV, B: 5CV (confirmation run), C: 6CV, and D: 7CV. The
different shades of blue and red of the PLS model prediction illustrate the
effects of smoothing.
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4.3.4 In-line Pooling Decisions
To show the usefulness of VP spectroscopy in conjunction with PLS mod-
eling, the implemented methods were used for process decisions. For both
case studies, the pooling decision for chromatographic runs with process dis-
turbances, i.e. away from the set point, were performed. For the first case
study, lys was purified from cyt c in a 6CV gradient with an increased salt
concentration in the elution buffer (550mM sodium chloride). The start of
the pooling was triggered by the PLS model as soon as the concentration of
lys exceeded 2 g/L and the cyt c concentration fell bellow 1.8 g/L (cf. Figure
4.6A). For the second case study, a 5CV gradient was performed also with
an increased salt concentration in the elution buffer (550mM sodium chlo-
ride). Furthermore, the loading density of the column was decreased from
40 g/L to 30 g/L. Such a situation may occur in production processes, when
the pool from the previous process step cannot be transferred to an integer
number of column cycles. Thus, a number of cycles are performed with fully
loaded columns. The remainder is then loaded onto a column resulting in
a lower loading density, which might change the separation and pool pu-
rity. This problem can be solved by applying the described in-line control.
The method was applied to trigger pooling as soon as the mAb monomer
concentration exceeded 2 g/L. Pooling was stopped, when the purity fell
bellow 95% (cf. Figure 4.6B). The collected pools were subsequently ana-
lyzed by off-line analytics. In both case studies, accurate predictions could
be made with minor deviations. For the separation of cyt c and lys, a
purity of 99.0% was predicted while off-line analytics measured a 99.7%
purity. For the mAb monomer product pool, the PLS model predicted a
purity of 94.4% compared to 94.2% measured by off-line analytics. Here,
Savitzky-Golay filtering did not lead to an improved prediction because the
measurement noise cancelled itself out over time (cf. Table 4.2). The re-
Table 4.2: Results of the in-line pooling decisions: For both case studies, the
pool purity was calculated based on the PLS model prediction and compared
with the corresponding results from off-line analytics as reference.




Prediction (no filter) 99.0 94.4
Prediction (with filter) 99.0 94.4
sults show that the proposed method may be applied for in-line control of
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Figure 4.6: Prediction of the PLS model during the in-line control run for
case study I (A) and case study II (B). The different shades of blue and red
of the PLS model prediction illustrate the effect of smoothing. Based on the
unsmoothed data, the pool purity was calculated (black). The thin black
vertical lines indicate the start and end of pooling.
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a chromatography system. The used residence time of 10min is above the
industrial standard. However, a reduction of the flow rate during elution
may be justifiable as the elution phase is relatively short compared to the
complete process. It is worth noting that the discussed approach is sig-
nificantly faster than on-line HPLC PAT methods proposed in literature.
In production scale, on-line HPLC was applied with 2.5 to 3 times slower
response time (1.3min resp. 96 s) [16], [75]. Thus, the applicability of VP
spectroscopy should be further evaluated on a case-to-case basis.
4.4 Conclusion and Outlook
In-line monitoring of preparative chromatography was successfully realized
in this study. It was demonstrated, that the combination of VP UV/Vis
spectroscopy and PLS modeling allows for a selective in-line protein quan-
tification in a broad dynamic range of concentrations. The method enabled
the monitoring of chromatography runs with highly loaded columns. Prod-
uct peak concentrations varied between 30 g/L to 80 g/L, while contaminant
peak concentrations were only 4 g/L to 20 g/L. Consequently, the proposed
method has potential for the in-line monitoring and control of preparative
chromatography. It might also be applicable for controlling switching times
in continuous chromatography. Future challenges are especially related to
the scale up and robustness of the method as well as to the optimization
of the measurement time of VP spectroscopy. As each VP measurement
relies on accurate mechanical positioning of the optical fiber, an increase in
measurement speed is challenging. Additionally, further investigations have
to be made to improve understanding and sensitivity for HMW detection.
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Abstract
The conjugation reaction of mAbs with small molecule drugs is a central
step during production of ADCs. The ability to monitor this step in real-
time can be advantageous for process understanding and control. Here, we
propose a method based on UV/Vis spectroscopy in conjunction with PLS
regression for non-invasive monitoring of conjugation reactions. In experi-
ments, the method was applied to conjugation reactions with two surrogate
drugs in microplate format as well as at 20mL scale. All calibrated PLS
models performed well in cross-validation (Q2 > 0.975 for all models). In
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microplate format, the PLS models were furthermore successfully validated
with an independent prediction set (R2pred = 0.977 resp. 0.894). In sum-
mary, the proposed method provides a quick and easily implementable tool
for reaction monitoring of ADC conjugation reactions and may in the future
support the implementation of PAT.
5.1 Introduction
ADCs are among the most promising new formats in the biopharmaceutical
industry [83]. More than 60 candidates are currently evaluated in clinical
trials. ADCs gain their potential from combining the high selectivity of
mAbs with the high cytotoxicity of small-molecule drugs. Next to specificity
and cytotoxicity, ADCs also inherit other attributes of both species, such
as the absorption bands of both protein and drug and an often increased
hydrophobicity compared to unmodified mAbs due to the apolar character
of the drugs [84]–[86].
One of the most central steps during ADC production is the conjuga-
tion reaction which links the drug to the mAb via a linker. The conju-
gation reaction may either be site-specific or unspecific, with the currently
developed ADCs mainly focusing on site-specific conjugation reactions with
well-defined Drug-to-Antibody Ratios (DARs) [87]–[89]. The conjugation
yield and DAR are generally measured off-line by analytical Hydrophobic-
Interaction Chromatography (HIC) or Reversed-Phase (RP) chromatogra-
phy, often in combination with mass spectrometry [90]. This is, however,
time-demanding and needs manual sample handling. Due to the toxicity of
the drugs, analytical chromatography often is performed in a chemically se-
cured environment. If only the DAR is needed without the concentration of
each conjugate species, a simple method relying on UV/Vis absorption mea-
surements can be applied [90]. It requires the drug to have an absorption
band different from the one of the protein (280 nm). Using the absorption
at both maxima and the respective extinction coefficients, the concentra-
tions of protein and drug can be mathematically determined without further
analytical methods. The technique has been used for conjugations with dif-
ferent drugs like the maytansinoid DM1 and dipeptide-linked auristatins
(e.g. vcMMAE) [91], [92], but is limited to purified conjugates, as residual
free drug and other possibly UV-active contaminants have to be removed.
As a consequence, this approach as well as analytical chromatography are
not very well suited for fast and prompt characterization of ADC conju-
gation reactions. Therefore, only complex analytical solutions are found
so far for the monitoring of these reactions. SEC with a post-column re-
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action was proposed for DAR determination of cysteine-conjugated ADCs
[93]. Tang et al. present an approach for rapid DAR measurement by fast
deglycosylation and LC-MS detection [94].
It would be highly beneficial to establish a fast analytical method for
monitoring the progress of conjugation reactions without any sample pro-
cessing. Ideally, such a method would also provide the means for application
as a PAT in accordance with the PAT initiative by the FDA. For this, the
applied method needs to be fast, without manual sample handling, and ro-
bust [18]. To monitor the process, the method should be sensitive to the
progress of protein conjugation reactions. UV/Vis absorption spectroscopy
is a rapid, noninvasive, and quantitative method which is widely established
in biopharmaceutical manufacturing. It has previously been applied to pro-
cess monitoring of proteins and small molecules [2], [18], [39], [74]. Hansen
et al. showed the potential of UV/Vis spectroscopy to distinguish between
different proteins based on their content of aromatic amino acids and their
solvatization [39]. The method was later transferred to chromatographic
separations by Brestrich et al. [42]. There are some examples of UV/Vis
spectroscopy in reaction monitoring applications. Quinn et al. followed a
small-molecule reaction in lab scale using fiber-optic UV/Vis spectroscopy
[95]. Gurden et al. employed a model based on UV/Vis absorption data to
detect and diagnose process variations in a non-protein biochemical conver-
sion reaction [96].
Drugs used in ADCs frequently feature delocalized electron systems thus
providing absorption bands in the UV/Vis range [90] besides the ones of
the aromatic amino acids of the mAbs. Spectral shifts of UV/Vis absorp-
tion may not only be caused by a structural change in the UV/Vis active
compounds, they can also occur as a result of changes in the local environ-
ment of the chromophores [97], [98], e.g. a change in solvent composition.
If the conjugation reaction thus causes a change in the environment of the
aromatic amino acids or the drug, it will cause spectral shifts which in turn
may help to monitor this type of reaction.
This work investigates a new and easily applicable method for on-line
conjugation reaction monitoring. Monitoring was accomplished by a combi-
nation of UV/Vis spectroscopy and PLS modeling. Spectra were recorded
and analyzed during conjugation reactions in two different scales with dif-
ferent UV/Vis detectors. Based on the results, a method was established
for small scale screening in 96-well plates which provides an estimate of
the amount of drug conjugated to the antibody by PLS regression. Two
different surrogate drugs, 7-Diethylamino-3-(4’-Maleimidylphenyl)-4-Meth-
ylcoumarin (CPM) and N-(1-Pyrenyl)maleimide (NPM), were applied in
both setups. Additional variability was introduced by changing the con-
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centrations of the reactants. The method was then adapted to a lab-scale
conjugation reaction with an on-line DAD to show applicability as a PAT
tool.
5.2 Materials and Methods
5.2.1 Chemicals
For disulfide reduction, we used Tris(2-Carboxyethyl)phosphine Hydrochlo-
ride (TCEP) (Sigma-Aldrich, catalog number C4706). (L)-Dehydroascorbic
Acid (DHA) (Sigma Aldrich, catalog number 261556) was used as oxida-
tion agent for re-oxidation of interchain disulfides. As non-toxic substi-
tutes for cytotoxic drugs, NPM and CPM (both Sigma-Aldrich, catalog
number C1484 and P7908) were selected. Their structural formulae is are
shown in Figure 5.1. Dimethyl Sulfoxide (DMSO) (Sigma Aldrich) was
used to dissolve DHA, CPM, and NPM. N-Acetyl Cysteine (NAC) (Sigma
Aldrich, catalog number A7250) was applied to quench residual free drug.
For buffer preparation, NaH2PO4 · 2H2O was obtained from VWR Interna-
tional GmbH. The buffers were titrated to the desired pH with 4M NaOH
(Merck KGaA) and filtered through a 0.2 µm cellulose acetate membrane
filter (Sartorius AG, Göttingen, Germany).
A B
Figure 5.1: The structure of conjugated NPM (Figure 5.1A) and conjugated
CPM (Figure 5.1B) are shown. R denotes the protein.
5.2.2 Model System and Conjugation Process
Purified Immunoglobulin G (IgG)1 mAb with two engineered cysteines as
conjugation sites was provided at a concentration of 12.4mg/mL in phos-
phate buffered solution with 5mM EDTA, pH 7.2 by MedImmune, LLC.
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CPM and NPM were used as non-toxic maleimide-functionalized surrogate
drugs and conjugated to the antibody’s two engineered cysteines via their
maleimide linker. For the conjugation experiments, aliquots of the engi-
neered mAb stock solution were thawed and diluted to the desired concen-
tration (2mg/mL) with 50mM sodium phosphate buffer (pH 7.2). The re-
sulting mAb concentrations were determined with a NanoDrop 2000c spec-
trometer (ThermoFisher Scientific, Waltham, USA).
The following mAb preparation steps (reduction and re-oxidation) were
conducted in 50mL centrifugation tubes (VWR International GmbH). A
reduction step was performed to uncap engineered cysteine residues. For
this purpose, a 40-fold molar excess of TCEP (over mAb concentration) was
added to the mAb solution. After 3 h of incubation at room temperature,
the reduced mAb solution was transferred into a dialysis cassette with a
10 kDa molecular weight cut-off to remove TCEP. The dialysis was per-
formed in a volume of 1.7 L of 50mM sodium phosphate buffer at 5 ◦C over
night (approx. 19 h). The mAb concentration after dialysis was determined
with the NanoDrop spectrometer.
For re-oxidation of the interchain disulfide bonds, 20-fold molar excess
of DHA (3mM stock solution in DMSO) was added. The mixture was incu-
bated at room temperature for 4 h. Through addition of the DHA solution,
DMSO content was increased to around 8.5%. To remove potential pre-
cipitate before spectroscopic conjugation monitoring, the mAb solution was
filtered through a 0.2 µm polyethersulfone syringe filter (VWR International
GmbH). The final mAb concentration for the conjugation experiments was
set via dilution with 50mM sodium phosphate buffer containing 10% of
DMSO. Conjugation experiments were executed with mAb concentrations
in the range of 1.0mg/mL to 2.0mg/mL.
The conjugation reaction in the different experimental setups was ini-
tialized by addition of the surrogate drug (NPM or CPM) to the re-oxidized
mAb solution. The molar ratio (drug to mAb) was set to 2 for the NPM
conjugations and to 3 for CPM. The concentration of the surrogate drug
stock solutions was varied (from 2mM to 6mM) depending on the mAb con-
centration to result in a final DMSO content of approximately 10%. This
content of DMSO was maintained to ensure solubility of the hydrophobic
surrogate drugs in the water-based solution. The conjugation reaction was
quenched by addition of a 12-fold molar excess of NAC (over the applied
amount of surrogate drug) to ensure the immediate termination of the con-
jugation reaction.
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5.2.3 High-throughput On-line Monitoring
Experiments in Microplate Format
The high-throughput conjugation experiments were conducted in 96-well
UV-transparent microplates (UV-STAR, Greiner bio-one GmbH, Fricken-
hausen, Germany). The reaction was monitored by the acquisition of UV/
Vis absorption spectra of the reaction mixture in the range from 250 nm
to 450 nm with an Infinite M200 microplate spectrometer (Tecan Group
Ltd., Männedorf, Switzerland). To allow for the correlation of UV/Vis ab-
sorption data with the progress of the conjugation reaction, spectra had to
be recorded while different time points of the reaction were sampled. The
used experimental setup is depicted in Figure 5.2. The UV-microplate was
divided into monitoring wells designated for UV/Vis absorption measure-
ments and quenching wells designated for off-line analytics. In the latter,
the reaction was quenched at different time points to generate samples for
off-line analysis. The six monitoring wells contained 200 µL of liquid and
were further separated into two blank wells and four reaction wells. One
blank well contained buffer solution, the other one re-oxidized mAb. The
remaining monitoring wells were used for reaction monitoring in duplicates
at two different conditions. There were 16 quenching wells for each of the
two screened conditions, containing 100 µL of the corresponding reaction
mixture. In this study, the mAb concentration was varied in the range of
1.0mg/mL to 2.0mg/mL while all other process conditions were kept con-
stant for all experiments. This resulted in 6 calibration and 2 prediction
runs for NPM and 5 calibration and 2 prediction runs for CPM. The conju-
gation reaction was started by adding the surrogate drug to the re-oxidized
mAb solution in a 50mL centrifugation tube. After short mixing, aliquots
were transferred immediately to the microplate. The reaction in the first
quenching well was instantly stopped by addition of NAC solution before
placing the microplate into the reader and starting the on-line monitoring
procedure. The UV/Vis spectra acquisition was controlled by the software
Magellan (Tecan Group Ltd.) according to the following process: Prior to
each measurement, the plate was shaken for 15 s (orbital shaking, 1.5mm
amplitude, 335.8 rpm). For the first 22min or 25min, single spectra were
recorded and after each measurement one well was quenched. At later time
points more spectra were acquired between each quenching step, resulting
in quenching time intervals of 4min to up to 10min. The spectral range for
the conjugation reaction with NPM was defined at 250 nm to 390 nm and for
CPM at 250 nm to 450 nm (step size 4 nm, 5 reads) to cover the character-
istic absorption maxima of the surrogate drugs. The conjugation reaction
was monitored over a run time of 50min. Afterwards, the microplate was
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Figure 5.2: Experimental setup used for high-throughput on-line monitor-
ing in microplate format. UV/Vis spectra were recorded during the conju-
gation reaction using the integrated Tecan plate reader. Reactions in the
quenching wells were stopped at different time points and analyzed by RP-
UHPLC. On-line and off-line data was used for the generation of PLS regres-
sion models.
centrifuged (1789 g, 7 ◦C) to remove potential precipitate prior to off-line
analysis. The supernatants were measured by RP Ultra High Performance
Liquid Chromatography (UHPLC).
5.2.4 Lab-scale On-line Monitoring Experiments
Preparation of the mAb was conducted as described above in the conju-
gation process section. The re-oxidized mAb solution at a concentration
of 2mg/mL was used for the experiments. Here, the acquisition of UV/
Vis spectra was performed with an Ultimate 3000 DAD (Dionex Softron
GmbH, Germering, Germany) with a semi-preparative flow cell (volume
0.7 µL, 0.4mm optical path length) at a spectral resolution of 1 nm. The
experimental setup consisted of a 50mL beaker glass as reaction vessel, a
peristaltic pump (Minipuls 3, Gilson, Villiers de Bel, France) with marprene
pump tubing, and the DAD. All elements were connected via Polyether
Ether Ketone (PEEK) tubing (0.5mm diameter). By attaching the beaker
glass to a thermal shaker (HLC BioTech, Bovenden, Germany), the solution
was continuously mixed at 200 rpm and the temperature was kept constant
around 23 ◦C. The reaction mixture was circulated from the reservoir via
the peristaltic pump through the DAD flow cell and back into the reservoir.
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In- and outlet were placed below the liquid surface. The flow rate was ap-
proximately 3mL/min which equaled the maximum speed of the peristaltic
pump (48 rpm).
Prior to monitoring the reaction, the DAD was equilibrated with sodium
phosphate buffer for 2 h and with re-oxidized mAb solution for 15min. Au-
tozero of the DAD signal was performed either with re-oxidized mAb (NPM
experiments) or with sodium phosphate buffer (CPM experiments). After
DAD ”warm-up“, the reactions were started by addition of the surrogate
drugs in the molar ratio of 2 for NPM and 3 for CPM. Three runs were
performed for each surrogate drug.
The conjugation reactions were monitored over 30min while UV/Vis
spectra were acquired by the DAD every 0.2 s. To reduce noise, the spectra
were then averaged over 10 s. The recorded spectral range was 250 nm to
390 nm for NPM experiments and 250 nm to 450 nm for CPM experiments.
Over the runtime of 30min, 21 samples were taken and transferred to
a 96-well microplate for off-line analysis. The wells were previously loaded
with NAC stock solution to facilitate immediate quenching of the reaction
upon sampling. After termination of the experiment, the microplate was
centrifuged (1789 g, 7 °C). The supernatant was analyzed by RP-UHPLC.
5.2.5 RP Chromatography
To assess conjugation results, RP-UHPLC was applied. An Ultimate 3000
system was used, equipped with pump unit, RS autosampler, RS column
compartment and diode array detector (Dionex Softron GmbH). Reduction
or different sample preparation was not required. An Acquity UPLC Pro-
tein BEH C4 column (Waters Corporation, Milford, USA; 300Å, 1.7 µm,
2.1mm×50mm) was run at a flow rate of 0.45mL/min. The column oven
was heated to 80 ◦C. Solvent A consisted of 0.1% Trifluoracetic Acid (TFA)
in ultrapure water, solvent B was 0.1% TFA in acetonitrile. After equili-
bration and injection at 26% B, content of B was raised to 30%. Next, a
4.8min gradient from 30% B to 38% B was used for separation of the conju-
gate species. Including strip at 95% B and re-equilibratio,n the runtime was
7min. UV signals at 280 nm and at the corresponding absorption maximum
of the used surrogate drug were recorded (384 nm for CPM and 338 nm for
NPM). The resulting chromatograms yielded peak areas of unconjugated,
mono-conjugated and di-conjugated mAb, as well as of the remaining free
drug. Using the areas at 280 nm and 384 nm or 338 nm, concentrations of
the different conjugate species could be calculated with a previously deter-
mined calibration curve for the mAb peak area. From these concentrations,
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the amount of conjugated drug was calculated to be used as response for
PLS modeling.
5.2.6 Data Analysis
All data analysis was performed in Matlab R2016a (The MathWorks). For
lab-scale experiments, the spectral band shifts were additionally analyzed
by interpolation similar to methods proposed in the literature [32]. First,
the spectra were smoothed with a 5th order Savitzky-Golay filter with a 9
point window. Subsequently, the 1 nm resolved spectral data was interpo-
lated with a cubic spline to a final resolution of 0.01 nm. The wavelength
of the maximal absorbance λmax was obtained from the interpolated data.
In the case of microplate experiments, the experiments were split into
calibration runs (at mAb concentrations of 1.0mg/mL, 1.5mg/mL, and
2.0mg/mL; NPM 86 samples, CPM 75 samples) and prediction runs (at
mAb concentrations of 1.28mg/mL and 1.7mg/mL; NPM 28 and CPM
30 samples). The prediction runs were excluded from model calibration
and only used for evaluating the model prediction and calculating Root
Mean Square Error of Prediction (RMSEP) values. No prediction runs
were performed in case of the lab-scale experiments.
For model calibration, the spectroscopic data was first preprocessed and
subsequently fitted with a PLS-1 model by the SIMPLS algorithm [99]. Pa-
rameters for preprocessing and model fitting were selected based on an op-
timization. Preprocessing consisted of multiple steps. First, a baseline was
subtracted from each spectrum to reduce possible effects of baseline drifts.
For NPM and CPM 390 nm, respectively 450 nm, were selected as refer-
ence wavelength. Subsequently, a Savitzky-Golay filter with a second-order
polynomial was applied to the spectra, and, optionally, the first or second
derivative was taken [82]. Finally, and only for the lab scale experiments,
the spectra were normalized by a 1-norm to further decrease instrumental
drifts.
For all models, cross-validation was performed by successively excluding
each batch, calibrating a PLS model based on the remaining runs and cal-
culating a residual sum of squares for the excluded batch. All residual sums
of squares of the different submodels were summed yielding the Predicted
Residual Sum of Squares (PRESS). The PRESS was scaled according to
Wold et al. by the number of samples and latent variables used in the PLS
model [27]. Based on the scaled PRESS, an optimization was performed us-
ing the built-in genetic algorithm of Matlab for integers [100]. The genetic
algorithm optimized the window width of the Savitzky-Golay filter, the or-
der of derivative, as well as the number of latent variables for the PLS-1
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model. The Root Mean Square Error of Cross Validation (RMSECV) was
calculated from the PRESS by dividing through the total number of sam-
ples. The Q2 values were calculated by dividing the PRESS through the
summed squares of the response corrected to the mean [27]. The coefficient
of determination for the prediction R2pred was calculated in the same way
for the prediction set.
For lab-scale experiments with CPM, the spectral band shift at 394 nm
was additionally analyzed by interpolation similar to methods proposed in
literature [32]. First, the spectra were smoothed with a 5th order Savitzky-
Golay filter with a 9 point window. Subsequently, the 1 nm resolved spectral
data was interpolated with a cubic spline to a final resolution of 0.01 nm.
The wavelength of the maximal absorbance λmax was obtained from the
interpolated data.
5.3 Results
5.3.1 Analysis of UV/Vis Absorption Spectra
In Figure 5.3, the measured spectra of two of the six lab-scale calibration
runs are shown (spectra of all experiments, both microplate and lab scale,
are shown in the supplementary data; see Figure 5.7). The different spectra
are colored according to the reaction progress (blue to red). The autozero
for NPM was performed while already flushing the DAD with mAb and,
thus, the protein band does not show in the spectra. For comparison, pure
component spectra of mAb, NPM, and CPM are supplied in the supplemen-
tary material (Figures 5.9, 5.10, and 5.11). In both experiments, a baseline
drift is visible at all wavelengths.
NPM features a structured absorption band between 300 nm and 360 nm;
CPM a broad band between 330 nm and 450 nm. During NPM conjugation
reaction (Figure 5.3), a small bathochromic (red) shift (up to 2 nm) of all
NPM bands upon conjugation can be observed. Looking at the bottom
graph in Figure 3, a bathochromic shift is also observed for CPM. The
maximum around 390 nm is shifted by more than 2 nm. On the right side
of Figure 3, the location of the band maxima over time is compared to con-
jugated drug concentrations from off-line analytics. The two curves show
a high degree of correlation for both NPM and CPM (Pearson correlation
coefficient > 0.97). This is also true for the remaining lab-scale runs, except
for the CPM run 1 which reached a correlation coefficient of 0.92.
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t = 30 min
t = 0 min
t = 30 min
t = 0 min
Figure 5.3: The raw spectra of two lab-scale experiments for NPM (top)
and CPM (bottom) are shown. The spectra are colored according to the
reaction progress from blue to red. The location of the band maxima of the
first (0min) and the last spectrum (30min) are marked by vertical lines. On
the right side, the time evolution of the band maxima location is compared
to the amount of conjugated drug measured by off-line analytics.
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5.3.2 PLS Model Calibration and Validation for
Microplate Experiments
For the microplate experiments, the data was split in a calibration set
and an independent prediction set. Multiple parameters were set during
model calibration (Savitzky-Golay window width, derivative, number of la-
tent variables). As a systematic approach, a numerical optimization was
chosen with the scaled PRESS from cross-validation as an objective. Fig-
ure 5.4 shows the calibrated model for the NPM and CPM experiments.
For all experiments, the measured concentration of conjugated drug first
increases quickly and approximates a limit after 10min to 20min. For
all calibration experiments, the PLS prediction follows the concentrations
from off-line analytics. Tabel 5.1 summarizes the optimized parameters.
For NPM and CPM, RMSECV values of 0.60 µmol/L (Q2 = 0.9856) and
0.56 µmol/L (Q2 = 0.9875), respectively, were reached.The calibrated PLS
















Figure 5.4: PLS model calibration for the microplate experiments is shown
for NPM (Figure 5.4A) and CPM (Figure 5.4B). The mAb concentration of
the different experiments are: red/blue 1mg/mL, yellow/violet 1.5mg/mL
and green/cyan 2mg/mL.
models were then validated by applying them to a prediction set (Fig-
ure 5.5). The shape of the conjugated drug concentration is similar to the
calibration set and captured by the PLS prediction in all experiments. In
case of CPM, the PLS prediction is offset for both experiments to higher
concentrations. RMSEPs of 0.57 µmol/L (R2pred = 0.9770) and 0.90 µmol/L
(R2pred = 0.8940) were reached for NPM and CPM, respectively.
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Table 5.1: Summary of optimized parameters for the spectral preprocessing
and PLS model as well as the performance of each model in cross-validation
and on independent prediction sets.
Microplate Lab-scale
NPM CPM NPM CPM
Number of latent variables 6 5 4 2
Window for Savitzky-Golay 17 13 35 71
Derivative 1 0 1 1
Q2 0.9856 0.9875 0.9792 0.9755
RMSECV (µmol/L) 0.60 0.56 0.56 0.57
R2pred 0.9770 0.8940 - -
RMSEP (µmol/L) 0.57 0.90 - -
















Figure 5.5: PLS model prediction for the microplate experiments is shown
for NPM (Figure 5.5A) and CPM (Figure 5.5B). The mAb concentration of
the different experiments are: blue 1.3mg/mL and red 1.7mg/mL.
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5.3.3 PLS Model Calibration for Experiments at
Lab-Scale
PLS model calibration for lab-scale experiments was optimized in the same
way as the calibration for experiments in microplates (Table 5.1). Due
to material limitations, no experiments were designated for a prediction
set. Instead, the PLS models were assessed only by cross-validation. For
NPM, an RMSECV of 0.56 µmol/L (Q2 = 0.9792) was reached. For CPM,
the RMSECV was 0.57 µmol/L (Q2 = 0.9755). For ADCs, the degree of
conjugation is commonly expressed as DAR. By normalizing the conjugated
drug concentration by the initial mAb concentration, the DAR was derived
and used for plotting (Figure 5.6).
5.4 Discussion
To correlate the progress of conjugation reactions with changes in the UV/
Vis absorption spectra, reactions were performed in microplate format as
well as in a lab-scale setup while measuring absorption spectra. First, the
spectra were interpreted qualitatively to justify the assumption that the
conjugation reaction affects the absorption spectra of the protein/drug mix-
ture. Subsequently, the obtained datasets were used to calibrate four PLS
models predicting the concentration of conjugated drug for CPM or NPM
in the two different setups.
During the conjugation reaction, UV/Vis absorption spectra are ex-
pected to change for multiple reasons. While reacting, the drug moves
from an aqueous to the proteinaceous environment. Due to solvatochroism,
the absorption bands of the drug thus may shift.21 Second, the proximity
of the drug to aromatic amino acids can change the local hydrophobicity
which in turn impacts the absorption spectra of aromatic amino acids [32],
[101], [102]. Finally, maleimide has been reported to generate a relatively
weak absorption band around 273 nm [103]. During the conjugation re-
action, the double bond in maleimide is reduced and the band at 273 nm
is expected to disappear. For the used surrogate drugs (NPM and CPM,
cf. Figure 5.1), the maleimide linker is coupled to the chromophores of
pyrene and phenylcoumarin. Thus, they may not have the same absorption
bands as free maleimide, and the conjugation reaction may also influence
the chromophore intramolecularly.
Based on the spectral changes clearly correlated to the reaction progress
observed in Figure 5.3, it was concluded, that the conjugation reactions of
both NPM and CPM indeed affect the respective absorption spectra. For
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Figure 5.6: PLS model calibration for the lab-scale experiments is shown
for NPM (left column) and CPM (right column). Each model was calibrated
on 3 replicates shown in the different subplots. We decided to use the DAR
for plotting as it is frequently used to specify the conjugation degree of ADCs.
For calculating the DAR, a constant protein concentration was assumed over
the course of the reaction.
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further verification, experiments with previously quenched NPM and CPM
were conducted, and spectra were recorded over 15min. Here, no spectral
shift was detected, since no reaction was taking place (Figure 5.8). As
a consequence of the spectral change caused by the conjugation reaction,
predicting the reaction progress from the spectra should be possible. Fur-
ther data analysis focused on establishing quantitative PLS models for each
setup and drug.
For each model, parameters for Savitzky-Golay smoothing and deriva-
tive as well as the number of latent variables were optimized. We decided
to rely on a numerical optimization with an integer based genetic algorithm
to implement a systematic selection of model parameters. For the opti-
mization, the scaled PRESS served as an objective function. In more de-
tail, cross-validation was performed by iteratively excluding a complete run
from PLS model calibration. The reasoning was to make cross-validation
representative for the prediction of future runs and thereby maximize the
predictive power of the PLS model. The so calibrated models were able to
predict most of the variation of the measured concentrations based on the
spectral data (Q2 > 0.9750).
For the microplate setup, it is worth noting that the calibration data
spans a range from 1mg/mL to 2mg/mL of mAb with the correspond-
ing surrogate drug concentrations. As the external validation shows, the
model is able to predict the reaction course for different concentrations in
the calibration space. Interestingly, the RMSEP for NPM lies below the
corresponding RMSECV. For CPM, the RMSEP is noticeably higher than
the RMSECV. This seems to be related to a slight offset in the PLS pre-
diction (Figure 5.5B). Nevertheless, the results show that it is possible to
quantitatively monitor conjugation reactions of NPM and CPM to an IgG1
antibody in the microplate format by UV/Vis spectroscopy. The results
furthermore show that the chosen way of model optimization did not cause
a strong overfit.
Lab-scale experiments led to RMSECV and Q2 values similar to those
found in the microplate experiments. The smooth prediction of the PLS
models indicates that the error of the model is mainly related to systematic
errors and not to the measurement noise. For reactions with varying protein
concentration, it would be possible to estimate the concentration by a PLS
model. The DAD experiments successfully show the ease of implementation
of the approach in a lab-scale format. As the DAD measurements are very
fast, the approach facilitates real-time monitoring, which may be beneficial
for kinetic studies or process monitoring and control.
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5.5 Conclusion
In summary, we established a novel spectroscopic PAT approach for mon-
itoring ADC conjugation reactions. In two experimental setups, with two
different detectors, the conjugation process of surrogate drugs to a mAb
was monitored by UV/Vis absorption spectroscopy and PLS regression.
The results show that UV/Vis spectroscopy allows to monitor conjugation
reactions in microplates as well as in lab-scale. The method may thus sim-
plify process development by reducing the analytical bottle neck. This may
be especially interesting in combination with High-throughput Process De-
velopment (HTPD) on liquid-handling stations for ADCs [104], [105]. In
lab-scale, the method allows for real-time process monitoring. Due to the
flexibility and ease of implementation, the method may be further developed
to a PAT approach for conjugation monitoring at commercial scale.
Future steps should focus on testing the method with cytotoxic drugs.
While common drugs contain chromophores, the solvatochromic behavior
of those drugs is unknown. Furthermore, the position of the engineered
cysteines may have a strong impact on the solvent exposure of the drug
and, thus, the change in hydrophobicity in the environment of the drug
upon conjugation. Other techniques more sensitive to solvatochromism
(e.g. fluorescence spectroscopy) or the changing of covalent bonds (e.g.
vibrational spectroscopy) could be evaluated. Due to the simplicity of UV/
Vis absorption spectroscopy, it is still a reasonable first choice for future
studies.
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5.6 Supplementary Material




















































































Figure 5.7: Raw spectra of all calibration samples. The spectra are col-
ored according to the reaction progress from blue to red. The microplate
experiments are depicted in the top row, while the bottom row shows the
spectra recorded in the lab-scale setup. Since the lab-scale experiments were
performed at the same nominal mAb concentration, the different runs are
artificially offset by 50 mAU. The left column shows experiments with NPM,
the right column shows experiments with CPM.
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Figure 5.8: Raw spectra of a mixture of mAb and quenched drug recorded
over the course of 15min. The spectra are colored according to “reaction
time” from blue to red. mAb, drug and NAC concentrations are the same
as in the lab-scale experiments. The surrogate drugs were quenched prior to
addition to the mAb solution in order to prevent the conjugation reaction.
DMSO content is 10% as in the other experiments. The evolution of the
band maxima of the drugs over time is shown on the right side. No shift in
band maxima is observed.
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Figure 5.9: Pure component UV/Vis absorbance spectrum of mAb mea-
sured in Tecan plate reader M200 Pro at a concentration of 2 g/L (in

























Figure 5.10: Pure component UV/Vis absorbance spectrum of NPM in
phosphate buffer containing 10% of DMSO measured in Tecan plate reader
M200 Pro.
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Figure 5.11: Pure component UV/Vis absorbance spectrum of CPM in
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Abstract
FTIR is a well-established spectroscopic method in the analysis of small
molecules and protein secondary structure. However, FTIR is not com-
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monly applied for in-line monitoring of protein chromatography. Here, the
potential of in-line FTIR as a PAT in downstream processing was investi-
gated in 3 case studies addressing the limits of currently applied spectro-
scopic PAT methods. A first case study exploited the secondary structural
differences of mAb and lysozyme to selectively quantify the two proteins
with PLS giving RMSECV of 2.42 g/l and 1.67 g/l, respectively. The cor-
responding Q2 values are 0.92 and, respectively, 0.99, indicating robust
models in the calibration range. Second, a process separating lysozyme
and PEGylated lysozyme species was monitored giving an estimate of the
PEGylation degree of currently eluting species with RMSECV of 2.35 g/l
for lysozyme and 1.24 g/l for PEG with Q2 of 0.96 and 0.94, respectively.
Finally, Triton X-100 was added to a feed of lysozyme as a typical pro-
cess related impurity. It was shown that the species could be selectively
quantified from the FTIR 3D-field without PLS calibration. In summary,
the proposed PAT tool has the potential to be used as a versatile option
for monitoring protein chromatography. It may help to achieve a more
complete implementation of the PAT initiative by mitigating limitations of
currently used techniques.
6.1 Introduction
Preparative chromatography of biopharmaceuticals is typically monitored
by measuring univariate signals such as pH, conductivity, pressure and UV/
Vis absorbance at a given wavelength [19], [106]. Among those, especially
single wavelength UV/Vis spectroscopy has been a staple for process mon-
itoring of biopharmaceutical chromatography due to its linear response to
protein concentration as well as its broad dynamic range, sensitivity, and
robustness. For all the advantages, single wavelength UV/Vis absorption
measurements generally do not allow for selective quantification of multiple
co-eluting proteins [58].
Even before the PAT initiative by the FDA in 2004 [1], research to-
wards more selective monitoring methods for preparative chromatography
was conducted. But the often small differences between biopharmaceutical
product and protein as well as non-protein contaminants make this a non-
trivial task [8], [74]. As a possible solution, fast at- or on-line analytical
methods, such as analytical chromatography, have been established. Dis-
crete samples are taken from the process stream and analyzed on the spot.
This approach has been proposed for controlling capture [13], [107], [108]
and polishing steps [11], [14]. However, at- or on-line analytical chromatog-
raphy is equipment-wise complex requiring a sampling module as well as
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an analytical chromatography system close to the process stream. Further-
more, the sampling and analysis time may be too long compared to the
typical time frame available for taking process decisions.
An alternative approach exploits slight differences in UV/Vis absorp-
tion spectra of different components to selectively quantify different species
by chemometric methods [74]. The approach yields results quickly enough
to allow for real-time process decisions in chromatography [42], [43], [76]
and works for minute spectral differences [39]. However, in the commonly
measured spectral ranges, UV/Vis spectroscopy lacks sensitivity towards
relevant aspects of protein structure, notably the secondary structure [32].
Furthermore, organic compounds are often not UV active (e.g. sugars, poly-
ols, and PEG [109], [110]) or they may obscure the protein signal (e.g. Tri-
ton X-100 [111] and benzyl alcohol [32]). Due to the high sensitivity, UV/
Vis absorption spectroscopy is also prone to detector saturation [74], [81].
FTIR allows to address several of those short-comings. Similar to UV/
Vis spectroscopy, FTIR is a non-destructive, quantitative, and quick method
which can be performed in-line [112]–[114]. FTIR measures the vibrational
modes of samples and thereby provides a spectroscopic fingerprint for dif-
ferent organic molecules. Proteins absorb in the Infrared (IR) spectral
range mainly due to vibrations of the polypeptide backbone [32], [35], [36].
Based on the backbone vibrations, FTIR grants insight into the secondary
structure of the measured proteins. In consequence, FTIR is a widely used
method for assessing the structural integrity of proteins during protein pu-
rification and formulation [32]. Furthermore, FTIR was previously used
as an at-line PAT tool in downstream processing of biopharmaceuticals for
quantifying product content, HMWs, and HCPs [45], [47].
In this work, in-line FTIR as a PAT tool for preparative protein purifi-
cation was implemented. An FTIR instrument was coupled to a lab-scale
preparative chromatography system to perform the experiments. Three case
studies were selected to investigate potential applications of FTIR as PAT
tool. First, a mixture of lysozyme and mAb was chosen due to the signifi-
cant differences in secondary structure of the two proteins. While lysozyme
mainly consists of alpha-helices (PDB ID 193L), mAb largely consists of
beta-sheets (PDB ID 1HZH). The expected spectral differences can be used
to selectively quantify the 2 proteins by PLS regression. 4 linear gradient
elutions with varying gradient lengths were performed. Based on the re-
sults, a PLS model for each protein was optimized. The error of the PLS
model was assessed by cross validation. Second, the preparative separation
of PEGylated lysozyme was monitored. In contrast to UV/Vis spectroscopy,
PEG gives a distinct signal in IR which can be used for quantification by
PLS regression. Again, 4 linear gradient elutions were performed for the
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calibration of two PLS models. Finally, the potential to monitor process
related impurities using in-line FTIR was demonstrated by adding Triton
X-100 to a feed solution of lysozyme. Triton X-100 is employed for virus in-
activation in biopharmaceutical production and has to be removed from the
product [111], [115]. Based on an off-line calibration curve, mass-balancing
of Triton X-100 in the flow-through during product loading was performed.
6.2 Materials and Methods
6.2.1 Experimental Setup
In-line FTIR measurements were performed using a Tensor 27 by Bruker
Optics (Ettlingen, Germany) connected to an ÄKTApurifier system by
GE Healthcare (Little Chalfort, UK). The chromatography system was
equipped with a P-900 pump, a P-960 sample pump, UV-900 UV/Vis cell,
and a Frac-950 fraction collector (all GE Healthcare). Unicorn 5.31 (GE
Healthcare) was used to control the system. The FTIR was equipped with
a liquid nitrogen cooled Mercury Cadmium Telluride (MCT) detector and a
BioATR II (Bruker Optics) with a flow-cell insert and a 7 reflection silicon
crystal. The instrument was controlled by OPUS 7.2 (Bruker Optics).
In this setup, the effluent stream from the column outlet was diverted
through the FTIR instrument and then back into the UV/Vis cell in the
ÄKTApurifier system. The flowpath is illustrated in Figure 6.1. The delay
volume between the FTIR and the fraction collector was determined gravi-
metrically. As the flow rate was set in the chromatographic methods, the
measurement of the delay volume enables the correlation of spectral data
from the FTIR to collected fractions.
The interconnection between OPUS and Unicorn was achieved using a
software solution developed in-house consisting of a Matlab (The Math-
works, Natick, MA, United States) script and a VBScript in the built-in
visual basic script engine of OPUS. The custom software enables the start
of a measurement at a time defined by Unicorn by sending a digital signal
through the I/O port of the pump of the ÄKTApurifier System. The signal
is captured by a USB-6008 data acquisition device (National Instruments,
Austin, Tx, United States) controlled by Matlab which in turn triggers the
measurement in OPUS.
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Figure 6.1: Schematic representation of the flow path in the custom chro-
matography setup, solid lines represent the common flow path in the ÄK-
TApurifier while the dashed line represents the modification.
6.2.2 Proteins and Buffers
All solutions were prepared using water purified by a PURELAB Ultra wa-
ter purification system by ELGA Labwater (High Wycombe, United King-
dom). Buffers were filtered using 0.2 µm filter purchased from Sartorius
(Göttingen, Germany) and degassed by sonification before use. All buffers
were pH adjusted using 32% HCl (Merck, Darmstadt, Germany).
Lysozyme was purchased from Hampton Research (Aliso Viejo, CA,
United States). mAb was provided by Lek Pharmaceuticals d.d. (Mengeš,
Slovenia) as a virus-inactivated Protein A eluate pool.
Preparative CEX chromatography runs in case study I and III were con-
ducted with 50mM sodium citrate buffer as equilibration buffer and with an
added 500mM NaCl as elution buffer. Both buffers were adjusted to pH 6.0.
Sodium citrate tribasic dihydrate was purchased from Sigma-Aldrich (St.
Louis, MO, United States), sodium chloride was purchased from Merck.
For the CEX chromatography experiments in case study II, 25mM sodium
acetate buffer (pH 5.0) was used as equilibration buffer. As elution buffer,
25mM sodium acetate buffer with 1M NaCl (pH 5.0) was used. Sodium
acetate trihydrate was purchased from Sigma-Aldrich. Batch-PEGylation
of lysozyme was performed in 25mM sodium phosphate buffer at pH 7.2 us-
ing sodium phosphate monobasic dihydrate (Sigma-Aldrich) and di-sodium
hydrogen phosphate dihydrate (Merck).
Analytical CEX was carried out at pH 8.0 using 20mM Tris (Merck)
buffer for equilibration and 20mMTris buffer with 700mMNaCl for elution.
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PEGylation of Lysozyme
The PEGylation protocol was adapted from [116]. Briefly, activated 5 kDa
PEG was purchased as Methoxy-PEG-propionaldehyde (mPEG-aldehyde,
Sunbright ME-050 AL) from NOF Corporation (Tokyo, Japan). Sodium
cyanoborohydride (NaCNBH3, Sigma Aldrich) was added to the reaction
buffer to a concentration of 20mM as reducing agent. mPEG-aldehyde was
added to a molar PEG-to-protein ratio of 6.67. After 3 h, the mixture was
diluted volumetrically 7-fold using acetate equilibration buffer and loaded
onto the chromatography column.
6.2.3 Preparative Chromatography Experiments
For all chromatography experiments, FTIR spectra were recorded contin-
uously in the chromatography mode of OPUS with a resolution of 2 cm−1
in a range from 4000 cm−1 to 900 cm−1 without averaging multiple scans.
In given setup, each measurement took 3.22 s. Background measurements
in the beginning of chromatographic runs were taken at the same resolu-
tion with 400 scans in equilibration buffer. All experiments were conducted
twice, once with protein injection and once with buffer only as a blank run.
The FTIR spectra from the blank runs were subsequently subtracted from
the protein runs to account for spectral effects by the gradient.
Case Study I: Selective Protein Quantification
For case study I, a HiTrap column by GE Healthcare prepacked with SP
Sepharose FF resin (Cross-Validation (CV) 5ml) was used. The column
was loaded to a density of 18.75 g/l, consisting of 12.5 g/l lysozyme and
6.25 g/l monoclonal antibody. The flow rate for all experiments was set
to 0.5ml/min. The column was equilibrated in low salt buffer for 5CV
before injection. The 50ml sample was injected using a 50ml superloop
from GE Healthcare. Elution was carried out with a linear gradient from
0% to 100% high salt buffer with gradient lengths of 1CV, 2CV, 3CV,
and 4CV. After elution a high salt wash of 8CV was performed for column
regeneration. The effluent was collected over the complete injection and
elution in 500 µl fractions for off-line analytics.
Case Study II: Separation of PEGylated Lysozyme Species
The experiments with different PEGylated lysozyme species were conducted
with Toyopearl Gigacap S-650M resin prepacked in a MiniChrom column
(CV 5ml) by Tosoh (Griesheim, Germany). The column was loaded to a
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density of 50 g/l of the heterogeneous batch PEGylation. The sample pump
was run at 1ml/min for loading. For the remaining chromatography run,
the flow rate was set to 0.5ml/min. The column was first equilibrated
for 1CV, followed by an injection of 57.6CV of sample solution. Linear
gradient elutions from 0% to 100% high salt buffer were conducted with
gradients of 2CV, 3CV, 4CV, and 5CV length, followed by 2CV high salt
rinse. The effluent was collected from the beginning of the gradient until
the end of the high salt rinse in 500 µl fractions for off-line analytics.
In some of the collected fractions unconjugated lysozyme started to
precipitate after elution probably due to the low pH, high salt concentration
or low temperature [116], [117]. Fractions and the corresponding spectra
showing signs of precipitation were excluded from PLS model calibration.
Case Study III: Process-Related Impurity
For the simulated process-related impurity experiments, a HiTrap column
by GE Healthcare prepacked with SP Sepharose FF resin (CV 5ml) was
used. Triton X-100 Biochemica was purchased from AppliChem GmbH
(Darmstadt, Germany). The column was loaded with 5ml of 25 g/l lysozyme
and 10 g/l Triton X-100 solution [115]. The elution step was set to 2CV.
Reference samples were generated by diluting defined amounts of Tri-
ton X-100 in equilibration buffer at concentrations from 1.25 g/l to 10 g/l.
To generate a calibration curve, the samples were manually applied onto
the ATR crystal. FTIR measurements were performed with 400 scans for
background and samples.
6.2.4 Analytical CEX Chromatography
As reference analytics for case study I, analytical CEX chromatography was
performed using a Dionex UltiMate 3000 liquid chromatography system by
Thermo Fisher Scientific (Waltham, MA, United States). The system was
composed of a HPG-3400RS pump, a WPS-3000TFC analytical autosam-
pler, a TCC-3000RS column thermostat, and a DAD3000RS detector. The
system was controlled by Chromeleon 6.80 (Thermo Fisher Scientific). Frac-
tions from preparative CEX chromatography were analyzed off-line on a
Proswift SCX-1S 4.6mm× 50mm column by Thermo Fisher Scientific. A
flow rate of 1.5ml/min was used. For each sample, the column was first
equilibrated for 1.8min with equilibration buffer. Next, 20 µl sample was
injected into the system and washed for 0.5min with equilibration buffer.
A linear gradient was performed during the next 2min from 0% to 50%
followed by a step to 100% elution buffer which was maintained for 2min.
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For the experiments in case study II, a Vanquish UHPLC system (Ther-
mo Fisher Scientific) was used. The Vanquish UHPLC System consisted of
a Diode Array Detector HL, a Split Sampler FT, a Binary Pump F and
a Column Compartment H including a preheater and post-column cooler
(all Thermo Fisher Scientific). The same buffers, column, and flow rate
were used as for case study I. After injecting 5 µl of sample, the column
was washed for 0.5min. Subsequently, a bilinear gradient was performed
from 0% to 50% elution buffer over 5min and 50% to 100% elution buffer
over 1.75min. After the elution a high salt strip at 100% was run for 1min.
Calibration was performed by a dilution series of pure lysozyme. Since PEG
does not absorb in UV/Vis, solely lysozyme contributes to the absorption
signal. Peak identification with respect to the PEGylation degree was con-
ducted using purified samples prepared according to [110]. From the molar
concentration of PEGylated lysozyme species, the molar concentration of
PEG was calculated.
6.2.5 Data Analysis
All data analysis was performed in Matlab. For case study I and II, the
data was first preprocessed and subsequently fitted with PLS-1 models by
the SIMPLS algorithm [99]. Preprocessing consisted of linearly interpolat-
ing off-line analytics to be on the same time scale as the FTIR spectra. For
case study I and II, spectral data above 2000 cm−1 resp. above 3100 cm−1
was discarded. Next, a Savitzky-Golay filter with a second order polyno-
mial was applied on the spectra and optionally the first or second derivative
taken [82]. Cross-validation was performed by excluding one chromatogra-
phy run, calibrating a PLS model on the remaining runs and calculating a
residual sum of squares on the excluded run. This procedure was repeated
until all runs had been excluded once. All residual sums of squares for
the different submodels were subsequently summed giving the PRESS. The
PRESS was scaled according to Wold et al. by the number of samples and
latent variables used in the PLS model [30]. Based on the scaled PRESS, an
optimization was performed using the built-in genetic algorithm of Matlab
for integers [100]. The genetic algorithm optimized the window width of
the Savitzky-Golay filter, the order of derivative, as well as the number of
latent variables for the PLS-1 model. The RMSECV was calculated from
the PRESS by dividing by the total number of samples. The Q2 values were
calculated by dividing the PRESS by the summed squares of the response
corrected to the mean [30].
For case study III, spectral data was smoothed both in direction of
time and wavenumber using a Savitzky-Golay filter with a second order
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polynomial and a frame length of 17 and 51 respectively. A linear baseline
was calculated and subtracted for each spectrum individually to account for
a non-horizontal non-zero baseline. The baseline subtraction was performed
on the reference spectra as well as the spectra from the chromatography
experiment. Based on the area under the spectrum between wavenumbers
1007 cm−1 to 1170 cm−1, a mass balance for Triton X-100 was calculated
from the spectral data of the chromatography run. The volume represented
by each spectrum was calculated from the recording time and the volumetric
flow rate of the experiment. Triton X-100 masses in each segment were
calculated utilizing the calibration curve and summed up over time.
6.3 Results and Discussion
In-line FTIR measurements were applied as a PAT tool for different prepar-
ative chromatographic protein separations. In three different case studies,
FTIR was used for selective quantification of different species. First, back-
ground correction of the FTIR chromatograms is discussed which was nec-
essary for further data processing. In a first case study, the capability of
FTIR to measure differences in secondary structure in-line and utilize the
differences for selective quantification of mAb and lysozyme was demon-
strated. A second case study made use of the absorption of PEG in IR
to monitor the PEGylation degree of eluting PEGylated lysozyme species.
Finally, the third case study used the selectivity of FTIR to selectively
quantify Triton-X 100, a detergent used for viral inactivation.
6.3.1 On Background Subtraction and Spectral
Preprocessing
Background subtraction for in-line FTIR measurements is of major im-
portance as water has an absorption band around 1600 cm−1 (cf. Figure
6.2A) which coincides with the most prominent protein band amide I .
The spectral processing workflow is illustrated in Figure 6.2 using data
from case study I. Specifically the elution of mAb and lysozyme using a
4CV gradient is shown. Most of the water absorption can be eliminated
by taking a background with the equilibration buffer in the beginning of
each chromatographic run. The water band is, however, also influenced by
the salt content of the buffer around 1650 cm−1. Salt gradients therefore
cause a change in absorption over the run (cf. Figure 6.2A and B). To
reduce buffer effects, it is important to find a suitable dynamic background
correction. An approach based on reference spectra matrices and chemo-
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metric correlations was not implemented due to the overlap of water and
protein bands [118]. Instead, an alternative approach was chosen. Based
on the retention time, a blank run without protein but including the salt
gradient was subtracted from the actual preparative run (cf. Figure 6.2C).
The resulting chromatogram provided a smooth baseline over the whole
experiment. After baseline correction, additional data preprocessing was
performed. The single scan spectra were smoothed by a Savitzky-Golay
filter to reduce random noise (cf. Figure 6.2D) and to take derivatives on
the spectral data.
6.3.2 Case Study I: Selective Protein Quantification
mAb and lysozyme feature significant differences in secondary structure.
While mAb consists largely of beta-sheets (PDB ID 1HZH), lysozyme con-
tains mainly alpha-helices (PDB ID 193L). These differences make the two
proteins simple model components to study the performance of in-line FTIR
for selectively quantifying proteins. The bands visible between 1200 cm−1
to 1700 cm−1 in Figure 6.2D are characteristic amide bands associated with
the protein backbone [32], [35], [36]. Especially the amide I band is fre-
quently used for assessing the secondary structure of proteins. For PLS
calibration, all wavenumbers below 2000 cm−1 were taken into account to
include all protein bands without interference at the boundary due to the
Savitzky-Golay filter.
Based on 4 CEX runs, 2 PLS-1 models were optimized for selective
quantification of mAb and lysozyme respectively. The resulting model pa-
rameters are listed in table 6.1. Figure 6.3 shows a comparison from off-line
analytics and the prediction of PLS models. Both PLS models match peak
maxima and peak widths well and are able to discern the two components.
For mAb, a root mean square error of cross validation (RMSECV) of 2.42 g/l
was reached. For lysozyme, the RMSECV was 1.67 g/l. The correspond-
ing Q2 values were 0.92 and 0.99, respectively. The high Q2 values show,
that a large part of the variation in the off-line concentration measurements
could be explained by the PLS model. The differentiation between differ-
ent proteins may however become more challenging for smaller differences in
secondary structure. Interestingly, the combination of Savitzky-Golay filter-
ing and PLS modeling allowed to reduce the measurement noise compared
to single-wavelength measurements. As shown by Figure 6.2C and 6.3, the
measurement noise in the IR spectra is higher than the noise observed in the
PLS prediction. By filtering and projecting the spectra to latent variables,
random noise is reduced [30], [82]. Furthermore, 3.23 s measurement time
makes FTIR quick enough for monitoring most practical preparative chro-
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Figure 6.2: (Continued on the following page.)
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Figure 6.2: Work flow for data treatment of chromatography spectra il-
lustrated with data from case study I, 4CV run: background run – salt
gradient without protein (A); raw spectra of the run with protein (B); spec-
tral data after the background has been subtracted (C); data after smoothing
by Savitzky-Golay algorithm (D).
matography applications in real-time. In-line FTIR spectroscopy allowed to
cover high concentration ranges. The predicted concentration of lysozyme
during the 1CV run reaches 112 g/l without any interference from detec-
tor saturation. The measurement setup therefore covers all concentrations
typically occurring in preparative protein chromatography.
Table 6.1: Model parameters for case study I and II are listed below in-
cluding the parameters for the Savitzky-Golay filter and the latent variables
of the PLS-1 model. Additionally, the RMSECV for each model is listed.
Case study I Case study II
mAb lysozyme lysozyme PEG
Savitzky-Golay Window 215 21 101 361
Derivative 0 0 2 2
Latent variables 3 7 6 8
RMSECV (g/l) 2.41 1.63 2.35 1.24
In summary, the results show that FTIR in conjunction with PLS mod-
eling can differentiate in-line between proteins based on their secondary
structure and has the potential to be applied for real-time monitoring and
control of preparative chromatography.
6.3.3 Case Study II: Separation of PEGylated
Lysozyme Species
In conventional chromatography systems, the separation of differently PEGylated
species cannot be monitored holistically as PEG does not absorb in UV.
Contrary to that, PEG produces a number of prominent bands in IR. A
strong band around 1090 cm−1 with multiple shoulders is characteristic for
C–O stretching [119]. Due to symmetric CH2 stretching, PEG further-
more generates a doublet at 2884 cm−1 and 2922 cm−1. Bands occurring
between 1200 cm−1 to 1700 cm−1 are related to the protein backbone with
some interference from PEG C–H bending.
Figure 6.4 shows a typical chromatographic separation of PEGylated
lysozyme species. During the elution, the ratio between PEG and protein
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Figure 6.3: 4 chromatographic runs are shown for in-line FTIR measure-
ments and selective quantification of mAb and lysozyme. The red bars and
lines refer to the mAb off-line measurement and mAb PLS prediction, respec-
tively. The blue bars and lines refer to the lysozyme off-line measurement and
lysozyme PLS prediction, respectively. The different subplots show different
gradient lengths: A 1CV, B 2CV, C 3CV, D 4CV.
bands decreases. First, with a retention volume of 6.8ml, the absorption
of the C–O band at 1090 cm−1 (denoted as CO1 in Figure 6.4) exceeds the
absorption of amide I band (AI1). For the second peak with a retention
volume of 10.3ml the absorption of the amide I (AI2) is higher than for the
C–O stretching band (CO2). The last peak does not show characteristic
PEG bands, i.e. consists of unconjugated lysozyme. The order of elution
followed a descending degree of PEGylation which is in line with previous
publications [110], [120], [121].
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Figure 6.4: Elution of PEGylated lysozyme species from a CEX col-
umn with a gradient length of 5 CV. Bands visible between wavenumbers
1200 cm−1 to 1700 cm−1 are the characteristic amide bands associated with
protein. The major protein bands amide I and amide II are mark as AI and
AII, respectively. The band at approximately 1100 cm−1 is characteristic for
PEG (C–O stretching, marked as CO). The subscript numerals refer to the
elution order.
Based on the evaluation of IR absorption bands, it was decided to in-
clude all wavenumbers from 900 cm−1 to 3100 cm−1 into PLS model calibra-
tion. Initial PLS calibration on the concentration of the different PEGylated
lysozyme species showed that the conjugation did not cause large enough
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band shifts to allow for selective quantification of the different PEGylated
lysozyme species. Instead, two PLS models were fitted on the total PEG
resp. lysozyme concentration independently. PEG concentration was cal-
culated by weighting the off-line lysozyme concentration according to the
PEGylation degree. In table 6.1, the optimization results are summarized.
Figure 6.5 compares the PLS prediction with off-line analytics. RMSECV
values of 1.24 g/l and 2.35 g/l were reached for the PEG and lysozyme con-
centration, respectively. The correspondingQ2 values were respectively 0.96
and 0.94 showing that the PLS models predicted the responses well. Based
on the PEG and lysozyme concentrations, a molar ratio could be calculated
corresponding to the current average PEGylation degree. To simplify visual
interpretation, the molar ratio is only plotted if the lysozyme concentration
exceeded its RMSECV 3-fold.
The predicted PEG and lysozyme concentrations accurately followed
the concentrations measured by off-line analytics. Furthermore, the molar
ratio gives a suitable tool for in-line monitoring of the elution of different
PEG species. Interestingly, the two PLS models are able to extend their
prediction over the calibration range, i.e. to perform a weak extrapolation.
This can be seen as the PEG to lysozyme ratio exceeds the value of two,
which limits the calibration range spanned by off-line analytics. Higher
PEGylated species of lysozyme do however occur and could be measured
by the FTIR [110], [122].
In summary, FTIR allows to monitor not only the protein and PEG
concentration but also the PEGylation degree during chromatographic sep-
arations.
6.3.4 Case Study III: Quantification of a Process
Related Impurity
Triton X-100 is used for viral inactivation of biopharmaceuticals if pH treat-
ment has to be circumvented, e.g. for Factor VIII or pH sensitive mAbs
[111], [115]. To achieve viral inactivation, Triton X-100 concentration needs
to be above a minimal level. Typically, a concentration of 1% (w/V) is used.
Here, Triton X-100 concentration of a mock virus inactivation batch was
monitored during the subsequent load phase onto a chromatographic col-
umn. During the chromatographic run, in-line FTIR measurements were
perform (cf. Figure 6.6).
In IR, Triton X-100 causes a characteristic band due to C–O stretching
at 1090 cm−1. By comparison of the blank run and the actual experiment it
was concluded that Triton X-100 is not retained on the column and is mainly
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Figure 6.5: 4 chromatographic runs are shown for in-line FTIR measure-
ments and selective quantification of PEG and lysozyme. The red bars and
lines refer to the PEG off-line measurement and PEG PLS prediction, respec-
tively. The blue bars and lines refer to the lysozyme off-line measurement and
lysozyme PLS prediction, respectively. Grey bars correspond to measured
protein concentrations on partially precipitated samples. Black dots show
the molar ratio between PEG and lysozyme, i.e. the current mean PEGyla-
tion degree. The different subplots show different gradient lengths: A 2CV,
B 3CV, C 4CV, D 5CV.
present in the flow-through. The flow-through occurred between 5.5ml to
11ml. As Triton X-100 and protein spectra only weakly interfere with each
other, the Triton X-100 content was measured by simply correlating the
band area of C–O stretching from 1007 cm−1 to 1170 cm−1 to the Triton X-
100 concentration. A linear regression for the calibration curve resulted in a
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Triton X-100
Figure 6.6: Triton X-100 as a process related impurity can be seen in
the flow-through of the cation-exchange experiment from 5.5ml to 11ml at
1090 cm−1.
R2 > 0.9997. Based on the calibration curve, in-line mass-balancing could
be performed. The mass balance for Triton X-100 showed a recovery rate
of 94.12% in the flow-through. This shows that it is possible to selectively
quantify Triton X-100 content during the chromatographic load phase.
6.4 Conclusion and Outlook
FTIR spectroscopy was successfully implemented in-line as a PAT tool for
biopharmaceutical purification processes. It was demonstrated that FTIR
is able to distinguish and selectively quantify proteins in-line based on their
secondary structure. Furthermore, FTIR presents a powerful tool for mon-
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itoring different chemical components such as PEG or Triton X-100. Based
on selective in-line quantification of PEG and protein, PEGylation degrees
could be measured in-line. Selective mass balancing was performed on the
process-related contaminant Triton X-100. In summary, FTIR provides or-
thogonal information to the typically measured UV/Vis spectra. It there-
fore is potentially interesting for monitoring process attributes which have
been previously hidden. FTIR may help to achieve a more complete imple-
mentation of the PAT initiative.
Future research should be directed towards making the setup more com-
patible with the production environment. Challenges include the use of
detectors without liquid nitrogen cooling and the application of fiber optics
for in-line process probes.
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Abstract
VLPs have shown great potential as biopharmaceuticals on the market and
in clinics. Non-enveloped, in vivo-assembled VLPs are typically dis- and re-
assembled in vitro to improve particle stability, homogeneity, and immuno-
genicity. At industrial scale, Cross-Flow Filtration (CFF) is the method of
choice for performing reassembly by diafiltration. Here, we developed an
experimental CFF setup with on-line measurement loop for the implemen-
89
Spectroscopic PAT for Protein Purification
tation of PAT. The measurement loop included an UV/Vis spectrometer as
well as a light-scattering photometer. These sensors allowed for monitoring
protein concentration, protein tertiary structure, and protein quaternary
structure. The experimental setup was tested with three Hepatitis B core
Antigen (HBcAg) variants. With each variant, three reassembly processes
were performed at different Transmembrane Pressures (TMPs). While light
scattering provided information on the assembly progress, UV/Vis allowed
for monitoring the protein concentration and the rate of VLP assembly
based on the microenvironment of Tyrosine-132. Furthermore, the exper-
imental results provided evidence of aggregate-related assembly inhibition
and showed that off-line SEC does not provide a complete picture of the
particle content. Finally, a PLS model was calibrated to predict VLP con-
centrations in the process solution. Q2 values of 0.947 to 0.984 were reached
for the three HBcAg variants. In summary, the proposed experimental setup
provides a powerful platform for developing and monitoring VLP reassem-
bly steps by CFF.
7.1 Introduction
VLPs are biopharmaceuticals with potential applications against various
diseases such as viral and bacterial infections, cancer, Alzheimer’s disease,
and autoimmune disorders [123]–[127]. They are generally designed to trig-
ger an immune response by presenting antigens on their surface. These
antigens are either part of the native viral capsid or introduced artificially.
Chimeric VLPs were, for example, constructed based on HBcAg [124],
[128], [129], Hepatitis B surface Antigen (HBsAg) [130], GH1-Qβ [131],
and Murine Polyomavirus VP1 (MuPyVP1) [123]. VLPs are resilient to
most environmental stresses, have great potential to be produced inexpen-
sively, and efficiently elicit potent immune responses due to their repetitive
and particulate structure [132], [133].
Similar to viruses, VLPs are assemblies of one or several types of capsid
proteins forming a higher-order structure [127]. VLPs are expressed in ge-
netically modified host organisms [125], [127], [134]. Subsequent production-
scale purification most frequently consists of precipitation, chromatography,
and Ultrafiltration/Diafiltration (UF/DF) [135]. In vivo self-assembled,
non-enveloped VLPs are often disassembled and subsequently reassembled
to remove impurities from within the capsid [136], [137]. Disassembling
and reassembling also leads to increased structural homogeneity, improved
overall stability, and enhanced antigenicity [138]–[140]. An overview of a
typical VLP production process is given in Figure 7.1.
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Figure 7.1: Illustration of a typical VLP production process. The down-
stream processing train may consist of eight or more unit operations. The
unit operation investigated here—the VLP reassembly—is marked in blue.
Generally, a change in the quaternary structure of VLPs is induced by
altering their physicochemical environment, i.e. the ionic strength of the
protein solution, the pH, or the concentration of a reducing agent [139]. At
lab scale, dialysis is the most common method for buffer exchanges [138].
Dialysis has, however, some drawbacks such as long processing times and
significant buffer consumption [141]. In preparative downstream processes,
CFF is more popular because of its simple scalability, a reduced buffer
consumption, and reduced processing time [141], [142]. CFF has been suc-
cessfully applied to VLPs for capture, buffer exchange, and concentration
[134], [143], [144]. Compared to dialysis and batch diafiltration, assembly
of VLPs by constant volume diafiltration was shown to increase VLP yield
[145]. Despite the many advantages, CFF may also cause problems due
to protein-membrane interaction [146], [147] which was observed to impact
process performance [148]. To reduce these problems, CFF process time
has to be minimized while maximizing the process efficiency.
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PAT [18], [74], [149] is thus of interest to monitoring the assembly
progress. Protein concentration measurements allow to detect protein ad-
sorption to the membrane. Particle size measurements provide information
on the assembly progress of the capsid proteins into VLPs. Previous pub-
lications have also reported effects of the VLP tertiary structure on UV/
Vis and fluorescence absorption spectra [150]–[154]. Following a system-
atic approach to process monitoring, a combination of PAT sensors should
be chosen which allows to monitor protein concentration, protein tertiary
structure, and protein size.
In this study, we developed a CFF setup consisting of a commercial lab-
scale CFF device with a custom-made on-line measurement loop for pro-
cess analytical instrumentation. The on-line measurement loop included a
light-scattering photometer (DLS and SLS) and a UV/Vis absorption spec-
trometer. DLS allowed for monitoring the mean hydrodynamic diameter
of particles. SLS outputs an aggregated scattered-light intensity influenced
by the particle concentrations and the diameters. Finally, UV/Vis spec-
troscopy provided information on the protein concentration and on changes
in the tertiary structure by second derivative spectroscopy [32]. The use-
fulness of the custom-made setup was tested for monitoring the reassembly
of three different chimeric HBcAg variants at three different TMPs.
7.2 Materials and Methods
7.2.1 Experimental Setup
A custom-made setup was developed for the CFF experiments. Figure 7.2
shows the setup as a Piping and Instrumentation Diagram (P&ID). A Kros-
Flo KRIIi CFF unit with a modified Polyethersulfone (mPES) hollow fiber
membrane module (10 kDa cutoff, 13 cm2 membrane area) and a 50mL
conical tube retentate reservoir (all Spectrum Labs, Rancho Dominguez,
USA) made up the core of the CFF unit. A Topolino magnetic stirrer
(IKA Werke, Staufen im Breisgau, DE) ensured homogeneous mixing of
the retentate reservoir. A T-piece with injection plug (Fresenius Kabi, Bad
Homburg, DE) was inserted into the retentate line as sample port to draw
liquid for off-line analytics. The retentate reservoir was modified with two
additional PEEK capillaries to supply the on-line measurement loop with
liquid from the process.
In the direction of flow, the on-line measurement loop consisted of a
Gilson Minipuls 3 peristaltic pump, a 0.7 µm particle retention Minisart
glass fiber syringe filter (Sartorius Stedim Biotech, Göttingen, DE), a Ze-
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Figure 7.2: Piping and instrumentation diagram of the experimental setup.
At the bottom right, the online measurement loop is shown. The remaining
piping is required for the CFF. All sensors are connected to a computer for
capturing the data centrally. Electronic communication lines are indicated
by dashed lines. I-5 is a pinch valve actuated by a closed-loop controller for
the TMP. The letters indicate: C control, I indicate, P pressure, R record,
U multivariable, W weight, DAD diode array detector, LS light scattering.
tasizer Nano ZSP photometer (Malvern Instruments, Malvern, GB) with
a 10mm pathlength flowcell (Hellma Analytics, Müllheim, DE), an Ulti-
mate DAD-3000 DAD (Dionex Corporation, Sunnyvale, US) with a 0.4mm
pathlength flowcell, and a FR-902 flow restrictor (GE Healthcare, Chalfont
St Giles, GB). The pump of the on-line measurement loop was controlled
via a NI USB-6008 data acquisition device (National Instruments, Austin,
USA).
7.2.2 Proteins, Chemicals, and Buffers
Three chimeric HBcAg constructs , i.e. VLP A, B, and C provided by
BioNTech Protein Therapeutics GmbH (Mainz, DE), were used in this
study. The HBcAg variants were recombinantly modified in the Major Im-
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munodominant Region (MIR) to display three different peptides on their
surfaces (see also Figure 7.3).






Tyr 38, 6, 118
Figure 7.3: An assembled HBcAg VLP is shown on the left side (PDB ID
1QGT, [155]). The right side shows a cartoon of a single homodimer (adapted
from PDB ID 4BMG, [156]). The tryptophan (Trp) and tyrosine (Tyr) side
chains are depicted as sticks and colored in yellow and red, respectively.
Tyrosine and tryptophan side chains located in the base of the molecule
are numbered. These residues undergo a change of hydrophobicity in their
environment during assembly. The MIR loop, whereto the foreign epitope is
inserted, is shown in blue.
All variants were present as homodimer stock solutions in disassembly
buffer (3.5M urea, 50mM Tris(hydroxymethyl)-aminomethane, pH 9.0) as
obtained after purification (see also Figure 7.1). Protein concentration cal-
culations were based on extinction coefficients derived from the primary
structure as provided by the ProtParam tool [157] of the Swiss Institute of
Bioinformatics. Immediately before each experiment, stock solutions were
diluted with disassembly buffer to a protein concentration of 1 g/L (by
UV absorbance at 280 nm) and filtered through a 0.2 µm Polyethersulfone
(PES) filter (VWR International, Radnor, US). The reassembly buffer was
a high-salt buffer at pH 7.0.
For SEC, 50mM potassium phosphate at pH 7.0 was used as running
buffer. If not mentioned otherwise, chemicals were purchased from Merck
KGaA (Darmstadt, DE). All buffers and solutions were prepared with ultra-
pure water (arium pro UV, Sartorius, Göttingen, DE) and filtered through
a 0.2 µm pore size Supor filter (Pall, Port Washington, US) immediately
before each experiment.
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7.2.3 VLP Reassembly Monitoring
The CFF unit and the measurement loop were filled with ultrapure water
for pre-experimental preparation. The lamps of the DAD were turned on
at least 1 h before starting the experiments. At the end of the equilibration
phase, the absorbance signal was zeroed in ultrapure water. Subsequently,
the CFF unit and measurement loop were first flushed with disassembly
buffer and then changed into 25mL of protein solution. The CFF pump was
set to 70mL/min corresponding to a shear rate of approximately 6000 s−1
in the hollow fibers. The measurement loop pump (1mL/min) and data
acquisition were started.
After 5min, constant TMP diafiltration was initiated by applying a
TMP of 0.25 bar, 0.5 bar, or 1 bar with reassembly buffer as diluent. 0.4mL
samples were taken every 0.5Diafiltration Volumes (DVs) via the sample
port. Experiments were stopped after 3DV except for VLP C for which
the runs had to be terminated early due to membrane clogging. After each
run, the CFF membrane was cleaned with ultrapure water, a 0.1M sodium
hydroxide solution, and a 15 vol% ethanol solution.
For SEC analysis, samples were centrifuged (Centrifuge 5810R, Eppen-
dorf, Hamburg, DE) at 3220 rcf for 5min to settle large particles. The su-
pernatant was analyzed with a Sepax SRT SEC-1000 column (Sepax Tech-
nologies, Newark, US) on an Ultimate 3000 RS UHPLC system consisting
of a Pump HPG-3400RS, an Autosampler WPS-3000TFC, a Column Com-
partment TCC-3000RS, and a Diode Array Detector DAD-3000 controlled
by Chromeleon version 6.8 SR15 (all Thermo Fisher Scientific, Waltham,
US). The run duration was 7min with a flow rate of 0.8mL/min and SEC
buffer as a mobile phase. 20 µL were injected for each analysis. Samples
were analyzed in triplicates.
Off-line DLS analysis was performed using a sample volume of 45µL in
a 3x3mm quartz cuvette (Hellma Analytics, Müllheim, DE) and the same
DLS spectrometer as mentioned above. Unfiltered samples were measured
three times, each measurement consisting of 12 to 14 10 s runs at 25 ◦C, and
173° backscatter. Lower and upper limits for data processing were 1 nm and
6000 nm, respectively. The measurements were compared based on the VLP
peak diameter in the regularization fit.
The spectrometer was also used for electrophoretic mobility measure-
ments of pooled and formulated samples of each construct. The samples of
different TMPs were pooled and dialyzed into a pH7.2 buffer of 50mM Tris
and 100mM sodium chloride. Samples were filtered with a 0.2 µL polyether-
sulfone (PES) filter (VWR International, Radnor, USA) and concentration
was adjusted with Vivaspin 20 filters with a 30 kDa pore rating (Sartorius,
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Göttingen, DE). 50 µL of sample was inserted into buffer-filled folded dis-
posable capillary cells (DTS1070, Malvern Instruments Ltd., Malvern, UK)
using a diffusion barrier technique (Patent WO2012083272A1). Samples
were measured in pentaplicates in automatic mode. Each measurement
comprised a 120 seconds equilibration and five runs with up to 15 sub runs.
The measurements were performed at 60mV and 25 ◦C. Zeta potential was
calculated by Zetasizer Software version 7.12 (Malvern Instruments Ltd.,
Malvern, UK) assuming a material refractive index of 1.45, absorption of
0.001, a viscosity of 0.8872mPa s, a dielectric constant of 78.54, and a
Smoluchowski approximation of 1.5 [158].
7.2.4 Data Acquisition and Analysis
During experiments, all integrated sensors communicated with a custom
application developed in Matlab (version R2016b, The Mathworks, Natick,
US). Next to starting and stopping measurements, the application gathered
the sensor signals (3 pressure signals, the permeate weight, z-average, and
UV/Vis absorbance spectra). Communication and control were performed
through software libraries provided by the different instrument softwares.
The signals were displayed on the Graphical User Interface (GUI) and stored
on the hard drive with a time stamp. For calculating the permeate volume,
the density of the permeate was assumed to be 1 g/cm3. Data acquisition
and analysis of light scattering and UV/Vis measurements were performed
as described below.
Light-scattering Measurements
The Zetasizer Nano ZSP was utilized for DLS and SLS measurements us-
ing the chromatography flow Standard Operating Procedure (SOP) of the
Zetasizer software (version 7.12, Malvern Instruments). The Zetasizer ac-
quires data in a back-scattering geometry at 173°. Each measurement du-
ration was 10 s. While DLS measurements were exported on-line, SLS data
was extracted off-line. From the DLS measurement, the z-average was
obtained as calculated by the Zetasizer software by the method of cumu-
lants [159]. Viscosity (0.8872mPa s), refractive indices (protein 1.45; water
1.33) (as provided by the Zetasizer software), temperature (25 ◦C), and flow
rate (1mL/min) were assumed to be constant for the calculation of the z-
average. The z-average data was subsequently filtered by a moving median
over 60 s to remove outliers. The SLS signal was not filtered. The transition
from process phase I to process phase II was detected from the scattered-
light intensity by the CUSUM algorithm [160], [161]. The transition from
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process phase II to process phase III was set at the global maximum of the
scattered-light intensity.
UV/Vis Absorption Measurements and Processing
During VLP assembly, UV/Vis spectra were continuously acquired at 1Hz
in the spectral range from 240 nm to 340 nm with a resolution of 1 nm. To
gain information on the local environment of aromatic amino acids, the
spectral data was filtered by a moving average over 30 s and the second
derivatives were computed with a Savitzky-Golay filter [82] of order 5 with
a 9-point window [32], [151]. An example spectrum with the subsequent
data evaluation is shown in the Supplementary Material 7.6. The resulting
second-derivative spectra were interpolated with a cubic spline to a final
resolution of 0.01 nm. From the interpolated data, the location of the min-
imum near 292 nm was used as a measure of tryptophan solvent exposure
[32], [162]. The exposure of tyrosine was assessed based on the a/b-ratio as
defined by Ragone et al. [101]. Briefly, the vertical distance between trough
and peak near 285 nm a was normalized by the trough-peak distance near
294 nm b. The inflection point of the a/b-ratio over time was computed by
taking the first derivative with a second-order Savitzky-Golay filter (window
width 501 points corresponding to 8.35min) and finding the minimum.
PLS Model Calibration
PLS model calibration was performed in Matlab (version 2016a). For each
VLP, a PLS model was calibrated based on the UV/Vis spectroscopic data
in combination with the off-line SEC VLP concentration. Data of all three
TMPs were included into one model. PLS model calibration was performed
similarly as described previously [163]. The data were first preprocessed
and subsequently fitted with a PLS-1 model by the SIMPLS algorithm [99].
For preprocessing, a Savitzky-Golay filter with a second-order polynomial
was applied on the spectra and, optionally, the first or second derivative was
taken. Cross-validation was performed by iteratively excluding one sample









of the data), and calculating a residual sum of
squares on the excluded run. This procedure was repeated until all runs had
been excluded once. All residual sums of squares for the different submodels
were subsequently accumulated yielding the PRESS. The PRESS was scaled
according to Wold et al. by the number of samples and latent variables used
in the PLS model [30]. Based on the scaled PRESS, an optimization was
performed using the built-in genetic algorithm of Matlab for integers [100].
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The genetic algorithm optimized the window width of the Savitzky-Golay
filter 5 ≤ w ≤ 21, the order of derivative 0 ≤ n ≤ 2, as well as the number
of latent variables for the PLS-1 model 4 ≤ N ≤ 14. The RMSECV was
calculated from the PRESS by dividing by the total number of samples. The
Q2 and R2 values were calculated by dividing the PRESS, respectively the
residual sum of squares, by the summed squares of the response corrected
to the mean [30].
7.3 Results
In this study, a new UF/DF setup with on-line measurement loop was de-
veloped to monitor VLP reassembly steps. In the measurement loop, a
UV/Vis spectrometer and a light-scattering photometer were integrated.
Furthermore, an application was implemented in Matlab providing a GUI,
communication capabilities to the different sensors, as well as a common
time base for all performed measurements. This allowed for acquiring and
synchronizing measurements in a controlled manner. Within the applica-
tion, UV/Vis spectra, DLS measurements, pressure, and weight readings
were immediately available for processing and display. To demonstrate the
advantages of this experimental setup, nine UF/DF runs with three differ-
ent HBcAg constructs at three different TMPs were performed.
7.3.1 Monitoring of Standard Processes Parameters
During the UF/DF processes, the initial buffer was replaced by reassem-
bly buffer to form HBcAg VLPs from homodimers. In Table 7.1, process
data of all runs are summarized (original data plotted in Supplementary
Material 7.8). The tables also show that the feed stock purity of VLP A is
higher than VLP C and VLP B. At 0.25 bar TMP, VLP A, B, and C showed
nearly constant increases in permeate mass over time implicating constant
fluxes. The average flux for these three runs was 25.8 L/m2h to 29.1 L/m2h.
At 0.5 bar and 1 bar TMP, the average flux was higher for all three VLPs
(from 36.3 L/m2h to 48.7 L/m2h). CFF processes at 0.5 bar and 1 bar TMP
showed a decreasing flux over time after an initial constant phase (except
for VLP B at 0.5 bar). A decrease in flux at constant TMP indicates the
formation of a fouling layer on the membrane [164], [165].
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Table 7.1: Process data is summarized for all performed runs.
VLP A
TMP / bar 0.25 0.5 1
Feed stock puritya / % 73.5
Zeta potentialb / mV −7.9(7)
Total run time / min 118 78 75
Mean flux / (Lm−2 h−1) 30.5 46.9 48.4
Max. VLP conc. / (g/L) 0.248 0.275 0.250
Inflection a/b-ratio / DV 1.5 0.8 0.7
VLP peak diameterc / nm 40(6) 46(11) 42(7)
VLP B
TMP / bar 0.25 0.5 1
Feed stock puritya / % 22.6
Zeta potentialb / mV −11.8(6)
Total run time / min 133 75 79
Mean flux / (Lm−2 h−1) 26.8 48.7 45.9
Max. VLP conc. / (g/L) 0.126 0.133 0.116
Inflection a/b-ratio / DV 1.5 1.4 0.7
VLP peak diameterc / nm 35(5) 40(11) 46(10)
VLP C
TMP / bar 0.25 0.5 1
Feed stock puritya / % 44.1
Zeta potentialb / mV −9.5(8)
Total run time / min 108 71 70
Mean flux / (Lm−2 h−1) 27.6 36.3 40.0
Max. VLP conc. / (g/L) 0.134 0.103 0.126
Inflection a/b-ratio / DV 1.6 0.9 0.6
VLP peak diameterc / nm 41(12) 48(5) 36(11)
a assessed by reversed-phase chromatography as described in the Supplementary
Material 7.7.
b denotes median and median absolute deviation in parenthesis.
c denotes mean and standard deviation of all DLS acquisitions (n = 36− 42) in
parenthesis.
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7.3.2 Process Monitoring with On-line PAT Sensors
In Figures 7.4, 7.5, and 7.6, the on-line PAT sensor measurements as well
as off-line analytics are shown for VLP A, B, and C, respectively. All data
were plotted over DV indicating the progress of buffer exchange. Each figure
shows the absorbance at 280 nm, off-line VLP concentration measurements
by SEC, second-derivative spectral analysis, and light-scattering data. It is
important to note that an insufficient scattered-light intensity was recorded
for VLP C at 1 bar TMP due to an incorrectly set laser attenuation. The
corresponding light-scattering results were excluded. The run could not be
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Figure 7.4: The figure displays the on-line sensor measurements as well as
off-line analytics against the DV of VLP A. The rows display measurements
of different sensors. Top row: Off-line VLP 3 and aggregate # concentration
measurements by SEC, UV absorbance at 280 nm –. Middle row: DLS and
SLS measurements. Roman numbers indicate the different process phases.
Bottom row: Second-derivative spectral analysis for tyrosine (a/b-ratio) and
tryptophan (location of the minimum around 292 nm). The inflection point of
the a/b-ratio is marked by a vertical bar. The columns correspond to different
TMPs. Left column: 0.25 bar, middle column: 0.5 bar, right column: 1 bar.
At 0.25 bar TMP the z-average is corrupted with noise early in the process.
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Figure 7.5: The figure displays the on-line sensor measurements as well as
off-line analytics against the DV of VLP B. The rows display measurements
of different sensors. Top row: Off-line VLP 3 and aggregate # concentration
measurements by SEC, UV absorbance at 280 nm –. Middle row: DLS and
SLS measurements. Roman numbers indicate process phases. Bottom row:
Second-derivative spectral analysis for tyrosine (a/b-ratio) and tryptophan
(location of the minimum around 292 nm). The inflection point of the a/b-
ratio is marked by a vertical bar. The columns correspond to different TMPs.
Left column: 0.25 bar, middle column: 0.5 bar, right column: 1 bar.
Off-line SEC was performed in triplicates resulting in standard devia-
tions smaller than 0.011 g/L. In all runs, the off-line VLP concentration
first remained at zero followed by an increase to the maximum VLP con-
centration. Thereafter, the concentration was approximately constant or
decreased slightly. Depending on the TMP, off-line VLP concentration
started to increase at 0.5DV to 1.5DV. The onset occurred at a DV that
was lower the higher the TMP. The maximum observed VLP concentration
was between 0.248 g/L and 0.275 g/L for VLP A, between 0.116 g/L and
0.133 g/L for VLP B, and between 0.103 g/L and 0.134 g/L for VLP C. The
SEC aggregate content was between 5% to 15% of the VLP concentration.
UV absorbance at 280 nm decreased in all runs over time. Small step-
like decreases were due to sampling for off-line analytics. The drawn sample
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Figure 7.6: The figure displays the on-line sensor measurements as well as
off-line analytics against the DV of VLP C. The rows display measurements
of different sensors. Top row: Off-line VLP 3 and aggregate # concentration
measurements by SEC, UV absorbance at 280 nm –. Middle row: DLS and
SLS measurements. Roman numbers indicate process phases. Bottom row:
Second-derivative spectral analysis for tyrosine (a/b-ratio) and tryptophan
(location of the minimum around 292 nm). The inflection point of the a/b-
ratio is marked by a vertical bar. The columns correspond to different TMPs.
Left column: 0.25 bar, middle column: 0.5 bar, right column: 1 bar. DLS and
SLS measurements at 1 bar were excluded because of an erratically set laser
attenuator.
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volume was replaced by reassembly buffer resulting in dilution of the process
liquid. For VLP A, B, and C, a rapid decrease in the absorbance at 0.25 bar
TMP occurred towards the end of the runs, suggesting a loss of protein.
Solvatization of aromatic amino acids and particle formation were ob-
served during CFF by on-line UV/Vis and light-scattering measurements.
UV/Vis spectral data were examined by second derivative analysis. From
the derived spectra, characteristics were calculated for the solvatization of
tryptophan (location of the minimum around 292.5 nm) and tyrosine (a/b-
ratio) [32]. For all runs, a shift towards longer wavelengths of the trypto-
phan minimum was observed, while the a/b-ratio decreased. Both trends
indicated an increase in the mean hydrophobicity around tryptophans and
tyrosines. Especially for higher TMPs, the characteristics followed a sig-
moidal curve shape. The inflection points of the a/b-ratio in all runs were
marked by a vertical line and were located either around 0.8DV or 1.5DV
(see Table 7.1).
DLS measurements were interpreted based on the z-average. In all ex-
periments, an initial phase of relatively constant z-average values below
20 nm was observed. The second phase was characterized by a rapid in-
crease in z-average to around 40 nm for TMPs of 0.5 bar and 1 bar. At
a TMP of 0.25 bar, the second phase showed a larger increase of the z-
average to 50 nm to 80 nm. The third phase resulted in relatively constant
z-averages over time.
SLS measurements are influenced by the particle diameter and con-
centration. Similar to the z-average, scattered-light intensities started to
increase after an initial constant phase. The increase continued even after
the z-average reached a plateau and eventually flattened. For VLP A and C
at 0.25 bar TMP, scattered-light intensities rapidly decreased towards the
end of the runs.
At 0.5 bar and 1 bar, z-averages, scattering intensities, and SEC VLP
concentrations of each run started to increase simultaneously within off-line
time resolution. Interestingly, for processes at 0.25 bar, the z-averages and
scattering intensities increased earlier than VLP and aggregate concentra-
tion by SEC. The initial increase in phase two at 0.25 bar ended at high
z-averages > 45 nm, not observed in the other processes. In all runs, the
inflection point of the a/b-ratio occurred around the steepest increase in
the VLP concentration by SEC.
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7.3.3 Selective Prediction of VLP Concentration by
PLS Modeling
The PLS model calibration results are shown in Figure 7.7 and Table 7.2.
Figure 7.8 shows the PLS regression coefficients. All PLS models were
fitted to the second derivative of the UV/Vis spectral data with 6 to 9
latent variables. The achieved Q2 values were 0.984, 0.984, and 0.947 for
VLP A, B, and C, respectively.






















0 1 2 3
DV
VLP B
0 1 2 3
DV
VLP C
1 bar TMP 0.5 bar TMP 0.25 bar TMP
Figure 7.7: A PLS model was fitted to the UV/Vis spectral data for each
construct to predict the concentration of assembled VLPs. The concentration
predicted by the calibrated PLS model is compared to off-line analytics in
the current plot. Each TMP is reflected by a color. The markers show the
concentration measured by off-line analytics while the lines correspond to
the concentrations predicted by the PLS model.
Table 7.2: Spectral preprocessing parameters, parameters for the PLS
model, and the prediction quality of the chemometric models are summa-
rized.
VLP A VLP B VLP C
No. of samples 21 21 18
No. of cross-validation groups 7 7 6
No. of latent variables 6 9 7
Window Savitzky-Golay filter 7 9 9
Derivative 2 2 2
R2 0.995 0.997 0.994
Q2 0.984 0.984 0.947
RMSECV / (g/L) 0.01 0.01 0.01
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Figure 7.8: Regression coefficients of the three PLS models. Each row
corresponds to the regression coefficients of one VLP in black while the other
regression coefficients are supplemented in gray.
7.3.4 Analysis of Post-Assembly Samples
Off-line DLS data was measured at the end of all processes. The VLP peak
diameter data is shown in Table 7.1. 36 to 42 acquisitions were used to cal-
culate a mean diameter and standard deviation. The mean diameter across
all runs was 41 nm nm with a standard deviation of 11 nm. Median zeta po-
tentials and corresponding median absolute deviations were calculated from
25 runs of the 5 measurements for each VLP construct (compare Table 7.1).
VLP B was had the most negative zeta potential with−11.8(6)mV, followed
by VLP C with −9.5(8)mV, and VLP A with −7.9(7)mV.
7.4 Discussion
7.4.1 On-line Measurement Setup
As shown in Figure 7.2, the experimental setup included a flow restric-
tor and a filter next to the sensors in the on-line measurement loop. The
flow restrictor and filter were added to improve the measurement quality.
The flow restrictor set a minimal back pressure in the measurement loop
reducing pressure fluctuations and air bubbles. The filter (cut-off 0.7 µm)
retained bubbles and large particles adversely affecting light-scattering mea-
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surements. The light-scattering measurements depend strongly on the par-
ticle diameter d [166]. Thus, large particles, such as air bubbles or large
aggregates, can completely obliterate the light scattering of smaller particles
in SLS and DLS measurements.
7.4.2 Interpretation of SLS and DLS Measurements
During VLP reassembly, anticipated particles in the process solution were
homodimers, VLPs, VLP aggregates, and process-related impurities, all of
which contributed to light scattering. Thus, the scattered-light intensity is a
sum signal generated by all scattering species. By neglecting any interaction
between the particles and assuming Rayleigh scattering, the scattered-light







where i iterates over all species, ci is the molar concentration of species
i, and di is the diameter of species i. Based on this formula, it can be
verified that particle agglomeration and concentration leads to increased
scattered-light intensities.
The z-average is the intensity-weighted harmonic mean hydrodynamic
diameter [167]. Therefore, the z-average is not proportional to the concen-
tration but reflects an apparent mean particle diameter. A small fraction
of large particles can still significantly increase the z-average. During re-
assembly, an increase of scattered-light intensity and z-average was expected
because of the formation of VLPs and aggregates.
7.4.3 DLS Measurements in Flow
DLS measures the time correlation of scattered-light intensity. In contrast
to the typical DLS measurement setup, the time correlation in the on-line
measurement loop was not only influenced by diffusion but also by convec-
tive flow [168]. It has been previously demonstrated that the convective
flow results in increased estimated diffusion coefficients and thus in reduced
particle diameters [169]. The effect was shown to be more pronounced for
larger particles. Consequently, underestimation of particle sizes was ex-
pected to be more pronounced for aggregates than VLPs than homodimers.
No effect on SLS was expected from convective flow.
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7.4.4 General Considerations on the VLP Assembly
Processes
During the diafiltration process, the disassembly buffer was gradually ex-
changed by an assembly buffer. The chemical environment of the HBcAg
dimers increasingly favored assembly. This is different to the conventional
approach in VLP kinetic studies where the composition of the assembly
reaction liquid is usually adjusted by rapid dilution [170], [171]. In said
studies, assembly equilibrium phases were reached in a few minutes. Given
the comparably large time frame of diafiltration experiments (75min to
135min), we assume that the VLP concentration was almost exclusively
dependent on the buffer composition.
Figure 7.9 illustrates the formation of particles out of HBcAg dimers
during a diafiltration process and expected sensor responses. The diafil-
tration process was split into phases 1 to 3 based on different reactions
occurring during each phase.
In phase 1, buffer exchange starts but no assembly occurs, i.e. the VLP
concentration remains zero. However, aggregates may form resulting in an
increase in scattered-light intensity and z-average, as seen in Figures 7.4,
7.5, and 7.6.
In phase 2, homodimers assemble into VLPs. Native HBcAg VLPs are
30 nm to 34 nm in diameter [172]. VLP concentration increases to its max-
imum, while the scattered-light intensity and z-average continue to rise.
To explain the sensor response more comprehensively, phase 2 was sub-
divided into two subphases, 2a and 2b. In subphase 2a, z-average and
scattered-light intensity both increase. In subphase 2b, scattered-light in-
tensity further increases while z-average remains constant. The increase in
scattered-light intensity is caused by the ongoing formation of VLPs and ag-
gregates. Conversely, the z-average stagnates as it is an intensity-weighted
harmonic mean. When the z-average is close to the size of VLPs, further
assembly has only a small effect on the z-average, while the scattered-light
intensity still increases due to the formation of particles.
In phase 3, the VLP concentration no longer increases. Thus, the end
of the assembly process is reached. A loss of aggregates is reflected by a
decrease in z-average and scattered-light intensity. A decrease in scattered-
light intensity and UV absorbance with constant z-average reflects a de-
crease in overall protein concentration with constant particle size distribu-
tion.
Towards the end of some processes (most pronounced for VLP A and
C at 0.25 bar), both light-scattering signals decreased combined with a de-
crease in the UV signal at 280 nm. Thus, the protein concentration de-
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CFF process progress

































Figure 7.9: Theoretical consideration of particle formation during the as-
sembly process by CFF. Homodimers, aggregates, and VLPs are shown as
schematics. The expected development of SLS, z-average, and VLP concen-
tration signals is shown over the CFF process progress subdivided into four
phases. In the process, the buffer of a homodimer solution is gradually ex-
changed by assembly buffer to initiate VLP assembly. In phase 1, few aggre-
gates are formed and no assembly takes place. The formation of aggregates
increases the light-scattering signals while the VLP concentration remains
at zero. As a consequence of exceeding a critical buffer composition, VLPs
start to form in phase 2a, visualized by an increase in VLP concentration.
The light-scattering signals continue to increase as a response to particle for-
mation. In phase 2b, assembly continues, indicated by a further increase in
VLP concentration and static light scattering. The z-average remains com-
parably constant as its value is already close to the actual VLP diameter
and is thus only marginally influenced by further assembly. In phase 3, the
assembly reaction is no longer proceeding. Particles are depleted resulting
in a decrease in the light-scattering signals.
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creased due to adsorption to the CFF membrane or retention on the mea-
surement loop filter. The elevated salt concentration of the process liquid
at this stage of the process may have promoted adsorption of protein to
the hollow fiber membrane [146]. In both runs, the z-average started to
decrease already earlier than the UV signal at 280 nm around the location
of the inflection point of the a/b-ratio while the UV absorbance was still
approximately constant. This could indicate a partial disintegration of ag-
gregates. Phase 3 was generally short, as either its onset was close to the
final DV or the process was stopped early due to membrane fouling.
The assembly of HBcAg VLPs also induces changes in mean hydropho-
bicity around aromatic amino acids as capsid assembly relies on hydropho-
bic interaction forces [155], [173]. Tyrosine-132 is especially important for
the assembly [174]. In homodimers, tyrosine-132 is highly solvent-exposed,
as shown in Figure 7.3. After VLP assembly, tyrosine-132 is buried in a
hydrophobic pocket of the neighboring homodimer. During diafiltration,
the solvatization of tyrosine changes because of aggregation as well as VLP
assembly. If the mean effect on hydrophobicity by aggregation is small com-
pared to the mean effect caused by assembly, the change over time of the
a/b-ratio correlates to the rate of assembly. As a result, its inflection point
marks the point of the highest rate of assembly. Similarly, the increase in
the wavelength of the tryptophan absorption minimum marks an increase
in hydrophobicity around tryptophans. Since the change in the solvent ex-
posure of tryptophans during VLP assembly is less pronounced, the effect
is weaker and more biased by aggregation.
7.4.5 CFF for VLP Assembly
VLP A was assembled from the purest dimer stock solution of the three
investigated VLPs. The process was thus expected to perform comparably
well. This agreed with the experimental results at 0.5 bar and 1 bar TMP.
The observed z-averages of 28 nm to 29 nm in phase 3 showed that there
was a significant fraction of VLPs. Few large particles were generated while
other factors such as the flow reduced the z-average compared to off-line
DLS analytics (see Table 7.1). The higher final z-average and an elevated
scattered-light intensity at 0.25 bar TMP provided evidence of the formation
of large aggregates. The observations made for VLP A were in general also
applicable to VLP B and C. Both VLPs were adversely affected at lower
TMPs by aggregation reflected by increased z-averages and light-scattering
intensities.
A further interesting result of this study was the clustering of the in-
flection points of the a/b-ratio either around 1.5DV or around 0.8DV. An
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early inflection point is consistent with early VLP formation. Conversely, a
late inflection point correlated to an early increase in aggregates. By keep-
ing in mind that the DV is indicative of the progress of buffer exchange, the
conclusion may be drawn that VLP assembly is inhibited by aggregates.
Indeed, a similar conclusion was previously proposed for MuPyVP1 VLPs
[175]. Ding and coworkers described a competition of capsomere association
into aggregates and precursors of MuPyVP1 VLPs.
The results of the diafiltration experiments for all VLPs showed that a
low TMP of 0.25 bar lead to an increased aggregation propensity and an
increased process time compared to the other conditions. At 0.5 bar and
1 bar TMP, the process time, VLP concentration, and aggregate content
depended on the VLP construct and stock purity but were not solely de-
pendent on the TMP. For increased yield and decreased aggregate content,
it could be helpful to introduce a further purification step for VLP B and
C. In all runs, aggregate concentration by SEC did not reflect the data
obtained by light scattering. The reason for this seemed to be that large
aggregates were depleted during sample preparation or in the SEC column.
As a consequence, light scattering provided a more complete picture of the
aggregate content.
Process phase III is characterized by product loss. The process should
therefore be terminated at the end of phase II. It is worth noting that
the end of phase II is influenced by the VLP construct but seems to be
independent of the applied TMP. No plateau or decrease in assembly was
observed for VLP B. VLP B was charged strongest, requiring higher ionic
strengths to overcome the electrostatic charges of the homodimers during
assembly (see Table 7.1). Zeta potentials of VLP A and C are similar. For
both, a transition into phase III was observed.
To compare the assembled VLPs with standard characterization meth-
ods, we performed DLSmeasurements on the assembled VLPs. Off-line DLS
VLP peak diameters are comparable to that of wild type HBcAg VLPs (typ-
ically 30-34 nm [172]) with a mean of 41 nm and a standard deviation of
11 nm. No significant influence of the TMP or construct on the final VLP
peak diameter could be observed.
In summary, the analytical measurements of the VLP size and structure
confirm the information obtained from the PAT tools.
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7.4.6 Benefits of Using PAT for Process
Development and Production
PAT is currently a frequently investigated approach of increasing the ac-
quired information about unit operations in biopharmaceutical process de-
velopment and production by timely measurements. Generating informa-
tion on the process in (near) real time potentially results in a better un-
derstanding, faster optimization, and reduced off-line analytical samples
[18].
Here, the UV absorbance at 280 nm provided insight into changes in
the concentration of protein and other absorbing species in real time. This
can be of advantage for assessing the membrane performance (e.g. mem-
brane fouling, pore rating out-of-specification, or membrane damage). A
mechanistic understanding is, however, often not possible solely based on
a single wavelength. A more in-depth view on the on-going processes dur-
ing UF/DF could be realized based on the acquired UV/Vis spectra. For
HBcAg, tyrosine-132 is especially important for the VLP assembly. The
a/b-ratio provides a mechanistic insight into the assembly reaction based on
the mean tyrosine solvatization. Furthermore, other UV/Vis chromophores
are phenylalanine, tryptophan, and disulfide bridges [32]. These may be
affected during the assembly of other VLPs. For example, during the as-
sembly of human papilloma virus-like particles, disulfide bridges are the key
to the formation of higher-order structures [176]. Next to means for quan-
tification, the UV/Vis spectrometer implemented in the presented setup
thus provides mechanistic process understanding.
Another changing protein attribute, which can be monitored, is the par-
ticle size. The significant increase in size has a large impact on the scattering
characteristics of the process fluid. The light-scattering spectrometer thus
allowed for the detection of the start of the assembly reaction and maximal
VLP concentration. Light-scattering spectrometers are universal detectors
that are not dependent on the protein primary structure. As a consequence,
any VLP assembly reaction can be monitored with this technique. In de-
velopment and production, light-scattering detectors provide the means for
detecting the ideal point to stop CFF or to initiate the next process step.
This can improve the product quality (as process phase III is omitted) and
allow for process intensification.
Generally, the on-line sensors provide data with high temporal resolution
which typically is difficult to achieve with off-line analytics. In consequence,
smaller changes in process characteristics (e.g. assembly onset, end of phase
II) can be detected. This may be helpful for the further assessment of
111
Spectroscopic PAT for Protein Purification
different processes in development or for detecting deviations or hidden
trends in production.
For process monitoring in production, it may be beneficial to retrieve
VLP concentrations in real time. A PLS model was thus developed to
demonstrate the possibility to monitor VLP concentration on-line by UV/
Vis spectroscopy. The model was optimized by a constrained heuristic
search algorithm. The minimal number of four latent variables was set to
reflect the minimal amount of independent UV-active species (VLP concen-
tration, DNA concentration, urea concentration, and aggregates). Reliable
VLP concentration predictions were possible for all three constructs. In
production, UV/Vis measurements in conjunction with a PLS model could
thus be used for the real-time assessment of the assembly progress and ulti-
mately for process control. Based on the regression coefficients of the PLS
model (Figure 7.8), it is clearly visible that the fine structure of the tyro-
sine and tryptophan absorption is of major importance for the regression.
Therefore, the PLS model accesses information similar to that provided by
the a/b-ratio and the tryptophan minimum. The differences between the
regression coefficients for VLP A, B, and C were attributed to the changing
purity of the stock solutions. Provided that no additional chromophores are
introduced into the MIR, a universally applicable PLS model for different
HBcAg constructs is conceivable. This may be evaluated further in future
studies.
7.5 Conclusion and Outlook
In this study, we investigated HBcAg assembly by diafiltration of three
different constructs at three different TMPs. We developed an on-line mea-
surement setup consisting of a UV/Vis and a light-scattering sensor (DLS
and SLS) with a unified software platform. This setup allowed for monitor-
ing mean particle sizes, hydrophobicity around tyrosine and tryptophan as
well as UV/Vis spectra. Based on the UV/Vis spectra, we calibrated three
PLS models for predicting VLP concentrations in real-time. Regarding pro-
cess performance, we observed that processes with hollow fiber modules at
0.25 bar TMP resulted in increased aggregation. In all processes, the maxi-
mum rate of assembly occurred around two characteristic DV. This behavior
was interpreted as a result of aggregation-related inhibition of VLP assem-
bly, which makes it especially important to prevent aggregation in a VLP
assembly process. In summary, the established setup has shown great po-
tential for improving process monitoring, development, and understanding
during VLP assembly by diafiltration.
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In the future, strategies may have to be developed for process control
during VLP reassembly. The proposed setup allowed for monitoring central
quality attributes during the process with and without calibrated chemo-
metric models. It is therefore a good starting point for any further research
in this direction. From a process development point of view, the current
results have not yet shown a reduced process efficiency at the highest TMP.
A further increase in TMP may thus be attractive. Alternative membrane
options, such as membrane cassettes, could strongly affect the process and
may be interesting to evaluate with the setup.
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7.6 Supplementary Material: Calculation of
Local Hydrophobicity around Aromatic
Amino Acids
The local hydrophobicity around tryptophan and was assessed by perform-
ing a second derivative on the UV/Vis spectra and interpolating the result-
ing data. An interpolated derivative spectrum is shown in Supplementary
Figure 7.10. The spectrum is annotated with the tryptophan minimum, the
a-value, and the b-value. The a and b values are used for calculating the
a/b-ratio by dividing the former through the latter.
7.7 Supplementary Material:
Reversed-phase Chromatography
The purity of the stock solutions was assessed by reverse-phase chromatog-
raphy based on the absorbance of the eluting species at 280 nm. The stock
solutions were analyzed with a Waters Acquity BEH300 C4 1.7 µm column
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Figure 7.10: An interpolated second derivative spectrum of VLP A is
shown. The tryptophan (Trp) minimimum, the a-value, and the b-value
are marked.
(Waters Corporation, Milford, US) on an Ultimate 3000 RS UHPLC sys-
tem consisting of a Pump HPG-3400RS, an Autosampler WPS-3000TFC,
a Column Compartment TCC-3000RS, and a Diode Array Detector DAD-
3000 controlled by Chromeleon version 6.8 SR15 (all Thermo Fisher Sci-
entific, Waltham, US). The run duration was 6.8min with a flow rate of
0.45mL/min at a temperature of 80° with solvent A as 0.1% TFA in wa-
ter and solvent B as 0.1% TFA in acetonitrile. Equilibration was done at
5% B, and a gradient of 4.7min was run from 23.5% to 63.5% B. The
column was stripped with 95% B for 0.5min and then reequilibrated at
5% B for 1.3min. 2 µL were injected for each analysis. Samples were ana-
lyzed in triplicates. The purity of the stock solutions was calculated as the
percentage of absorbance at 280 nm of the respective HBcAg construct of
the total absorbance of all eluting species.
7.8 Supplementary Material: CFF Process
Progress
For interested readers, the permeate mass over time of the different pro-
cesses is shown in Supplementary Figure 7.11.
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VLP A VLP B VLP C
1 bar 0.5 bar 0.25 bar
Figure 7.11: In the top row, the permeate mass over process time is shown.
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Abstract
Current biopharmaceutical production heavily relies on chromatography
for protein purification. Recently, research has intensified towards finding
suitable solutions for monitoring the chromatographic steps by multivari-
ate spectroscopic sensors. Here, hard-constraint MCR was investigated as
a calibration-free method for factorizing bilinear preparative protein chro-
matograms into concentrations and spectra. Protein elutions were assumed
to follow Exponentially Modified Gaussian (EMG) curves. In three case
studies, MCR was applied to chromatograms of second-derivative UV/Vis
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spectra. The three case studies consisted of the separation of a ternary
mixture (ribonuclease A, cytochrome c, and lysozyme), multiple binary
chromatography runs of cytochrome c and lysozyme, and the separation
of an ADC from unconjugated IgG. In all case studies, good estimates of
the elution curves were obtained. R2 values compared to off-line analyt-
ics exceeded 0.90. The estimated spectra allowed for protein identifica-
tion based on a protein spectral library. In summary, MCR was shown to
be well able to factorize protein chromatograms without prior calibration.
The method may thus substantially simplify analysis of multivariate pro-
tein chromatograms with multiple co-eluting species. It may be especially
useful in process development.
8.1 Introduction
In modern biopharmaceutical protein purification, preparative chromatog-
raphy is the method of choice for capturing and polishing steps [19]. Chro-
matography is popular because it can simultaneously deliver high purity and
high yield. To achieve the necessary performance, chromatographic steps
need to be well-designed. Already slight process changes can influence the
quality profile of the product [3]. The situation is further complicated due
to the necessity of complex off-line analytical methods for assessing the
quality of biopharmaceuticals.
As a means to improve process monitoring, control and understanding
in development and production, PAT has raised a lot of interest [2], [5], [18],
[76], [149]. The goal of PAT is to develop and implement sensors which allow
for (near) real-time monitoring of quality attributes. Most frequently, on-
line and at-line HPLC has been used for different applications including the
monitoring of capture and polishing steps [11], [13]–[16], [107].
Recently, spectroscopic approaches in combination with MVDA for the
retrieval of overlapping peaks have become more popular [76]. Spectroscopic
methods are often non-invasive, fast, and robust [18]. They have been
used for the selective in-situ quantification of proteins in multi-well plates
[39], [41] and selective in-line quantification in preparative chromatography
[42]–[44], [76], [163]. These applications have in common that they use
spectroscopic data and PLS modeling for selective protein quantification.
As PLS regression generates correlative models, a calibration has to be
performed prior to application. Furthermore, the model may be susceptible
to degeneration and needs to be tested regularly.
As an alternative method for evaluating spectra, MCR has been widely
discussed [177]–[179]. MCR maximizes the explained variance of factors
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while physically or chemically meaningful constraints are imposed on the
behavior of the pure components. Predominantly employed in analytical
chemistry, the evolution of MCR is still ongoing, regarding both theory and
application [178]. Nevertheless, it has already been used for the resolution of
complex chemical mixtures since the 1980s [180], [181]. Since then, different
algorithms have been developed for various applications [178].
Regarding the application of MCR for the resolution of protein chro-
matograms, literature is scarce. Compared to small molecules, different
protein spectra exhibit a lower degree of variability [39], which makes res-
olution more challenging. Additionally, observed ‘pure’ protein spectra are
often combinations of multiple heterogeneities. During a chromatographic
elution, these heterogeneities may be separated resulting in a variation of
the spectra even for ‘pure’ components. Vandeginste et al. published a
method for three-component curve resolution of proteins in 1985 [182].
More recently, a hybrid-MCR algorithm was shown to be able to deter-
mine accurate retention times of simulated SEC chromatograms for up to
four co-eluting proteins [183]. Due to the interesting findings of the above
study and the efforts necessary for calibrating a statistical model, a further
evaluation of MCR for preparative protein chromatography is of interest.
In this study, we investigated the factorization of UV/Vis spectral data
from preparative protein chromatography. To increase spectral differences
of proteins, second derivative spectral pretreatment was applied. The ob-
tained spectra were analyzed by an EMG-constrained MCR algorithm. The
factorization was based on the Pure Component Decomposition (PCD) al-
gorithm originally proposed by Neymeyr et al. [184]. In a first case study,
three model proteins (ribonuclease A, cytochrome c, and lysozyme) were
separated by CEX. A second case study factorized an augmented data ma-
trix from multiple binary elutions of the model proteins cytochrome c and
lysozyme. A third case study monitored the separation of a surrogate ADC
from its unconjugated IgG by HIC. In all case studies, the estimated concen-
tration profiles were compared to off-line analytics. The estimated spectra
of the three case studies were compared to a protein spectral library.
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8.2 Theory
8.2.1 MCR by PCD
Considering a spectroscopic transmission measurement, the absorbance gen-
erally follows the Lambert-Beer law. For a multi-wavelength and multi-com-
ponent case, it reads:
A = CST + E, (8.1)
where A ∈ Rn×m is the absorbance matrix, C ∈ Rn×o is the concentration
matrix, S ∈ Rm×o is the spectral matrix and E ∈ Rn×m is the residual ma-
trix. n, m and o refer to the number of samples, the number of wavelengths
and the number of species, respectively.
The goal of MCR is to retrieve approximate C and S from A under
certain constraints such as the chromatographic elution profile. As pro-
posed by Sawall et al. [185], this can be formulated by adapting the PCD
algorithm [184] as a minimization problem of the function
F (C, S, p) =
∣∣∣∣ A− CST ∣∣∣∣2
F
+ γ fhard(C, S, p). (8.2)
The first part on the right-hand side consists of the squared Frobenius
matrix norm of the residual matrix E. It thus describes the deviation of the
product of the computed matrices C and S from the absorbance data. For a
good solution, the Frobenius norm should be close to zero. The second part
fhard(C, S, p) defines an error term for additional hard constraints which are
discussed in subsection 8.2.2. p are the parameters for the hard constraints.
For the current application, fhard(C, S, p) was multiplied by a weighting
factor γ = 100 to penalize deviations from the hard constraints strongly
[185].
Estimating C and S can be difficult, as both matrices may contain a
large number of entries. It was previously proposed to retrieve estimates of
C and S by rotating a limited number of factors from an easy to compute
matrix factorization scheme such as Singular Value Decomposition (SVD)
[184]–[186] or PCA [187]. SVD factorizes the original absorbance matrix
into the matrices U ∈ Rn×n, Σ ∈ Rn×m and V ∈ Rm×m according to
A = UΣV T . (8.3)
U and V are orthonormal matrices. Σ is a rectangular diagonal matrix with
the singular values si on the diagonal. The entries are ordered according
to their magnitude, i.e. s1 ≥ s2 ≥ · · · ≥ 0. The original matrix A can now
be low-rank approximated with only a small number of q singular values
Σ̃ = Σ(1 : q, 1 : q) and singular vectors Ũ = U(:, 1 : q), Ṽ = V (:, 1 : q).
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The number of included factors needs to be evaluated depending on the
experiment. Often, q is equal to the number of species in the mixture o.
Importantly, the low-rank approximation by SVD captures the maximum
possible amount of variance from A with the given number of factors q.
The concentration matrix C and spectral matrix S can now be approx-
imated as a rotation of the singular vectors by T ∈ Ro×q.





T−1 denotes the matrix inverse. If o 6= q, T−1 is replaced by pseudo inverse
T+. Neymeyr et al. proofed that a perfect reconstruction of C and S
in Equation (8.4) is possible in the absence of noise [184]. The objective
function is now reformulated to
G(T, p) = F (ŨΣ̃T−1, Ṽ T T , p). (8.5)
Through the low-rank approximation of A, the matrix factorization problem
is thus simplified to estimating o× q rotational parameters and p.
8.2.2 Formulation of the EMG Hard Constraint
It is worth noting that Equation 8.1 and the Frobenius norm in Equa-
tion (8.2) and (8.5) do not take into account any time correlation of the
concentration. Thus, any intended time correlation needs to be captured
by fhard(C, S, p). In chromatography, the elution of different components
is often empirically described as EMG curves [19]. An EMG describes a
Gaussian peak convoluted with a continuously stirred tank reactor. It is
selected as a hard constraint on the columns of C. A similar approach was
recently taken by Arase et al. who factorized analytical chromatograms of
small molecules by MCR with a bidirectional EMG constraint [188]. In this
work, the EMG computation c(t;h, µ, σ, τ) proposed by Kalambet et al. is
used [189].
























































Here, t refers to the time. h is a scaling factor of the EMG. µ and σ
denote the mean value and standard deviation of a Gaussian peak before
convolution. τ is the decay constant of the continuously stirred tank reactor.
Additionally, fronting can be implemented by reflecting t at µ for negative
τ , i.e. t̂ = 2µ− t and c(t̂;µ, σ,−τ) if τ < 0.
For each species, an EMG peak shape is now included as a hard con-







(Cij − c (ti; p(:, j)))2 , (8.8)
where p is the parameter matrix containing 4 × o entries. As the EMG
is positive for h > 0, a constraint on C ≥ 0 is implicitly set. Due to
the application to second derivative spectra, the spectral matrix S is not
≥ 0 but may also have negative entries. As a result, no constraint on the
positivity of the spectral matrix must be set.
The objective function G(T, p) can now be solved with a deterministic
numerical solver. We used a quasi-Newton approach as implemented in
MATLAB (version 2016a, The Mathworks, Naticks, US). For our purposes,
the optimization is split into multiple substages. First, only p is released
for optimization. Next, T is optimized for the estimated p. After conver-
gence, the EMG scaling factors h are multiplied into the rotational matrix
T . Finally, all remaining parameters are released for optimization until
convergence is achieved. The staged approach helps to prevent the solver
from diverging.
8.3 Materials and Methods
8.3.1 Proteins and Buffers
In Table 8.1, the proteins used in this paper and their respective manu-
facturer are listed. All protein solutions and buffers were produced with
Ultrapure Water (PURELAB Ultra, ELGA LabWater, Veolia Water Tech-
nologies, Saint-Maurice, France). After thorough mixing, the buffers were
pH adjusted with HCl, filtrated with cellulose acetate filters with a pore size
of 0.2 µm (Sartorius, Göttingen, Germany) and degassed by sonification.
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Table 8.1: All proteins used for this study are listed with their respective
manufacturer.
Protein Manufacturer
Ribonuclease A from bovine pancreas Sigma Aldricha
Cytochrome c from bovine heart Sigma Aldrich




Bovine serum albumin Sigma Aldrich
apo-Transferrin human Sigma Aldrich
Myoglobin from equine skeletal muscle Sigma Aldrich
Glucose oxidase from aspergillus niger Sigma Aldrich
a St. Louis, US; b Gaithersburg, US; c Ljubljana, SL
8.3.2 Preparative Chromatographic Instrumentation
The preparative chromatographic runs were performed using a custom-
made experimental setup consisting of a conventional liquid chromatogra-
phy system and a DAD. The liquid chromatography system was an ÄKTA
purifier 10 equipped with pump P-900, sample pump P-960, UV moni-
tor UV-900 (10mm optical path length), conductivity monitor C-900, pH
monitor pH-900, autosampler A-905, and fraction collector Frac-950. The
liquid chromatography system was controlled with UNICORN 5.31 (all GE
Healthcare, Chalfont St. Giles, UK). In order to obtain in-line UV/Vis
absorption spectra, an UltiMate DAD-3000 was added to the flow path af-
ter the column. The DAD was equipped with a semi-preparative flow cell
(0.4mm optical pathlength) except for the ADC separation where an ana-
lytical flow cell (10mm optical path length) was used. The DAD was con-
trolled with Chromeleon 6.80 (all Thermo Fisher Scientific, Waltham, US).
The data acquisition of the DAD was triggered by custom-made software
written in MATLAB and Visual Basic for Applications (VBA, Microscoft,
Redmond, US). A detailed description can be found in [42].
8.3.3 Analytical Chromatographic Instrumentation
As reference analytics, analytical chromatography was performed with the
collected fractions, using a Dionex UltiMate 3000 liquid chromatography
system. The system was composed of a HPG-3400RS pump, a WPS-
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3000TFC analytical autosampler, a TCC-3000RS column thermostat, and
a DAD-3000RS detector. The system was controlled by Chromeleon 6.80
(all Thermo Fisher Scientific).
8.3.4 Preparative CEX Chromatography
Five CEX runs were performed with a 1ml MediaScout MiniChrom column
(Atoll, Weingarten, Germany) with dimensions 5mm× 50mm prepacked
with SP Sepharose FF (GE Healthcare). First, the column was equilibrated
(20mM sodium phosphate [Sigma Aldrich], pH 7.0) and then loaded with
500mg of each protein used in the run (injection volume 100 µL). Elu-
tion was performed with a linear gradient from 0% to 100% elution buffer
(20mM sodium phosphate, 500mM sodium chloride [Merck, Darmstadt,
Germany], pH 7.0). During all runs, the flow rate was 0.2mL/min and
200 µL fractions were collected. Spectra were acquired in the range from
240 nm to 310 nm. Four runs were executed with a two-component mix-
ture of cytochrome c and lysozyme. Gradients were run in 1CV, 3CV,
5CV, and 7CV. Additionally, a 3CV run with a three-component system
consisting of lysozyme, cytochrome c, and ribonuclease A was carried out.
Analytical Chromatography
The fractions from preparative CEX chromatography were analyzed by an-
alytical CEX chromatography on a Proswift SCX-1S 4.6mm× 50mm col-
umn (Thermo Fisher Scientific). A flow rate of 1.5mL/min was used dur-
ing the whole run. For each sample, the column was first equilibrated for
2.5min with load buffer (20mM TRIS [Merck, Darmstadt, Germany], pH
8.0). Next, 20 µL of sample was injected into the system and washed for
0.5min with load buffer. A bilinear gradient was performed during the next
4min with 0% to 10% (2min) and 10% to 100% elution buffer (20mM
TRIS, 700mM sodium chloride [Merck], pH 8.0). Finally, the column was
stripped for 0.5min with 100% elution buffer.
8.3.5 Preparative HIC of a surrogate ADC
The load for the preparative HIC step was produced by the conjugation
reaction of a surrogate drug (7-Diethylamino-3-(4’-maleimidylphenyl)-4-
methylcoumarin) with an IgG1. The resulting surrogate ADC had simi-
lar characteristics regarding structure and hydrophobicity to normal ADCs
however lacked their toxicity. The load was prepared by mixing IgG 1 with
surrogate ADC to a final concentration of 2 g/L for each component.
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A 1mL Toyoscreen 650M Phenyl column was purchased from Tosoh
(Tokyo, Japan). For the preparative chromatographic run, the flow rate
was set to 0.2mL/min. The column was equilibrated for 5mL with 25mM
sodium phosphate and 1M ammonium sulfate at pH 7.0. 100 µL of the load
were injected and washed for 2mL. Subsequently, a 15mL linear gradient
was performed with the elution buffer (18.75mM phosphate, pH 7.0, 25%
(V/V) 2-propanol) from 20% to 70%. The column was stripped with 8mL
elution buffer. During the whole chromatographic separation, spectra were
acquired in the range from 250 nm to 450 nm. The eluent was collected in
200 µL fractions in 96-well plates.
Analytical Chromatography
Analytics were performed by reversed-phase chromatography to quantify
the ADCs as well as the unmodified IgG1. Reduction or different sample
preparation was not required. An Acquity UPLC Protein BEH C4 column
(Waters Corporation, Milford, USA; 300Å, 1.7 µm, 2.1mm× 50mm) was
run at a flow rate of 0.45mL/min. The column oven was heated to 80 ◦C.
Solvent A consisted of 0.1% TFA in ultrapure water. Solvent B was 0.1%
TFA in acetonitrile. After equilibration and injection at 26% B, the fraction
of B was raised to 30%. Next, a 4.8min gradient from 30% B to 38% B was
used for separation of the conjugate species. The resulting chromatograms
yielded peak areas of unconjugated, mono-conjugated and di-conjugated
mAb. For the current application all conjugated species were summed.
8.3.6 UV/Vis Spectral Library
For the spectral library, all proteins in Table 8.1 except the IgG1 and IgG2
were dissolved at 2.5 g/L in 20mM sodium phosphate buffer at pH 7.0.
The IgG2 was provided as a virus inactivated solution from a Protein A
purification step. It was diluted in phosphate buffer to 2.5 g/L. The IgG1
was not included in the spectral library.
Each entry in the spectral library was generated by injecting the protein
solutions with the autosampler and a 100 µL sample loop into the chro-
matography system at a flow rate of 0.2mL/min. No column was attached
to the system. The samples were pumped through the DAD resulting in
chromatograms with EMG peak shapes due to the system dispersion. To
obtain spectra normalized by mass, the chromatograms were integrated
over time for each wavelength λi in MATLAB with a trapezoidal integra-
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tion scheme, multiplied by the flow rate u and normalized by the injected







All data analysis was performed in MATLAB on a personal computer equip-
ped with a Core i5-4440 CPU at 3.10GHz (Intel, Santa Clara, US). The
optimization problem was implemented as described in section 8.2. Sec-
ond derivatives were taken of the spectroscopic data with a second order
Savitzky-Golay filter [82] with a 7 point window width. The resulting ab-
sorbance matrix A was used for MCR.
8.4 Results and Discussion
In this publication, the factorization of multivariate UV/Vis data from pre-
parative protein chromatography by MCR was tested. Instead of using the
absorbance matrix directly for MCR, spectra were first derived twice. This
was done for two reasons: First, taking second derivatives of spectral data
helps to remove baseline offsets and measurement drifts [22]. Second, it is
also a popular technique in protein analytics to enhance the UV/Vis fine
structure. Generally, protein UV/Vis spectra are relatively uniform with
comparably little variation (see Figure 8.1). Taking the second derivative
enhances spectral differences of proteins [32], [162]. Contrary to the original
spectra, derived spectra contain positive as well as negative bands. Thus,
no positivity constraint was set on the spectral matrix S. The positivity of
the concentration was enforced by the EMGs. This approach was evaluated
in three case studies.
8.4.1 Analysis of a Three-Component Protein
Chromatogram
Three model proteins (ribonuclease A, cytochrome c, and lysozyme) were
eluted from a CEX column with a 3CV linear gradient. In Figure 8.2, the
resulting absorbance at 280 nm is shown. The normalized protein concen-
trations were color-coded into the absorbance trace. In the same figure, the
time-evolution of the original and derived spectra is depicted. Compared to
the original spectra, the second derivative spectra allow a distinction of the
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Figure 8.1: Protein spectra from a spectral library are shown. The protein
spectra are relatively uniform with an absorption maximum around 280 nm.
Differences are visible on the shoulder of the absorption bands and in the
through-to-peak distance between 250 nm and 280 nm.
different components based on spectral features. Furthermore, the observed
background drift could be reduced.






































































Figure 8.2: Spectral changes during elution are illustrated for case study I.
On the left side, the absorbance at 280 nm is shown. The absorbance trace
is color-coded with the normalized concentrations of ribonuclease A (green),
cytochrome c (red), and lysozyme (blue). The spectra in corresponding colors
are shown on the right side (top: original spectra, bottom: second derivative
spectra).
The second-derivative absorbance matrix A was subsequently analyzed
by SVD. In Figure 8.3, the singular values Σ as well as the first four left and
right singular vectors (U and V ) are shown. The singular values showed an
approximate exponential decay over the first five points and flattened out
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for latter entries. The left and right singular vectors one, two, and three
only seemed to contain little noise. However, the fourth left singular vector
was offset from zero over the whole elution, i.e. the fourth singular vectors
contain the baseline offset. The fourth right singular vector showed signs
of noise with high fluctuations between subsequent wavelengths. Based on
these observations, it was decided to use the first three singular vectors for
MCR. For the deterministic optimization of the objective function, initial





















































Figure 8.3: SVD of the UV/Vis spectral data of the first case study. The
plots show the first four left singular vectors (left), the singular values (mid-
dle), and the first four right singular vectors (right). The right singular
vectors are offset to simplify interpretation. The vectors are colored accord-
ing to their column number. Blue: first singular vector, red: second singular
vector, yellow: third singular vector, violet: fourth singular vector. It is
worth noting, that the extremes of the left singular vectors occurred during
the elution of the proteins.
values were set for T as well as p. Figure 8.3 shows that the first singular
vector followed the total protein concentration while vector two and three
contained information on the time evolution of the spectral differences of
the proteins. Consequently, the extremes of the vectors coincided with the
concentration maxima of the different components. Based on this argumen-
tation, the initial MCR parameters were set based on the SVD. The initial
mean values µ0 for the EMGs were selected based on the location of the
extremes of the left singular vectors. For the convergence of the algorithm,
it was of major importance to provide good initial values of the peak lo-
cation. The initial rotational matrix T0 was established by inspecting the
contribution of the left different singular vectors at the different µ0. If the
left singular vector contributed positively at µ0, it was added and otherwise
subtracted. To normalize the magnitude of the contributions, each entry
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was multiplied by the singular value. For the first case study, this resulted
in following rotational matrix:
T0 =
−s1 −s2 s3−s1 −s2 −s3
−s1 s2 s3
 . (8.10)
The initial standard deviations σ0 and decay constants τ0 were set for
all proteins to the values 10 and 1, respectively. σ0 was selected to be in
the range of the peak widths observed in U . τ0 was selected to initially
yield an almost symmetric peak. With this initial set of parameters, the
optimization converged in less than 30 s.
In Figure 8.4, the optimized MCR results are shown. The estimated
maximal concentration location from MCR coincided well with the results
from off-line analytics. The good overall agreement between MCR and off-
line analytics was also reflected by the high R2 values. Based on normalized
peak areas, values of 0.94, 0.93, and 0.92 were reached for ribonuclease A,
cytochrome c and lysozyme, respectively. Differences in the peak shape
were visible especially regarding peak tailing. As similar differences oc-
curred for all eluted proteins, the additional tailing in off-line analytics was
explained by the system dispersion between detector and fractionator. For









































Figure 8.4: Chromatogram of the first case study as retrieved by MCR and
compared to off-line analytics. The dashed red lines show the normalized con-
centration estimate from the hard model. The solid black lines correspond
to the rotated left singular vectors. The bars show the measured concentra-
tion by off-line analytics. Yellow: ribonuclease A, red: cytochrome c, blue:
lysozyme.
a single three-component run, the combination of MCR with an EMG hard
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constraint and second derivative spectra provided a good estimation of the
elution profile of the different protein components without prior calibration.
8.4.2 Simultaneous Application to Multiple
Chromatograms
Next, the PCD algorithm was tested for factorizing multiple binary chro-
matograms simultaneously. To this end, the absorbance matrices from the
individual chromatography runs were concatenated column-wise resulting
in Asuper ∈ Rn̄×m with n̄ =
∑
i ni and ni being the number of measurements
per run. For all subsequent analysis, Asuper was used.
Similar to the evaluation of the ternary protein elution, Asuper was first
analyzed by SVD (Figure 8.5). As expected for a binary mixture, the first
two singular values were significantly larger than the following. This was
also reflected by the shape of the singular vectors. The third left and right
singular vectors already contained a significant contribution of baseline drift
and noise. Thus, MCR was performed based on two singular vectors. The
initial rotational matrix was defined in the same manner as described above.
As each chromatography run was described by two EMGs and a total of four
runs were performed a total of eight sets of EMG parameters were neces-
sary. Initial parameter assignment followed the same reasoning as described











































Figure 8.5: SVD of the UV/Vis spectral data of the second case study.
The plots show the first three left singular vectors (left), the singular values
(middle), and the first three right singular vectors (right). The right singular
vectors are offset to simplify interpretation. The vectors are colored accord-
ing to their column number. Blue: first singular vector, red: second singular
vector, yellow: third singular vector.
a matter of minutes to the final solution (Figure 8.6). The peak-maxima
locations were again accurately determined by MCR. Similar to the sep-
aration of the ternary mixture, some deviations could be observed in the
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peak height and tailing. This was again attributed to system dispersion.
Interestingly, the differences between off-line analytics and MCR estima-
tion were more pronounced for steeper elution gradients (see Figure 8.6A
and D). This supported the assumption that the differences were caused
by system dispersion. The steeper gradients resulted in quicker changes
in protein concentrations which in turn were more affected by mixing and
diffusive peak broadening. Despite these deviations, good estimations were
obtained for the elution of cytochrome c and lysozyme with R2 values of
0.93 and 0.91, respectively. Between the concentrations by the rotated sin-
gular vectors and the hard model, only minor differences occurred. Thus,
the method could be extended to the case of multiple chromatographic runs





















































































Figure 8.6: Chromatograms of the second case study as retrieved by MCR
and compared to off-line analytics. The four plots show the different runs
with varied gradient length. A: 1CV, B: 3CV, C: 5CV, D: 7CV. The dashed
red lines show the normalized concentration estimates from the hard model.
The solid black lines correspond to the rotated left singular vectors. The bars
show the measured concentration by off-line analytics. Red: cytochrome c,
blue: lysozyme.
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8.4.3 Application of MCR to an ADC Purification
Step
In the third case study, an ADC conjugation reaction mixture was loaded
onto a HIC column. This purification step aimed to deplete chemical re-
actants and separate conjugated from native IgG1. Due to the reaction
chemicals, the loaded mixture was relatively complex. Additionally, the
protein concentration during elution was lower compared to the previous
case studies. This increased the perceived noise level and baseline drift. To
simplify the analysis of the chromatogram, the evaluation focused on the
main elution peak of native and conjugated IgG1.
In Figure 8.7, the results of an SVD are shown. The first two singular
values were noticeably larger than the following. Interestingly, the second
left singular vector already contained some baseline drift. Interestingly, the
baseline drift became stronger for the third left singular vector. The sec-
ond right singular vector was not influenced by noise and contained strong
spectral bands around 375 nm. These bands are typical for the used sur-
rogate drug. The third right singular vector was noticeably deteriorated
by noise. Based on these observations, two components were included into











































Figure 8.7: SVD of the UV/Vis spectral data of the third case study.
The plots show the first three left singular vectors (left), the singular values
(middle), and the first three right singular vectors (right). The right singular
vectors are offset to simplify interpretation. The vectors are colored accord-
ing to their column number. Blue: first singular vector, red: second singular
vector, yellow: third singular vector.
less than a minute. The resulting chromatogram is shown in Figure 8.8.
Similar to the previous case studies, the location of the concentration max-
ima corresponded well to the off-line analytics. Slight differences could be
observed in tailing and fronting. The good results were confirmed by the
R2 values of 0.99 and 0.97 for the native IgG and the ADC, respectively.
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The R2 was again calculated based on the normalized areas. The better
agreement between off-line analytics and MCR results were attributed to
the long elution gradient which reduced the effects of system dispersion
between detector and fractionator as well as possibly the bigger spectral
differences between the IgG and the ADC. Interestingly, the differences be-
tween the rotated singular vectors and the hard model were bigger in this
case. This was explained by the observed baseline drift included in the
second singular vectors which again is related to the matrix factorization.
SVD captured on each additional dimension as much variation as possible.
The information is however not necessarily useful for the estimation of the
elution profile. Thus, other matrix factorization approaches may outper-
form SVD. Nevertheless, the used PCD algorithm provided also in the last
case study promising results.









































Figure 8.8: Chromatograms of the third case study as retrieved by MCR
and compared to off-line analytics. The dashed red lines show the nor-
malized concentration estimate from the hard model. The solid black lines
correspond to the rotated left singular vectors. The bars show the measured
concentration by off-line analytics. Yellow: native IgG1, blue: ADC.
8.4.4 Protein Identification Based on the Estimated
Spectra
To assess how accurate the MCR algorithm estimated data in spectral di-
mension, the previously estimated spectra were compared to the second
derivatives of the spectral library shown in Figure 8.1. Prior to the com-
parison, all spectra were normalized by standard normal variate transfor-
mation to remove any concentration related information. In Figure 8.9, all
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spectra were projected onto a plane by PCA. Estimated spectra were pro-
jected into the vicinity of the corresponding reference spectra. The results
were even more pronounced when directly comparing Euclidean distances
between the second derivative spectra. For case study 1, the distances be-
tween the reference and estimated spectra of ribonuclease A, cytochrome
c, lysozyme were 0.5, 0.6, and 0.3, respectively. All other distances were
≥ 1.8. For the second case study, the Euclidean distances were 0.8 for cy-
tochrome c and 0.3 for lysozyme with all other distances being ≥ 2. For
the third case study, only the estimated spectrum from 240 nm to 310 nm of
the unconjugated IgG1 was used. The ADC could not be evaluated in this
manner, as the drug contributed to the absorption in the protein spectral
range and thus biased an identification. The Euclidean distance from the
IgG1 was smallest to the IgG2 with 2.1. All other distances were ≥ 2.5.
The bigger difference was explained by the structural differences of IgG1 to
IgG2 next to the error intoduced by the factorization by MCR. The results
show, that the estimated second derivative spectra of the MCR algorithm
are close to the spectra of the pure components and may even be used to
draw conclusions on the generating protein.




































Figure 8.9: Score plot based on a PCA of the spectral library. The spectra
from the protein library are marked by black circles. The retrieved spectra
from MCR are projected onto the plane. The position of the spectra of the
case studies are marked by diamonds (first case study), crosses (second case
study), and an asterisk (third case study).
8.5 Conclusion and Outlook
Here, the application of MCR with hard model constraints on preparative
protein chromatographic data was tested. The results show that MCR was
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well capable of factorizing chromatograms even though protein spectra are
subject only to small spectral variation. Differences in peak shape and
location of the estimated elution profiles remained small. The matrix fac-
torization of the protein chromatograms could be directly used for protein
identification. In summary, MCR seems to be a suitable tool for evaluating
protein chromatograms if the eluting species are spectroscopically different.
For UV/Vis spectroscopy, mainly the amount of aromatic amino acids, the
local environment of aromatic amino acids, and disulfide bridging affect
the protein spectra in the investigated spectral range [32]. The proposed
method may be especially useful for applications in process development as
it is readily applicable without prior calibration.
While the current algorithm is limited to EMGs, other curve shapes
could be implemented in a similar manner to also address different elu-
tion behavior. Furthermore, MCR is not limited to UV/Vis spectroscopy.
Other PAT sensors may benefit from its application as long as they follow
a bilinear relation. These occur for many (process) analytical technolo-
gies including IR spectroscopy, Raman spectroscopy, and on-/at-/off-line
HPLC. In consequence, a wide variety of applications in biopharmaceutical
purification are conceivable and may be explored in future.
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In this thesis, a toolbox of spectroscopic PAT sensors for monitoring bio-
pharmaceutical DSP operations was developed. All sensors were imple-
mented in- or on-line and each provided unique information on the product
and contaminants in the process stream. During the thesis, UV/Vis spec-
troscopy (Chapters 3, 4, 5, 7 and 8), FTIR spectroscopy (Chapter 6), and
light scattering detectors (Chapter 7) were investigated. With these sensors,
a broad range of quality attributes, concentrations and protein structural
elements were successfully analyzed in (near) real-time. By using a single
or multiple sensors in parallel, the toolbox allowed for versatile PAT.
UV/Vis spectroscopy provided high selectivity and sensitivity for pro-
teins coupled with fast measurement times. The method analyzed protein
primary, tertiary, and quaternary structure. Its high selectivity and quick
measurement times were leveraged in Chapter 3 to monitor the break-
through during a Protein A capture step in the complex background of
HCCF. Based on absorbance spectra in conjunction with PLS modeling, the
breakthrough concentration could be accurately predicted. The predicted
concentrations were then utilized to control the chromatography system in
real-time.
At high concentrations, the application of VP UV/Vis spectroscopy
was investigated to prevent detector saturation (Chapter 4). By dynami-
cally adjusting the optical pathlength, protein solutions at concentrations
higher than 75 g/L could be measured. PLS modeling was applied to ex-
tract protein concentrations from the measured UV/Vis spectra. Based on
this approach, elutions from preparative chromatography steps with model
proteins as well as a mAb and HMW were monitored selectively. The
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predicted concentrations could be used to control pooling decisions of a
chromatography system.
By exploiting the sensitivity of UV/Vis spectroscopy to the solvatiza-
tion of chromophores, the method was further developed to monitor ADC
conjugation reactions (Chapter 5). The conjugation reactions of a mAb
with two surrogate drugs were observed in-situ in a microplate format and
on-line in a lab-scale stirred vessel. From the spectral data, concentrations
were predicted by PLS regression. The results showed that the conjugation
reactions could be reliably monitored in (near) real-time, an approach which
could in future allow for kinetic studies of the ADC conjugation reaction.
In Chapter 6, FTIR spectroscopy was employed in-line to monitor pre-
parative protein chromatography. In contrast to standard UV/Vis spec-
troscopy, ATR FTIR was not limited by detector saturation at high protein
concentrations. The measurement method provided information on the pro-
tein secondary structure and the overall protein concentration. Due to the
sensitivity of FTIR spectroscopy to any polar covalent bond, it was not
only possible to monitor proteins but also the elution of PEGylated protein
species and the selective quantification of a process-related impurity.
In Chapter 7, a multimodal spectroscopic approach was chosen for mon-
itoring the reassembly of HBcAg VLPs from homodimers in a CFF process.
Light scattering methods contributed information on the molecular weight
and the hydrodynamic radius of the particles in solution. These two re-
sulting values allowed to monitor the assembly of VLPs and aggregation
directly. UV/Vis spectroscopy measured the protein concentration and
changes in tertiary structure around the aromatic amino acids tryptophan
and tyrosine. Due to the hydrophobic interaction forces involved in VLP
assembly, the changes in the microenvironment of the two aromatic amino
acids correlated to the rate of assembly. The rich information from the
sensors provided evidence that the VLP assembly process was inhibited by
aggregates.
Finally, work on the chemometric data evaluation of preparative chro-
matograms was performed in Chapter 8. While all other studies in this
thesis partly relied on calibrated statistical models, an alternative approach
based on MCR was evaluated. Chromatograms were analyzed by com-
bining second-derivative spectroscopy and hard-constraint MCR. This ap-
proach factorized preparative protein chromatograms without any informa-
tion from off-line analytics. The estimated concentration profiles corre-
sponded closely to off-line analytics. The estimated spectra could be used




In the last decade, research on PAT in DSP intensified. While other meth-
ods are investigated, a major focus still lies on on-line liquid chromato-
graphic methods. There are multiple reasons for the popularity of liquid
chromatography as PAT. Most importantly, liquid chromatography pro-
vides superior selectivity for proteins and features a remarkable dynamic
range of the analyte concentrations. Analytical liquid chromatography is
furthermore the method of choice for measuring many quality attributes in
biopharmaceutical industry and thus well established. Hence, future appli-
cations of liquid chromatography methods will keep emerging. Problematic
are however the long anaylsis times and technical complexity.
If necessary, the selectivity of liquid chromatography can be further en-
hanced by coupling the system to mass spectroscopy. With modern mass
spectrometers reaching acquisition rates above 1Hz, this is potentially a
very powerful method for process monitoring providing unparalleled selec-
tivity. Future applications in DSP may be related to monitoring glycosyla-
tion patterns and similar protein modifications as they are otherwise hard
to detect. Liquid chromatography coupled to a mass spectrometery is how-
ever currently technically complex and very expensive. Without a strong
drop in equipment prices, the routine application to all unit operations may
generate too high costs.
The application of on-line biochemical assays, microfluidic devices, plas-
mon surface resonance, quartz crystal microbalances, and similar methods
is also a regularly discussed topic in PAT for biopharmaceutical produc-
tion. The methods are potentially very selective. They are however often
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not plug and play and may indeed be very difficult to implement in a GMP
environment.
Given the high robustness and frequent application of spectroscopy in
other fields as PAT, it will also be established in DSP as one of the most po-
tent tools for process monitoring. The frequent application of spectroscopy
for protein structural analysis shows that the methods are also potentially
interesting for process monitoring. In other process fields, especially Near-
Infrared (NIR) and Raman spectroscopy have been widely applied. Both
methods are amendable to fiber optics. The measurement equipment is
very robust and for NIR comparably cheap. Due to the low absorption
coefficients in NIR, the methodology is not as prone to detector saturation
as UV/Vis spectroscopy or mid IR measurements. NIR spectroscopy how-
ever has a relatively low selectivity. Already with mid IR, selective protein
quantification is difficult. The broad bands in NIR may further compli-
cate analysis. Raman spectroscopy is frequently used for protein structural
analysis because of the information content on the primary, secondary and
tertiary structure. In upstream, it has shown a high selectivity even in
complex cell culture browth. Major drawbacks are the low scattering ef-
ficiencies of proteins and the resulting long measurement times. Especially
for chromatography, fast measurement times are essential and need to be
achieved for efficient process monitoring.
Regarding chemometric data evaluation, the development in DSP stands
very much at the beginning. Little research has been performed on soft
sensors or coupling measurement results from multiple sensors. Especially
chromatography has a strong mechanistic modeling theory already in place
which may be coupled with spectroscopic measurements.
Finally, a major challenge in future relates to a flexible implementa-
tion of PAT tools into different unit operations. Currently, disposable and
single-use technologies are gaining market shares especially during clini-
cal phases [190]. At the same time, the product portfolio of biologics is
broadening. New formats such as antibody fragments, nanobodies, con-
jugated proteins and vaccines, and Fc-fusion proteins are emerging [191].
Depending on the unit operation and biopharmaceutical product, differ-
ent sensors or sensor combinations may be of interest. Ideally, detectors
could therefore be exchanged with little effort. Such a flexible approach to
PAT however requires standardized communication between different com-
ponents e.g. through OPC Foundation’s OPC unified architecture (OPC
UA). Here, the support of the equipment manufacturer as well as dedicated
sensor manufacturer is key [18]. By providing a flexible platform which al-
lows to combine different manufacturing equipment with a range of sensor
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114
UV Ultraviolet 21–23, 31, 32, 35, 36, 41, 73, 82, 94, 100–102, 107, 109,
111, 112
UV/Vis Ultraviolet/Visible vi, vii, 7, 9–11, 14, 16–19, 21, 22, 26, 30, 33,
34, 47, 49–51, 54–56, 62, 64, 65, 72–74, 78, 88, 90, 92, 96–98, 103,
104, 111–113, 117, 119, 123, 126, 128, 130, 132, 135, 137, 138, 140
VLP Virus-Like Particle vii, viii, 14, 16, 18, 89–93, 95, 97–107, 109–113,
138
VP Variable Pathlength vi, 16, 31–34, 36, 39, 40, 43, 45, 47, 137
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